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Abstract 
Visualisation of the spatial distribution of biomolecules in biological substrates by mass 
spectrometry or spectroscopic imaging techniques plays a major role in biomedical, 
clinical, and pharmaceutical research. The work presented in this thesis investigates the 
capabilities of three imaging techniques, liquid extraction surface analysis (LESA) mass 
spectrometry imaging (MSI), matrix assisted laser desorption ionisation (MALDI) MSI 
and stimulated Raman scattering (SRS) microscopy, and combinations thereof, for the 
analysis of biological samples. A method for combined LESA and MALDI analysis was 
developed and results provided high resolution imaging of multiple analyte classes 
(proteins, lipids and small molecule drugs) in thin tissue sections. Moreover, this 
method enabled fundamentals of LESA sampling to be probed. Similarly, SRS 
microscopy was used for the quantitative imaging of MALDI surface sampling effects 
and sample preparation, providing insight into fundamental processes of MALDI MS 
including ion yields obtained under different experimental and instrumental parameters. 
Multimodal SRS, LESA and MALDI imaging was executed on a single tissue sample 
revealing the complementarity between the three approaches, and enabling high 
resolution imaging with high sensitivity and specificity. Specific challenges for LESA 
were further explored, namely protein quantification, improved spatial resolution and 
alternative biological substrates. A quantitative LESA method based on the production 
of mimetic tissue models containing stable isotope-labelled proteins was developed. An 
alternative platform, comprising continuous flow sampling, the Flow-ProbeTM, with 
the potential to achieve higher spatial resolution both in discrete ‘spot’ and raster mode, 
was assessed. Finally, a LESA method for the direct analysis of proteins from live 
bacterial colonies growing in Petri dishes was developed. 
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Chapter 1  
Introduction 
1.1 Theory of Mass Spectrometry 
A mass spectrometer is made up of three main parts; an ionisation source which 
produces ions from the sample, a mass analyser which separates ions according to mass 
to charge ratio (m/z) and a detector which measures the number and m/z of ions. From 
this information a chart indicating the number of ions detected with each m/z can be 
produced – this is known as a mass spectrum.1 
1.1.1 Ionisation 
Ionisation can be achieved via numerous methods. Traditional ionisation methods such 
as electron impact and chemical ionisation focussed on ionisation in the gas phase 
through collisions with charged particles. These methods were unsuitable for large 
biomolecules due to extensive fragmentation and degradation during transition to the 
gas phase.2 In the 1980s two new methods of ionisation were developed which made 
possible the ionisation and analysis of proteins and other macromolecules such as 
oligonucleotides and complex carbohydrates. Matrix assisted laser desorption ionisation 
(MALDI) mass spectrometry was first introduced in 1987 by Karas et al.3 and 
electrospray ionisation (ESI) followed two years later in a report by Fenn et al.4  
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1.1.1.1 MALDI Ionisation 
MALDI MS involves dissolving the sample in a solution of matrix material, commonly 
an organic acid, which has a high molar absorptivity in the ultra-violet or infra-red 
range. As the carrier solvent evaporates, the matrix and analyte co-crystallise to form a 
‘solid solution’ structure with analyte molecules embedded throughout, see Figure 1.1. 
The sample may then be introduced to the ion source of the mass spectrometer. Under 
vacuum conditions, an ultraviolet or infrared laser is used to irradiate the sample with 
short pulses, causing a build-up of energy within the matrix. This heat causes localised 
sublimation of the matrix and analyte into a plume of particulate matter in which 
reactions may occur to produce singly charged analyte and matrix ions.3,5,6 Several 
ionisation models have been proposed although the exact mechanism by which this 
process occurs remains somewhat debated.7-9  
Ionisation by MALDI is now generally accepted to be a two-step process involving 
initial or primary ionisation before ion-molecule interactions occur in the ablation 
plume, known as secondary processes. The two most popular models of primary 
ionisation are the cluster model and the pooling model.9 The cluster model suggests that 
ions are pre-formed during matrix/analyte preparation and remain after crystallisation. 
Ions are therefore contained in clusters of matrix molecules ablated from the solid 
surface. Evaporation of molecules in the cluster may then release the ion. Alternatively 
charge may need to migrate from matrix to analyte in order to form analyte ions.7-9 The 
pooling model differs in that it suggests ions are formed after laser irradiation and are 
not pre-formed during sample preparation. Pooling is the redistribution of electronic 
excitation energy which can occur after initial photoexcitation of the matrix. If two 
neighbouring molecules are raised to the first excited singlet state (S1) or a higher 
excited singlet state (Sn) they can interact due to waveform overlap. The pooling event 
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can generate either a higher excited singlet state or an ion. Other primary ionisation 
models have been suggested, such as direct multi-photon ionisation, excited state proton 
transfer and the polar fluid model, but no single model has been universally agreed 
upon.9 Secondary processes occur after the initial desorption/ablation event and primary 
ions have been produced. There is a large excess of neutral matrix in the plume, so it 
can be assumed that ions within this plume will therefore undergo bimolecular 
collisions with neutral matrix molecules during expansion of the plume. The possible 
reactions leading from these interactions could be electron transfer, proton transfer and 
cation transfer.9  
The ‘soft’ nature of MALDI desorption/ionisation means the method is suitable for the 
analysis of large biomolecules because they remain intact during desorption/ionisation. 
There are several advantages of using the ‘matrix assisted’ method over traditional laser 
desorption ionisation. Firstly there is no requirement to adjust the laser wavelength to 
the absorption frequency of each analyte. Secondly, analytes of high molecular weight 
(~300,000 Da) can be detected because the ionisation/desorption process is independent 
of analyte molecular weight. Finally, due to the ratio of matrix to analyte ions in the 
sample being very high, the probability of forming sample clusters is decreased, thus 
increasing the chance of observing the molecular ion peak.1,3,7 
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Figure 1.1 Illustration of MALDI MS sample preparation and ionisation: sample is 
coated with a solution of matrix compound which forms a co-crystalline structure with 
analyte molecules embedded throughout. Upon irradiation with a laser 
desoption/ionisation of matrix and analyte occurs. Ions are directed towards the mass 
spectrometer via ion lenses. 
1.1.1.1.1 Matrix compounds 
The choice of matrix compound can affect the sensitivity and the type and number of 
analytes detected in a MALDI analysis.10 Different matrix compounds can be used to 
selectively analyse a particular class of analyte. Cinnamic and benzoic acid derivatives 
were quickly identified as useful MALDI matrices for the analysis of proteins.7,11 The 
majority of reports centre on a small group of acidic organic compounds such as α-
cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid (SA) and dihydroxybenzoic 
acid (DHB), which have all been widely reported for the analysis of proteins, peptides 
and lipids.10,12-14 A number of basic matrices such as anilines have also been suggested; 
para-nitroaniline (PNA) has been used for the analysis of lipids using instruments 
operating at intermediate pressure.15 A list of the matrix compounds used in this work is 
given in Table 1.1. The quality of a given analysis is dependent upon a number of 
matrix-dependent factors such as: physicochemical properties of the matrix which 
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determine co-crystallisation with analyte, co-desorption upon irradiation and efficiency 
of ionisation.12 The number of different instrumental set-ups available further 
complicates matrix assessment because different lasers operate at different repetition 
rates and have different wavelengths. The wavelength required for maximum absorption 
of laser energy is dependent on the UV absorption profile of the matrix compound 
which is determined by chemical structure and is therefore different for every matrix. 
Investigations into the ideal matrix and optimum preparation for different applications 
are ongoing. 
Table 1.1 A list of matrix compounds used in this work and their associated analytes. 
Matrix compound Molecular structure Analyte types 
CHCA 
 
Peptides and proteins16 
Lipids10 
DHB 
 
Peptides and proteins11 
lipids17 
Polymers18 
SA 
 
Peptides and proteins16 
PNA 
 
Lipids15,19 
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1.1.1.1.2 Matrix deposition methods 
In addition to the choice of matrix compound, the method of matrix/analyte preparation 
can also critically affect MALDI analysis. In imaging experiments successful 
preparation must incorporate deposition of sufficient quantities of matrix, minimisation 
of matrix crystal sizes, sufficient extraction of analyte and minimal delocalisation of 
analytes. The matrix is typically dissolved in a mixture of organic/aqueous solvent and 
applied to the surface using a microspotter,20 electrospray,21 airbrush10 or robotic spray 
device, such as the TM-Sprayer produced by HTX Technologies and used in this work. 
Alternatively the matrix can be applied without the use of a carrier solvent by 
sublimation.22 It has been suggested that this decreases the probability that analytes will 
dissolve in the solvent and spread away from their original location – hence preserving 
sample integrity. The small crystals typically produced by this method are also a benefit 
when high resolution imaging is desired.22 A possible drawback to solvent-free matrix 
deposition is poorer extraction efficiency resulting in lower sensitivity. 
1.1.1.1.3 Laser types 
In the past, MALDI MS has commonly been performed with a Nitrogen laser operating 
at a frequency of 20 Hz and a wavelength of 337 nm. This wavelength was ideal for 
many matrix compounds but the low repetition rate was unsuitable for high-throughput 
MALDI imaging applications.19 Diode-pumped solid state (DPSS) lasers, such as the 
Nd:YAG and the Nd:YVO4 are now commonly used in commercial MALDI 
instruments and were used in this work. The frequency tripled Nd:YAG and Nd:YVO4 
can operate at high repetition rates up to 20 KHz. This is ideal for high throughput raster 
mode imaging in which the energy from the laser must be delivered to the sample 
surface more quickly in order to obtain sufficient ion yields on a shorter timescale.19 
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These lasers have a wavelength of 355 nm which is also suitable for use in combination 
with the matrices listed above.  
1.1.1.2 Electrospray ionisation 
Electrospray ionisation involves three stages: production of charged droplets, droplet 
shrinkage and the production of gas-phase ions. A sample dissolved in solution is 
passed through a capillary held at high voltage, the tip of which is located close to a 
planar counter electrode, see Figure 1.2. Ions typically enter the mass spectrometer 
through an orifice in the counter electrode. The high electric field which is imposed 
partially penetrates the liquid inside the capillary. For simplicity, only the production of 
positive ions, in which a positive capillary potential is applied, will be discussed here. 
At the tip of the capillary, the liquid forms a meniscus where positive charge 
accumulates as a result of the movement of negative charge towards the capillary and 
positive charge to the liquid surface. The accumulation of positive charge destabilises 
the surface which is drawn downfield such that the liquid forms a cone shape, known as 
the Taylor cone. At sufficiently high electric field the cone is not stable and a liquid 
filament is drawn out, as illustrated in Figure 1.2. The filament becomes destabilised the 
further away from the cone it is and eventually breaks to form droplets. There is an 
excess of positive charge within these droplets.1,4,23,24 
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Figure 1.2 Illustration of electrospray ionisation, the sample is dissolved in a solvent 
and passed through a capillary held at either positive or negative potential. At the end of 
the capillary the liquid surface is drawn downfield into a cone shape known as the 
Taylor cone, this is further drawn into a long filament which eventually breaks up into 
droplets. Ions are released from the droplets and enter the mass analyser. 
The droplets shrink by evaporation of solvent ions and at some point they come close to 
the Rayleigh limit. At this point the charge in the droplet becomes sufficient to 
overcome the surface tension that holds the droplet together and fission can occur. The 
parent droplet oscillates and emits a tail of smaller offspring droplets in a manner 
similar to the disruption of the Taylor cone. This was observed by Gomez and Tang 
who imaged charged droplets undergoing fission.25  
There are two mechanisms which have been suggested for the formation of gas-phase 
ions from charged droplets: the first was first described by Dole in 1968 and involves 
the formation of very small droplets which contain only one ion.26 This is known as the 
charged residue model; evaporation of solvent from the tiny droplet converts the 
charged droplet to a single gas phase analyte ion.23 The other model was suggested by 
Iribarne and Thomson,27 and is known as the ion evaporation model. This mechanism 
involves small but very highly charged droplets which do not undergo fission but emit 
gas-phase ions.  
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Figure 1.3 Models of electrospray ionisation: ions can be released from charged droplets 
either by the ion evaporation model or the charged residue model. 
As previously mentioned, it is possible to generate multiply charged macromolecules 
such as proteins via ESI. A model suggested by Fenn28 postulates that polyprotonated 
protein species are contained within droplets and due to Brownian motion some portion 
of the protein may approach the droplet surface. If a charged residue approaches the 
surface then this charge replaces a charge on the droplet surface. Thermal activation 
could provide the energy for the charged residue to move outside the droplet. An elastic 
oscillation of the droplet could then facilitate uneven fission of the droplet in which the 
protein and a very small amount of solvent are released to form a highly charged 
droplet.23,28 
1.1.2 Mass Analysis 
Once gas-phase ions have been produced from the sample, a mass analyser is required 
to separate ions of different mass to charge ratio. The type of mass analyser required 
depends on the sample, ionisation source and type of analysis required; hence numerous 
mass analysers and combinations of mass analysers exist. Broadly, a mass analyser uses 
electric and or magnetic fields to separate ions based on differences in their behaviour 
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within the field. Commonly used mass analysers include the quadrupole, time-of-flight 
(TOF), linear ion trap and the Orbitrap.  
1.1.2.1 Linear Ion Trap 
Ion traps are devices which use electric fields to trap ions either in two (linear ion trap) 
or three (3D Ion trap) dimensions. The linear ion trap consists of four rods held at a 
potential and ending in lenses which reflect ions back and forth, see Figure 1.4. Ions 
enter the device along the z-axis and oscillate along the x,y plane due to application of 
an RF field. Ions are confined by the electric field at either end of the trap and are 
reflected between the two ends. As a result an ion cloud forms inside the trap and these 
ions can be mass selectively ejected. Ions are typically ejected axially through openings 
cut into two opposite rods by applying AC voltages between rods in the ion trap and the 
exit lenses. Linear ion traps can be used as stand-alone mass spectrometers by ejection 
of ions towards a detector, or can be combined in hybrid instruments in order to isolate 
ions of particular m/z, perform tandem mass spectrometry and study ion-molecule 
chemistry.1,29 An instrument employing an ion trap in combination with an orbitrap 
mass analyser – the Thermo Fisher Orbitrap Velos and Orbitrap Elite - was used in this 
work. 
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Figure 1.4. The linear ion trap: four parallel rods held at a potential with two end lenses 
which reflect ions back and forth trapping ions in cloud within the rods. Slits in two 
opposite rods allow for ejection of ions towards another mass analyser or a detector. 
Reproduced with permission from [1]. 
1.1.2.2 Quadrupole 
The quadrupole mass analyser consists of four parallel conductive rods held at 
alternating potentials, see Figure 1.5. The potential applied to the rods is described by 
equation 1.1, where U is the direct potential, V is the zero to peak amplitude of the RF 
voltage and ω is the angular frequency in radians per second.1  
Φ0 = 𝑈 − 𝑉𝑐𝑜𝑠𝜔𝑡 
1.1 
The application of voltages to these rods creates an oscillating electric field into which 
ions are accelerated. Ions are subject to accelerations along x and y axes as a result of 
forces induced by the electric field. The trajectory of ions through this field is 
determined by their m/z ratio so by adjusting the strength of these fields and the applied 
RF potential, ions of a particular m/z can be selectively transmitted. Ions of differing 
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m/z will have an unstable path and will be deflected towards one of the rods and will not 
reach the detector. Quadrupole mass analysers are often used as ion guides to direct and 
focus ion beams towards a second mass analyser, owing to their low mass resolution 
when used independently.1 Quadrupoles can be used in conjunction with other 
quadrupoles (for example in a triple quadrupole instrument) or with a time-of-flight 
mass analyser in a QqTOF instrument, such as the one used in this work.  
 
Figure 1.5 Schematic of the quadrupole mass analyser, ions enter the quadrupole along 
the z-axis and are subjected to the electric field imposed by the rods held at either 
positive or negative potential. 
1.1.2.3 Time of Flight 
Time of flight mass analysers separate ions based on their velocity which is dependent 
on their m/z. Ions are accelerated into the mass analyser by the difference in potential 
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between an electrode and an extraction grid. Ions acquire the same kinetic energy during 
this process and therefore their velocity will be related to their m/z ratio, see Equation 
1.2. In this equation, which describes time taken, t, for an ion of given m/z ratio to reach 
the detector, L is the distance ions travel to the detector and Vs is the initial acceleration 
potential.1  
𝑡2 =
𝑚
𝑧
(
𝐿2
2𝑒𝑉𝑠
) 
1.2 
Ions enter a field-free region known as the flight tube, where they separate according to 
velocity. A detector is located at the other end of the flight tube; m/z is subsequently 
measured by recording the time taken for ions to reach the detector. TOF mass analysers 
are generally associated with high transmission efficiency and therefore provide good 
sensitivity. Additionally, analysis time is short and upper mass limit of ions is high 
(>1,000,000 Th). The mass resolution achieved by TOF analysis is however poor 
(typically 5000 at m/z 1000). This can be somewhat improved through the use of a 
reflectron or ion mirror placed at one end of the flight tube, see Figure 1.6. Ions of the 
same m/z enter the reflectron with a kinetic spread and ions with larger kinetic energies 
will penetrate further into the ion mirror. Lower energy ions will therefore be reflected 
at an earlier timepoint thereby minimising the temporal spread of ions and improving 
mass resolution. Tandem instruments such as the QqTOF allow one to observe the 
fragmentation of ions by selecting and fragmenting ions in two sequential quadrupoles 
before scanning the resulting fragment ions in the TOF.1  
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Figure 1.6 Principles of the TOF mass analyser which measures the time taken for ions 
of different m/z to reach the detector and the reflectron which can be used to improve 
mass resolution when using a TOF. 
1.1.2.4 Orbitrap 
The Orbitrap is a relatively new mass analyser, developed by Makarov and first 
introduced in 2000.30,31 Branded as a smaller, cheaper and more energy efficient 
alternative to the high mass accuracy analysis provided by Fourier Transform-Ion 
Cyclotron Resonance (FT-ICR) mass spectrometry, the Orbitrap mass analyser has 
since been reported for the analysis of numerous analytes including proteins, peptides, 
oligosaccharides and glycoproteins. The high mass accuracy, mass resolving power and 
dynamic range of the Orbitrap make it the ideal choice for many types of analytical 
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experiment.31 Ions are injected into the space between two electrodes: an inner ‘spindle’ 
which is surrounded by an outer barrel-shaped electrode, see Figure 1.7. A voltage is 
applied to the inner electrode while the outer is held at ground potential. Injected ions 
rotate around the inner electrode and oscillate along the z-axis. The frequency of ions 
oscillating in this dimension is related to the m/z ratio of ions via equation 1.3.1 
𝜔 = √(
𝑧
𝑚
) 𝑘 
1.3 
Where k is field curvature and ω is frequency. Current is induced in the electrodes by 
oscillating ions and is measured, converted to frequency via the Fourier Transform and 
calibrated to m/z.1 
 
Figure 1.7 The Orbitrap mass analyser, ions are injected into the space between two 
electrodes where they oscillate along the z-axis with a frequency related to their m/z, 
reproduced with permission from [1]. 
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1.1.3 Ion detection 
Ions which pass through the mass analyser must be detected and a signal produced 
which is proportional to their abundance. Commonly, ions are detected using an 
electron multiplier in which a current is induced via collisions with accelerated 
incoming ions.1 In the case of the Orbitrap mass analyser no such detector is required 
because the signal is generated by induction of current by oscillating ions, as described 
above.31 
Mass spectrometry has proved a useful analytical tool and the advent of ion sources 
which could produce ions from large biomolecules was a turning point. The detection of 
such species with retention of spatial information was similarly important, and has 
enabled mass spectrometry imaging of thin tissue sections, whole body sections, 
bacterial colonies and plants.21,32-50 There are numerous ways in which ions can be 
produced for MSI and some of these methods will be discussed in more detail in the 
following section. 
1.2 Mass Spectrometry Imaging Methods 
1.2.1 Matrix Assisted Laser Desorption-Ionisation Mass Spectrometry Imaging 
Mass spectrometry imaging is made possible through sampling discrete spots or raster 
lines across a surface and the collection of mass spectra from each location. The 
intensity of a particular m/z species may then be mapped across the area by 
corresponding pixel intensity with spectral intensity for each pixel to produce an image.  
Since its inception numerous applications of MALDI MSI have been developed for both 
biological and synthetic species and sample types.18,51-53 MALDI MSI has been reported 
for thin tissue sections including whole body sections,34,39,54 with the detection of 
peptides, proteins, lipids, oligonucleotides and drugs and associated metabolites 
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reported.5,32,33,40,55-57 Clinical and pharmaceutical applications of such methods include 
the delineation of tumour margins via detection of characteristic proteomic and 
lipidomic signatures.37,38,58 This has clinical implications for classification and diagnosis 
of tumour type,36,59 which can greatly affect patient treatment and prognosis. There are 
also implications for the field of drug discovery and preclinical research because the 
localisation of a drug in tissues of a preclinical model could be mapped with respect to 
the exact location of the tumour. Whilst much work has focussed on applications in 
oncology, MALDI MSI is not limited to this and imaging of other types of tissue for 
research into other diseases has also been done. These include the imaging of peptides 
and proteins from brain sections of a Parkinson’s disease model, which found a number 
of differences in expression profiles between disease and wild-type samples.60 A 
number of recent reviews have discussed the use of MALDI MSI in clinical 
applications.61-63 
The capabilities of MALDI MSI have been improved through development of sources 
employing high repetition rate lasers which allow high-throughput analysis.15,64 Faster 
acquisition times will be essential as spatial resolution of images improves and larger 
quantities of data are acquired. Spatial resolution in MALDI MSI is typically limited by 
the diameter of the laser beam size. Pixel sizes of <20 μm can be routinely accessed by 
commercial instruments which is sufficient to distinguish between most tissue 
anatomies although imaging of organelles within single cells remains beyond the 
capabilities of MALDI.65 A method known as oversampling is commonly employed in 
MALDI MSI, in which the sample stage is scanned continuously beneath the laser beam 
and relies on complete ablation of matrix at each location has allowed pixel sizes 
smaller than the laser beam diameter to be accessed.66 Further improvements have been 
enabled through employing ‘transmission geometry’ in which a laser beam irradiates the 
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sample from behind therefore exhibiting a smaller beam diameter67 and the atmospheric 
pressure MALDI source developed by Spengler in which the laser optics are positioned 
close to the sample and ions are collected via an opening in the optics themselves.68 The 
drive towards higher spatial resolution in MALDI comes at the cost of sensitivity: the 
smaller the area irradiated per pixel the lower the desorption/ionisation yield. Therefore 
the requirements for individual experiments must be considered in advance. 
Another area of significant interest is the development of quantitative MALDI MSI 
methods. The ability to analyse not only what is there but how much is there is of 
particular importance in the field of pharmaceutical research. Barriers to absolute 
quantification using MALDI include poor understanding of ion suppression, analyte 
extraction, extraction efficiency, ionisation efficiency and ion stability.65,69,70 Ion 
suppression, or the competition for charge, during ionisation of a complex biological 
sample is common to many types of mass spectrometry analysis,71 however the addition 
of a matrix compound during MALDI further complicates this issue. Heterogeneity in 
tissue samples can result in changing ion suppression effects across a single tissue 
section which can be amplified during matrix application due to sample composition-
dependent changes in crystal size and morphology.65 Several methods incorporating the 
use of internal standards to correct for these effects have been reported.72-75 Such 
standards can be deposited directly onto the tissue or placed on the substrate prior to 
tissue sectioning which has been demonstrated to provide improved linearity.76 One 
problem with this method is differences in extraction efficiency between compounds 
which have been dosed in vivo and spiked standards. Methods in which tissue 
homogenate is mixed with a standard prior to freezing in a mould and sectioning have 
been suggested as more appropriate because both extraction efficiency and ion 
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suppression can be accounted for. Such methods have been reported for the 
quantification of pharmaceuticals in tissue.73  
A steady increase in the number and variety of applications employing MALDI MSI 
technology has increased the pressure for robust methods. Improvements in the 
publication and uptake of standardised, validated methods will be essential for routine 
clinical and biomedical analysis.77 It is common for different research groups to 
optimise analytical methods for their own individual applications. Various stages of 
sample preparation and data acquisition can be adjusted for optimal analysis including: 
tissue thickness, tissue washing, matrix choice, matrix application and instrumental 
parameters.65 Initiatives such as European COST Action BM1104 are working to 
improve guidelines around best practice by comparison and sharing of methods and 
techniques used in different laboratories.78 The introduction of an open access file 
format and conversion software have also opened possibilities for sharing data between 
laboratories; allowing data acquired using different instruments to be viewed and 
analysed.79,80 
Whilst highly successful MALDI MSI methods exist for the high resolution imaging of 
biological tissue, the fundamental requirement for the addition of a matrix compound 
raises the question of how useful and truly ‘untargeted’ MALDI MSI can be. 
Alternative ionisation methods in which the sample can be analysed with little or no 
preparation under ambient conditions could provide a more truthful analysis and 
provide a route towards more robust quantification of targets in tissue. 
1.2.2 Desorption Electrospray Ionisation Mass Spectrometry 
Desorption electrospray ionisation (DESI) mass spectrometry imaging was first 
described in 2004 by Takats et al.81 The technique allows for desorption of gas-phase 
ions from a surface of interest at ambient pressure from the sample in its native 
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environment. DESI analysis involves directing an electrospray ionisation source at the 
surface of interest, see Figure 1.8. Charged droplets impacting on the surface desorb 
soluble species from the sample before entering the mass spectrometer via a carefully 
positioned heated inlet.  
 
Figure 1.8 Illustration of desorption electrospray ionisation mass spectrometry. An 
electrospray ionisation source is directed towards a surface where analytes can dissolve 
into the electrospray droplets which are collected by an extended inlet. 
Over the last 10 years methods have been developed for DESI interrogation of a range 
of biomaterials including thin tissue sections, bacterial biofilms and polymers.41,45,82-89 
DESI mass spectrometry has been used to image the distribution of drugs and lipids in 
rat brain, lung, kidney and testis83, neurotransmitters in porcine and rabbit adrenal 
glands90 and a variety of lipids in human prostate cancer91, human liver 
adenocarcinoma84 and various human brain tumours.92 DESI has also been reported for 
mapping the exchange of metabolites between  Bacillus subtilis and Streptomyces 
coelicolor45 and identification of a range of bacterial species from colonies in petri 
dishes.93 
Several studies aiming to optimise and characterise the capabilities of DESI have been 
reported. Takats et al set out the optimal DESI experimental parameters including 
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sample-to-inlet distance, electrospray parameters and angles between electrospray tip, 
inlet and sample surface.81 Further to this, in 2008 Kertesz et al described an 
investigation into considerations of scanning and surface alignment.94 Green et al used a 
model sample consisting of a thin uniform film of Rhodamine B deposited on glass, to 
further optimise sampling geometry on a sample of uniform composition. 95,96 The 
spatial resolution of DESI is determined by the ‘erosion diameter’ of the sprayer; DESI 
sprayer geometry, solvent system, flow rate and sheath gas pressure all have a direct 
effect on erosion diameter.96 Recently Abbassi-Ghadi et al demonstrated that through 
the use of optimal DESI spray and geometry parameters, highly reproducible spectral 
profiles from a complex, biologically relevant sample could be obtained.97 Typical pixel 
sizes accessible by DESI MSI are in the region 50-250 μm.98  
1.2.3 Liquid-based surface sampling Mass Spectrometry  
1.2.3.1 Liquid extraction surface analysis 
Liquid based surface sampling was first described in 2002 in a report by Van Berkel.99 
In that work, the sampling probe consisted of two capillaries, one inside the other, in 
which solvent is delivered to the surface via the outer capillary and aspirated away 
through the inner capillary towards an ESI source. The solvent forms an interface 
between the sample surface and the probe tip which is known as the liquid micro-
junction (LMJ). Soluble analytes dissolve into the liquid which is aspirated away and 
introduced to the mass spectrometer via electrospray ionisation. The method was 
originally used to sample compounds separated on the surface of TLC plates. In this  
experimental set-up, solvent was delivered to the surface continuously; this was termed 
the liquid microjunction surface sampling probe (LMJ-SSP).100 Coupling of the LMJ-
SSP to a mass spectrometer allowed for the analysis of various small molecules such as 
dyes99 and drugs and their metabolites from tissue samples.101 The concept of sampling 
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a surface by a wall-less liquid microjunction was commercialised by Advion 
Biosciences who incorporated the technology into their Triversa NanoMate nano-
electrospray platform.100 This platform did not operate with a continuous flow of 
solvent but instead used disposable conductive pipette tips which performed both 
extraction and electrospray, see Figure 1.9. This method was termed liquid extraction 
surface analysis (LESA). 
Due to a combination of increased surface area sampled and improved extraction 
efficiency, LESA offers improved sensitivity over other ambient surface sampling 
techniques such as DESI. In addition, LESA has been successfully used in the 
extraction of intact protein species directly from biological samples such as tissue 
sections and dried blood spots (DBS).102-109  
 
Figure 1.9 Schematic illustration of liquid extraction surface analysis. A conductive 
pipette tip is collected by the robotic arm. A portion of solvent is aspirated and the tip 
relocates to the user-defined location on the surface. The solvent is dispensed on the 
surface whilst maintaining contact with the pipette tip. Soluble analytes dissolve into the 
solvent which is then re-aspirated and introduced to the mass spectrometer via 
electrospray ionisation. 
The study of proteins in biological systems is of great interest to the research 
community due to their ubiquity and the important roles they play in many processes. 
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Edwards et al reported the identification of a number of haemoglobin variants from 
neonatal blood samples, which are responsible for various haemoglobinopathies.104 
Schey et al describe the extraction and subsequent identification of proteins from a 
range of tissue types including mouse liver and kidney, and bovine ocular lens.110 Intact 
protein ions can be identified via ‘top-down’ proteomics experiments in which the ion 
of interest is fragmented and a mass spectrum of the resulting fragment ions is acquired. 
Fragment masses can then be searched against a known proteome database. Top-down 
identification provides several advantages over the more established ‘bottom-up’ 
method, in which proteins in a sample are enzymatically digested into peptides before 
the sample enters the mass spectrometer.111 Common problems with bottom-up methods 
include information loss, incorrect assignment of peptides and loss of peptides 
containing post-translational modifications.111 Whilst these issues are somewhat 
overcome through top-down methods, database searching software for top-down 
methods frequently mis-assign fragments and require improvement before top-down 
methods can be applied reliably. 
LESA also offers opportunities for further sample manipulation due to the decoupling 
of desorption/ionisation events. There have been several reports of coupling of LESA to 
HPLC-MS for improved separation, detection and identification of protein 
species.103,109,112 The additional potential for introduction of derivatisation compounds 
or internal standards makes LESA an attractive technique. Whilst LESA-MS does 
provide spatial information, its capabilities as an imaging technique are limited due to 
the area of sample covered per pixel.  
1.2.4 Flow-probe mass spectrometry 
The LMJ-SSP system which incorporates a continuous flow of solvent, a smaller probe 
diameter and the potential for raster sampling could provide a different route towards 
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improved spatial resolution for liquid-based methods. The Flow-probe (see Figure 
1.10), which was based on the LMJ-SSP developed by Van Berkel et al. was recently 
commercialised by Prosolia.49,113 Flow-probe mass spectrometry has been demonstrated 
in the analysis of lipids, drugs and metabolites.49,114-117 Van Berkel and Kertesz 
demonstrated the detection of multiply charged ions by Flow-probe mass spectrometry, 
however the resolution of the mass spectrometer was insufficient to identify the ions.113  
Imaging by the Flow-probe can be performed in spot-mode analysis in which the probe 
does not move while the LMJ is in contact with the surface. The probe analyses discrete 
locations across the surface and an image is reconstructed by relating ion intensity to 
pixel location. Tissue imaging with a pixel size of ~600 μm was reported by ElNaggar 
et al. and Prideaux et al.114,115 This level of spatial resolution was sufficient to establish 
the distribution of drugs within diseased lung tissue. It may also be possible to perform 
imaging in a continuous raster mode which could allow for further improvement of 
spatial resolution; a question which will be investigated in this thesis. 
 
Figure 1.10 Schematic diagram illustrating surface sampling via continuous flow. 
Solvent is delivered to the surface via a capillary at a user defined flow rate. Soluble 
analytes dissolve into the solvent before the solution is aspirated away from the surface 
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via an inner capillary. This solution is introduced to the mass spectrometer via 
electrospray ionisation. 
1.3 Raman Spectroscopy 
The Raman effect was first described in 1928118 and is a commonplace tool in chemistry 
laboratories for the analysis of reaction products, assessment of purity and confirmation 
of chemical identification. A sample is irradiated with an intense monochromatic 
(usually visible) light source. Most incident photons undergo elastic collisions in which 
the energy of the photon remains unchanged, however a small number undergo inelastic 
collisions with sample molecules resulting in a change in rotational or vibrational 
energy of the molecule. After the molecule absorbs energy from a photon, the molecule 
is raised to a higher, unstable energy state (known as the virtual excited state) and 
quickly returns to a lower energy state. If a molecule is initially in the ground state and 
after absorption returns to the ground state the overall energy remains constant. This is 
known as Rayleigh scattering. If however the molecule returns to an excited state then 
the energy of the molecules is increased by +ΔEm or the difference between the ground 
and excited state, see Figure 1.11. Alternatively the molecule could exist in the excited 
state prior to absorption of photon energy. If after promotion to the virtual excited state 
the molecule returns to the ground state the overall energy of the molecule has changed 
by - ΔEm. A change in the energy of the incident photon can be detected and recorded in 
a spectrum known as the Raman spectrum. An increase in energy is detected as a band 
known as the Stokes shift and a decrease is known as the anti-Stokes shift. Due to the 
fact that more molecules exist in the ground state than the excited, the Stokes band has a 
higher spectral intensity.119,120 
26 
 
 
Figure 1.11 Energy level diagram illustrating Raman and Rayleigh scattering. 
A relatively low number of photons go through the Raman scattering process, around 1 
in 108, which accounts for the low sensitivity of techniques relying on spontaneous 
Raman scattering.  Raman microscopy of biological samples can be achieved via 
scanning of the irradiating laser across a surface, but the long integration times required 
for sufficient signal to be acquired severely limit the use of Raman microscopy in 
biology.121 Advances in laser technology and instrumentation have allowed new and 
more sensitive techniques to be developed – which still exploit the fundamental 
principles of Raman scattering.122,123 
1.3.1 Theory of Coherent Raman Scattering 
It is possible to obtain stronger molecular vibrational signals using a phenomenon 
known as coherent Raman scattering (CRS). CRS processes occur when two spatially 
and temporally matched excitation fields are incident upon a sample.123 When the 
frequency difference between these two fields is resonant with a Raman active 
vibration, four major processes occur: coherent anti-Stokes Raman scattering (CARS) at 
two new frequencies, stimulated Raman gain (SRG) and stimulated Raman loss (SRL), 
see Figure 1.12.124 The two latter processes are known as stimulated Raman scattering 
(SRS). If excitation fields are scanned across a sample and the corresponding changes in 
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energy are detected, molecular vibrations from different chemical components of the 
sample can be mapped as an image. This is known as either CARS or SRS 
microscopy.125 SRS microscopy offers several advantages over CARS; firstly, there is 
no non-resonant contribution to the SRS signal which results in a linear relationship 
between intensity and concentration. Secondly, SRS produces signals identical to a 
spontaneous Raman spectrum which simplifies interpretation.124 These features enable 
quantitative chemical imaging. The near-IR radiation used for SRS is ideal for 
biological samples because it causes minimal damage. This non-destructive feature of 
SRS means it can be used to take measurements in vivo and is a step towards in situ, 
real-time, quantitative measurements of biological systems.123,126-132 
 
Figure 1.12 Energy level diagram depicting the stimulated Raman scattering process. 
1.3.2 Stimulated Raman Scattering Microscopy 
A number of applications of SRS microscopy have been reported. Biological analytes 
which have been imaged by SRS include drugs, water, lipids, proteins, nucleic acids and 
DNA.123,126-129,131,133,134 Fast acquisition rates enable near video speed imaging which 
makes possible the monitoring of processes in real time.126,131,133 In 2010, Saar et al. 
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demonstrated the real time in vivo imaging of water, lipids and proteins in skin and 
mapped the penetration of topically applied drug compounds.126 The quantitative nature 
of SRS has been taken advantage of by Fu et al. who determined the concentration of 
melamine, polystyrene beads and PMMA in a mixed system127 and also the 
concentration of a drug in biological cells.128 
 
Figure 1.13 Illustration of the custom-built SRS microscope used in this work: two 
overlapping laser beams are generated by the Nd:YVO4 laser and the laser pumped 
optical parametric oscillator (OPO). The pump beam is modulated at 80 KHz in order to 
distinguish the SRS signal from laser noise. A series of lenses and scanning mirrors 
direct the excitation beam towards the sample. Light exiting the sample is collected via 
the condenser lens onto a photo-diode which is connected to a lock-in amplifier which 
is tuned to the signal at 80 KHz. 
One of the main drawbacks of SRS is its non-specific nature. SRS signals are produced 
by probing chemical bond vibrations which may be common to multiple species – for 
example C-H bonds are common to all lipids, so it is only possible to image ‘lipids’ in 
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general. This becomes increasingly problematic when imaging complex biological 
systems. It is difficult to isolate peaks which are unique to a single chemical compound, 
so attempting to image for example a drug in tissue is very difficult. Judicious choice of 
compounds can somewhat mitigate this problem (for example some Raman active 
modes such as nitrile and carbonyl appear in the biologically ‘silent’ region of the 
spectrum) but this approach has limited applicability. Another problem is caused by 
other absorption phenomena interfering with SRS signal, such as two-photon absorption 
(TPA). This commonly occurs in compounds which are highly absorbing of UV energy, 
such as haemoglobin and chlorophyll.127,135,136 Such interference results in a non-linear 
intensity dependence with concentration – and hence measurements would no longer be 
quantitative. This thesis presents the use of SRS microscopy as a complementary tool in 
combined mass spectrometry imaging experiments and an assessment of its use as a 
quantitative technique. 
1.4 Multimodal methods 
There are numerous reports in the literature of different chemical imaging modalities 
being combined on the same sample - so called ‘multimodal’ imaging.137-140 Several 
reasons exist for pursuing such methods; firstly, it could be possible to use one imaging 
method to understand how another method caused changes to the sample and therefore 
infer qualitative/quantitative information about sampling effects. For example optical 
microscopy is frequently used following MALDI analysis to provide information about 
irradiated regions and pixel size. This enables better characterisation and metrology of 
the technique. The perhaps most widely reported reason for employing multimodal 
methods is to simply combine the advantages of each individual technique and use them 
to provide complementary information from a single sample. The importance of 
executing multimodal MSI workflows on the same or adjacent tissue sections has been 
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recognised in studies seeking to combine mass spectrometry techniques, these will be 
discussed in more detail in the following sections. 
1.4.1 Combined methods to study fundamental processes 
There have been various reports of different imaging methods being combined with a 
second technique in order to probe fundamental processes involved. Several groups 
have used this approach to study the MALDI desorption/ionisation process. Fournier et 
al. imaged various matrix crystals after laser irradiation using white light microscopy 
and scanning electron microscopy (SEM) to assess any resulting morphology 
changes.141 This method is a quick and simple way to visually assess irradiation effects, 
however provides no chemical or quantitative information. Tarzi et al. reported various 
chemical analyses including UV-Vis absorption spectroscopy and H1-NMR of thermally 
treated matrix compounds.142 This allowed for the identification of thermal 
decomposition products of matrices but measurements were not carried out in situ, or on 
samples analysed directly by MALDI. Leisner and co-workers used an in-source, time-
resolved imaging system to capture images of the desorption/ionisation process and 
allow for the elucidation of plume dynamics for two different laser pulse durations.143 
Photoacoustic measurements were used by Soltwisch et al. to study ejection yields 
under different laser wavelength and fluence conditions.144 This provided a measure of 
quantitation of in-source events and allowed ionisation yields to be calculated because 
the amount of material removed from the surface relative to the number of ions detected 
could be measured. As yet, no method combining the ability to quantitatively measure 
changes to the sample surface and simultaneously image surface morphology has been 
reported.  
Combined methods have also been demonstrated by various groups who have sought to 
better understand MALDI sample preparation by imaging the distribution of analytes 
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within single matrix crystals. The incorporation of peptides and proteins has been 
imaged using confocal laser scanning microscopy,145,146 field emission scanning 
electron microscopy,147 and time of flight secondary ion mass spectrometry.148,149 
1.4.2 Combined methods for enhanced analysis 
Through combining techniques such as MALDI and LESA, it is possible to maximise 
the advantages of each and use them in complement. Several examples of such an 
approach exist in the literature, MALDI MSI and LESA MS have been used on adjacent 
tissue sections to study drug absorption into skin; LESA MS was used as a verification 
step to complement the MALDI MSI data.
150
 Quanico and co-workers used a MALDI 
MSI-guided approach to identify regions of anatomical interest. These regions of an 
adjacent section were then analysed by LESA coupled to LC-MS for improved 
sensitivity, resulting in more complete identification of proteins.
151
 Griffiths et al. used 
MALDI MSI and LESA MS to demonstrate that a sample preparation technique for 
improved lipid analysis yielded similar results when two different ionisation methods 
were employed.
13
 The potential for inclusion of internal standards in LESA extraction 
solvents was exploited by Tomlinson et al. who used LESA coupled to nano-
electrospray ionisation and LC-MS to investigate ion suppression effects in MALDI.
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Swales and co-workers demonstrated the complementary capabilities of various MSI 
techniques including MALDI MSI and LESA MS. They employed each on adjacent 
sections of organs from cassette- and discrete-dosed animals and compared their ability 
to detect four different target compounds.
153
 It is important to note that each of these 
methods have employed MALDI MSI and LESA MS on adjacent sections which are 
therefore non-identical. This increases the challenge when attempting to correlate, 
compare or combine the data acquired with each technique. Additionally, this would be 
impossible in situations where no adjacent section is available. 
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Repeat analysis of a single tissue section was reported by Steven et al.
10
 and Garrett et 
al.,
154
 who demonstrated that multiple MALDI MSI datasets could be acquired from a 
single sample, either by taking advantage of remaining matrix after initial analysis or by 
addition of a tissue wash and re-application of matrix. These results show that re-
analysis of tissue samples is an avenue towards obtaining complementary data. The 
importance of executing multimodal MSI workflows on the same tissue section has been 
recognised in studies seeking to combine other mass spectrometry techniques. Eberlin et 
al. reported a method for combining desorption electrospray ionisation (DESI) MSI for 
lipid imaging, MALDI MSI for protein imaging and H&E staining for morphological 
information on the same tissue section.
86
 Eijkel and co-workers performed MALDI MSI 
and SIMS imaging on the same tissue section and outlined a workflow for correlating 
these datasets.
155
 
1.5 Quantification by MALDI MSI 
The development of methods which can be used to provide quantitative mass 
spectrometry images have been the focus of much research. Techniques which could 
provide quantitative data could also be used in combination with methods more 
traditionally used for non-quantitative imaging. During pharmaceutical preclinical 
studies it is necessary to establish absolute quantities of drugs and their metabolites 
within tissues of dosed animals.69 Whole body autoradiography (WBA) or quantitative 
whole body autoradiography (QWBA) is the current preferred method for obtaining 
such information.134,156,157 The technique involves tagging the drug compound with a 
radiolabel which may be imaged to determine the location of the drug. The advantages 
of this method are that it is highly sensitive and can be made quantitative by the use of a 
calibration radiation source; however it is limited by a lack of specificity. These data 
only measure the radiolabel and not the drug itself therefore it gives no indication as to 
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whether the drug has been metabolised. Furthermore, any metabolites which do not 
contain the radiolabel cannot be imaged so accumulation of such metabolites in an 
organ or tissue could be missed. Additionally, the process of tagging the compound of 
interest can be expensive and time consuming and could potentially alter the properties 
of the drug itself.69 One of the biggest advantages of mass spectrometry is its label-free 
nature. Anything present in a sample which can be ionised will be present in the 
spectrum; there is no requirement for a priori knowledge. A single MSI experiment 
could in theory yield the distribution of a drug, its metabolites and colocalised 
endogenous species which could be a biomarker of disease progression, toxicology or 
therapeutic effect.69  
Whilst MSI provides several advantages over traditional methods, ion suppression 
effects and variation in tissue extraction efficiencies present problems when using MSI 
as a quantitative technique. SRS microscopy, as a non-destructive technique whose 
signals are linear in concentration, could be used to quantify targets in tissue. This 
information could then be used to validate relative concentration distributions detected 
using mass spectrometry. This could help lead to a better understanding of ion 
suppression effects observed during mass spectrometry of complex samples and could 
aid validation of current ‘quantitative’ mass spectrometry methods. 
1.6 Sample types used in this work 
Methods in this thesis were developed using a variety of sample types. Tissue from 
control animals was used for initial optimisation studies. Mouse and rat brain thin tissue 
sections are widely used in MSI method development studies due to their abundance of 
lipid and protein species which are readily analysed by techniques such as MALDI and 
DESI. In addition rodent brain is small enough to image full sections relatively quickly 
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and contains easily defined anatomical features which have been well characterised by 
projects such as the Allen Brain Atlas.158 
In addition to control rodent tissue, methods were further developed using drug-dosed 
tissue to demonstrate how such methods could be of use in pharmaceutical research. 
Thin tissue sections from various organs from a rat which had been cassette-dosed with 
four different drug compounds were used. Cassette dosing involves careful selection of 
drug compounds and simultaneous dosing for higher throughput screening of 
physiochemical and pharmacokinetic properties. The potential presence of four different 
drug compounds in tissues provides a good platform from which to assess the relative 
sensitivities of the different techniques studied. 
Whilst many MSI techniques have been developed for tissue imaging purposes, another 
significant area of research is MSI analysis of microbial samples. For the period 2013-
2016, the World Economic Forum has listed the rise of antibiotic- resistant bacteria as 
one of the greatest threats to human health globally.
159-162
 Addressing this complex 
problem requires a better understanding of basic microbial functions such as 
intercellular communication and biofilm formation, pathways to resistance and a large-
scale search for novel therapeutic compounds or anti-microbial substances. Methods for 
the fast and accurate chemical analysis of microbes and their metabolites could aid in all 
three facets of this work.
41,43,45,159
 Ambient mass spectrometry techniques are ideal for 
the analysis of bacterial colonies because they can directly sample living colonies 
growing in petri dishes.
44,163
 Mass spectrometry imaging of bacterial colonies has 
allowed for the mapping of metabolites and could aid in elucidation of pathways and 
processes, many of which remain poorly understood.
41
 Diverse classes of analytes 
including lipids, peptides, and metabolites have been detected from bacterial colonies 
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by ambient MS techniques such as DESI, nano-DESI, LESA and the Flow-
probe.
45,48,49,87,164
  
1.7 Project aims 
This thesis presents the development of methods to provide insight into the metrology 
of MALDI MSI and liquid surface-sampling methods alongside SRS microscopy. 
Additionally, methods for acquiring enhanced information from biological samples 
have been developed. Practical considerations for combination of the techniques are 
presented, such as suitable sample substrate and sample preparation methods. Analysis 
of the same complex, biological sample type and also of specially designed and 
prepared calibration references on each instrument has provided novel information 
pertaining to their capabilities in terms of spatial resolution, chemical identification and 
sensitivity. The specific aims of this project are: 
 To combine MALDI and LESA MSI on the same tissue section and 
evaluate the individual capabilities of each technique in terms of 
spatial resolution, relative sensitivity and breadth of molecular classes 
analysed. This work is presented in Chapter 3. 
 To use SRS microscopy to image MALDI sampling effects on model 
samples which will be designed and prepared in this work. The 
removal of material under different experimental parameters will be 
measured. This work is presented in Chapter 4. 
 To assess how suitable a multimodal MALDI, LESA and SRS method 
for tissue imaging would be and characterize any associated problems. 
This work is presented in Chapter 5. 
 To develop a LESA MS method for the quantification of intact 
proteins from tissue and assess the capabilities and scope of such as 
method. This work is presented in Chapter 6. 
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 To develop methods for the analysis of proteins in tissue using the 
Flow-probe and compare such methods with more established LESA 
methods. This work is presented in Chapter 7. 
 To develop methods for the analysis and imaging of proteins from 
microbiological samples using LESA MS. This work is presented in 
Chapter 8.  
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Chapter 2  
Materials and Methods 
Materials 
Ethanol, methanol, dimethylformamide, acetonitrile and formic acid were purchased 
from Fisher Scientific (Leicestershire, UK). Trifluoroacetic acid was purchased from 
Acros Organics. α-cyano-4-hydroxycinnamic acid (α-CHCA), para-nitroaniline (PNA), 
dihydroxybenzoic acid (DHB), sinapinic acid (SA) and picolinic acid (PA) matrices 
were purchased from Sigma Aldrich (Gillingham, UK) and glass slides from Thermo 
Scientific. Ubiquitin protein standard and stable-isotope labelled ubiquitin (98% atom 
13-C and 15-N) were purchased from Sigma Aldrich (Gillingham, UK). Fresh frozen 
mouse brain tissue was provided by Prof. Steve Watson at the University of 
Birmingham. Cassette-dosed rat tissues, control rat tissues and drug compounds were 
provided by Dr Richard Goodwin at AstraZeneca.  
Methods 
2.1.1 Sample preparation 
2.1.1.1 Tissue preparation 
A cassette-dosed rat was euthanized 2 hours post oral administration (of moxifloxacin, 
olanzapine, erlotinib and terfenadine at 25, 10, 10 and 25 mg/kg respectively). Tissues 
were snap-frozen and stored at -80°C until required. Rat organs were sectioned at a 
thickness of 14 μm and thaw mounted on either glass slides (for MALDI and LESA) or 
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glass coverslips (for SRS). Coverslips were turned face-down onto a glass slide and 
sealed with nail varnish to protect the sample from objective lens immersion oil. Control 
mouse brain tissue was sectioned (Leica CM 1850 Cryostat, Milton Keynes, UK) at 10 
µm thickness and thaw-mounted onto glass slides. Mimetic tissue models were 
sectioned at 14 μm and thaw-mounted onto glass slides. 
2.1.1.2 Tissue preparation for MALDI MS analysis 
Tissue sections were coated with CHCA or PNA matrix (5 mg/mL in 80% MeOH, 0.1% 
TFA) using a TM-Sprayer (HTX Technologies, LLC). Matrix was sprayed with a flow 
rate 0.115 mL/min and track speed of 1333 mm/min. The capillary temperature was 90 
°C and the spacing between tracks was 3 mm. A total of 8 spray cycles were used to 
deposit matrix. 
2.1.1.3 Model sample preparation 
Model samples for analysis by MALDI and SRS were prepared using a TM-Sprayer 
(HTX Technologies, LLC). Thin films of various drug and matrix compounds were 
deposited on glass coverslips (thickness 170 μm).  
2.1.1.4 Preparation of bacterial samples 
A strain of Escherichia coli K-12 was inoculated onto solid LBA medium (LB 20 g L
-1
 
Agar 20 g L
-1
) in 6 cm diameter petri dishes. The smaller size of petri dish allows it to 
fit inside the sample tray of the Advion TriVersa NanoMate system. Bacteria were 
incubated at 21 °C for 3 days before storing in the dark at 4°C or were allowed to grow 
at room temperature on the bench and were stored at room temperature (~20 °C). The 
solvent system for surface sampling/electrospray ionisation consisted of acetonitrile 
(J.T. Baker, The Netherlands) and water (J.T. Baker, The Netherlands) (39.6:59.4) with 
1% formic acid (Sigma-Aldrich Company Ltd., Dorset, U.K.).  
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2.1.2 Analytical Techniques 
2.1.2.1 Liquid extraction surface analysis 
Surface sampling was performed using a TriVersa Nanomate chip-based electrospray 
device (Advion, Ithaca, NY). The electrospray device was coupled to a Thermo Fisher 
Orbitrap Velos (Thermo Fisher Scientific, Bremen, Germany) instrument. The robotic 
system was controlled through LESA Points and ChipSoft 8.3.3 software. The sample 
was mounted in the LESA universal adaptor plate and scanned using an Epson flatbed 
scanner. The scanned image was imported into LESA Points and the sampling locations 
were defined. Sampling locations were selected with an x,y spacing of 1mm, covering 
the whole tissue section. For contact LESA the z coordinate was set to a height 0 mm 
relative to the sample surface. For ‘non-contact’ LESA experiments, the pipette tip 
descended to a height ~0.2 mm above the surface of the sample. The solvent system for 
extraction and electrospray was methanol, water and formic acid (69.3:29.7:1). The 
robotic arm collected a conductive pipet tip and aspirated 0.7 µL of solvent from the 
reservoir. The arm relocated to the x,y coordinates specified by LESA Points software. 
The pipette tip descended to the predetermined height (see above) and dispensed 0.5 µL 
solvent. The liquid microjunction was maintained for 4 seconds before re-aspiration. 
Each sample was delivered for 1 minute via the Triversa Nanomate with a gas pressure 
of 0.3 psi and a tip voltage of 1.4 kV. Positive ion mass spectra were acquired in full 
scan mode (m/z 150-2000) at a resolution of 100 000 at m/z 400. The Automatic Gain 
Control was turned off and the injection time fixed at 100 ms. Each scan was comprised 
of 5 coadded microscans.  
2.1.2.2 MALDI mass spectrometry imaging 
MALDI MS imaging was carried out on a QSTAR XL QqTOF mass spectrometer (AB 
Sciex). An Elforlight (Daventry, UK) Nd:YAG laser with λ=355 nm was coupled to the 
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MALDI source via a 100 µm diameter fibre (OZ Optics Ltd) and was operated at a 
frequency of 1 kHz. The fluence at the sample surface was ~120 J m
-2
. The sampling 
raster speed was 0.2 mm/s. Data were acquired in positive ion mode with a pixel size of 
100 x 100 µm or 50 x 50 µm. 
2.1.2.3 DESI MS analysis mouse brain tissue 
Mouse brain tissue was sampled using a Prosolia DESI source coupled to a Thermo 
Fisher Orbitrap Velos (Thermo Fisher Scientific, Bremen, Germany) instrument. The 
solvent system used was 1:1 dimethylformamide:acetonitrile, delivered with flow rate of 
1 μL/min and a nebulising gas pressure of 175 psi. The electrospray voltage was 5 KV 
and the inlet capillary temperature was set to 300°C. Raster speed was set to 88.88 μm/ 
sec, which corresponded to a pixel size of 200 μm in the x-dimension. Positive ion mass 
spectra were acquired in full scan mode (m/z 650 - 1000) at a resolution of 100 000 at 
m/z 400. The Automatic Gain Control was turned off and the injection time fixed at 500 
ms. Each scan was comprised of 1 single microscan. Optical images were acquired after 
DESI analysis. The section and an adjacent control section were then prepared and 
analysed by MALDI mass spectrometry imaging under the same conditions outlined 
above. 
2.1.2.4 SRS microscopy 
SRS images were acquired using a custom-built system operated with an Nd:YVO4 
laser and a tunable OPO. This involves two collinear laser beams focussed to a single 
focal point; the Stokes beam has a wavelength of 1064 nm, the Pump beam can be tuned 
between 790-950 nm. The resulting signal was detected by a lock-in amplifier. The 
Stokes beam was modulated at high frequency (80 MHz) in order to distinguish SRS 
from low frequency laser noise. A series of scanning mirrors direct the beam at the 
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sample and scan in x,y and z dimensions to produce 3-dimensional image stacks. 
Sample regions were selected by white light microscopy prior to SRS. Integration times 
were optimised for each individual sample/analyte.  
2.1.2.5 UV-Vis absorption spectroscopy 
UV-Vis absorption spectra of matrices were acquired using a Lambda 850 
(PerkinElmer) spectrometer.  
2.1.2.6 Hematoxylin and Eosin Staining 
H&E staining was performed by Epistem according to standard protocols. 
2.1.2.7 Optical Microscopy 
Optical microscopy was performed on a Pathscan Enabler IV slide scanner and an 
Olympus CX40 microscope fitted with 5, 10 or 20x magnification objective lenses. 
2.1.3 Image Generation 
2.1.3.1 LESA 
A separate RAW file was generated for each LESA experiment (corresponding to a 
single pixel), consisting of multiple scans. Data were converted from RAW to mzML 
using msconvert as part of ProteoWizard.
165
 The mean spectrum within a single mzML 
file (for each pixel) was calculated and output to a new mzML file, resulting in a 
spectrum per pixel. These were combined, along with the spectra locations, into an 
imzML file using imzMLConverter to produce an MS image. 
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2.1.3.2 MALDI 
WIFF files generated by the QSTAR XL QqTOF mass spectrometer were converted to 
mzML files using MS Data Converter (AB Sciex). One mzML file was produced per 
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raster line of the image. These were converted to a single imzML file using 
imzMLConverter.
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2.1.4 Data analysis 
2.1.4.1 Multivariate analysis 
Image files (imzML) were viewed and processed using in house software, running in 
MATLAB (R2014b). Memory efficient PCA and k-means (k = 7) were applied as 
described by Race et al.
166
 with the smoothing step in the preprocessing workflow 
modified to dual-pass Savitzky-Golay (window size of 11).  
PC1 and PC2 score images were used in combination to generate a binary mask for 
isolating the on tissue spectra. MALDI MSI on tissue spectra were further reduced by 
selecting peaks from the total spectrum using a gradient based method,
166
 using the 
modified preprocessing workflow described above. NMF (k = 25. MATLAB) and t-
SNE
167
 were applied to the reduced data.  
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Chapter 3  
MALDI and LESA Mass Spectrometry 
Imaging of Biological Tissue 
Work presented in this chapter was published in the following paper: Randall, E. C.; 
Race, A. M.; Cooper, H. J.; Bunch, J. Analytical Chemistry 2016, 88, 8433-8440. This 
is included in Appendix 1.  
3.1 Overview 
Reports of LESA MS imaging in the literature have so far focussed on the detection of 
single classes of analytes.
153
 This chapter presents the optimisation and combination of 
MALDI and LESA MSI for sensitive analysis and high spatial resolution imaging of 
drugs, lipids and proteins in tissue. The method could be suitable for use in pre-clinical 
pharmaceutical studies in which the distribution of drugs alongside endogenous 
molecules is desired.  
In this work MALDI MSI was used to image post-LESA analyte distribution in tissue 
and indicated how LESA sampling had altered the sample composition. Therefore in 
addition to demonstrating the complementary use of LESA and MALDI, this experiment 
provided insight into aspects of LESA sampling such as the area of tissue surveyed and 
variation and spatial precision of sampling. Previously this has only been assessed using 
optical images. A number of multivariate analysis techniques were applied to the 
MALDI MSI data to determine spectral and spatial changes to the sample which 
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occurred as a result of LESA sampling. This analysis indicated how MALDI spectra 
change as a result of LESA sampling. Practical considerations for combining MALDI 
and LESA on the same sample, e.g., the optimal order for sampling are also discussed. A 
further ambient mass spectrometry technique, DESI, which is more traditionally used for 
tissue imaging was also assessed by the combined MALDI method and results were 
compared with those from LESA.  
3.2 Experimental 
3.2.1 Tissue sample preparation 
Tissue was prepared as described in section 2.2.1. One section of mouse brain was 
spotted with 4 x 0.1 μL of 2 mM solutions of erlotinib, propranolol and verapamil. The 
section which was destined for imaging by LESA-MS was spiked with 0.3 μL 200 nM 
erlotinib solution (80/20 methanol/water).  
3.2.2 Optimisation of MALDI MS analysis of drug compounds 
Solutions of nine different drug compounds (erlotinib, propranolol, verapamil, imatinib, 
amiodarone, retinoic acid, tiotropium bromide, neratinib and moxifloxacin) were made 
up to a final concentration of 2 mM in 80:20 methanol:water solvent. Matrix solutions 
(α-CHCA, PNA, DHB, SA and PA) were made up to a final concentration of 50 mM in 
80:20 methanol:water solvent with 0.1% trifluoroacetic acid modifier. Stainless steel 
MALDI target plates were spotted with 0.3 μL of each drug/matrix combination, 3 
repeats of each combination were deposited. MALDI data were acquired in positive ion 
mode with 1 second accumulation time and 5 scans coadded per spectrum. The average 
ion intensity across 3 repeats was plotted for the [M+H]+ ion of each drug compound. 
MS/MS spectra of erlotinib were acquired between m/z 50 and 410 via fragmentation in 
the collision cell with a normalised collision energy of 35%. 
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3.2.3 Liquid extraction surface analysis 
LESA sampling was performed as described in section 2.2.4. A grid of 108 sampling 
locations was selected with an x,y spacing of 1mm, covering a single mouse brain tissue 
section. 
3.2.4 MALDI mass spectrometry imaging 
The tissue section which had been imaged by LESA MS and a control section placed 
adjacent on the slide were coated with CHCA matrix as described in section 2.2.2. 
MALDI data were acquired as described in section 2.2.5, with a pixel size of 100 x 100 
µm. In a repeat experiment the same data were acquired from a replicate sample with a 
pixel size of 50 x 50 μm. 
3.2.5 DESI MS analysis mouse brain tissue 
A section of mouse brain tissue was imaged using the DESI method described in section 
2.2.6. This section, along with a control section placed adjacent on the slide was coated 
with CHCA matrix as described in section 2.2.2. MALDI data were subsequently 
acquired as described in section 2.2.5, in positive ion mode with a pixel size of 100 x 
100 µm.  
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3.3 Results and Discussion 
3.3.1 Selection of suitable pharmaceutical compound 
A study was conducted to select a suitable drug compound which could be used in 
combined MALDI and LESA experiments. A list of possible compounds was identified 
from the literature, see Table 3.1. The suitability of these drugs for use in Raman 
spectroscopy and SRS microscopy was also considered, this will be discussed in more 
detail in Chapter 4. 
Table 3.1 List of drug compounds identified from the literature as used in chemical 
imaging experiments. 
Drug 
compound 
Molecular structure Drug target/use Reference of use in 
chemical imaging  
Erlotinib 
 
Tyrosine kinase 
inhibitor, used to 
treat certain types of 
cancer. 
 SRS 
microscopy of 
colon cancer 
cells 
168
 
 MALDI MSI 
169,170
 
Amiodarone 
 
Antiarrhythmic used 
in treatment of 
cardiac 
dysrhythmias.  
 Raman 
spectroscopy
171
 
 SIMS 
imaging
172
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Drug 
compound 
Molecular structure Drug target/use Reference of use in 
chemical imaging  
Moxifloxacin 
 
Antibacterial agent  MALDI MSI
173
 
 Raman 
spectroscopy
174
 
Retinoic acid 
 
Used as a topical 
formulation  in 
treatment of various 
skin conditions 
 MALDI MSI 
(as matrix)
175
 
 SRS 
microscopy
123
 
Tiotropium 
bromide 
 
Anticholinergic 
bronchodilator 
 MALDI MSI176-
178
 
Imatinib 
 
Tyrosine-kinase 
inhibitor 
 Atmospheric 
pressure 
MALDI MSI
179
 
 SRS 
microscopy
128
 
Propranolol 
 
Beta blocker  LESA MS
112
 
 DESI MS180 
 MALDI MSI75 
Verapamil 
 
Calcium channel 
blocker used to treat 
 Laser ablation 
electrospray 
(LAESI) MS
181
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Drug 
compound 
Molecular structure Drug target/use Reference of use in 
chemical imaging  
hypertension. 
 
Analysis of each compound listed in Table 3.1 was performed by MALDI mass 
spectrometry with a selection of matrix compounds commonly used for the analysis of 
drugs and tissue.10,15,182-187 Droplets of each drug and matrix solution were deposited on 
MALDI target plates. Both the total number of moles of each drug deposited and the 
molar ratio of analyte:matrix were kept constant for each combination. Average ion 
intensity detected for the protonated species of each drug (n=3) is plotted in Figure 3.1. 
Erlotinib was found to exhibit the highest ion intensity with almost every matrix 
compound; in addition ions of erlotinib were detected in the absence of a matrix. 
Erlotinib, in addition to propranolol and verapamil, were identified as suitable 
candidates for further study. Interestingly the lowest ion yields were obtained for 
experiments using retinoic acid which is contrary to its reported use as a matrix 
compound.175 An example MALDI mass spectrum (acquired using CHCA) is presented 
in Figure 3.2. CID of parent ions detected with m/z 394.2 confirmed the detection of 
erlotinib, with characteristic fragment ions170 detected at m/z 336.1 and 278.8, see 
Figure 3.2.  
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Figure 3.1 MALDI mass spectrometry analysis of selected drug compounds in 
combination with a variety of matrices, each data point represents the average of three 
repeats, errorbars represent ±1 standard deviation. 
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Figure 3.2 Top: MALDI mass spectrum acquired from sample of erlotinib in 
combination with CHCA, ions with m/z 394.2 correspond to [M+H]+ ions of erlotinib. 
Bottom: MS/MS spectrum of parent ions with m/z 394.2, major fragment ions were 
detected with m/z 278.8 and 336.1 confirming the detection of erlotinib. 
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The three drug compounds identified as suitable for MALDI analysis were then used in 
a further experiment to establish whether they could be detected in a complex biological 
mixture. Erlotinib, propranolol and verapamil were spotted onto sections of mouse brain 
tissue; the tissue was coated with α-CHCA matrix and imaged using MALDI MSI, see 
Figure 3.3. Both erlotinib and verapamil were detected as the protonated species as well 
as the potassium adduct, due to large amounts of potassium and sodium in biological 
tissue. No ions were detected with m/z corresponding to ions of propranolol.  
 
Figure 3.3 MALDI MS imaging of drug compounds in mouse brain tissue: a) diagram 
of location of spiked drug compounds 1) erlotinib, 2) propranolol, 3) moxifloxacin, 4 
spots of each compound were deposited, b) ion intensity map of ions with m/z 826.6 
tentatively assigned as [M+K]+ phosphatidylcholine lipid (PC 36:1), c) ion intensity 
map of ions detected at m/z 432.2 assigned as [M+K]+ ions of erlotinib, d) ion intensity 
map of ions with m/z 493.4 assigned as [M+K]+ ions of verapamil, e) example single 
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pixel spectrum acquired from tissue region spiked with erlotinib, the majority of ions 
detected in the region m/z 700 – 850  are lipid ions, f) overlay of ions in b,c and d. 
3.3.2 Optimisation of LESA MS analysis of mouse brain tissue 
Erlotinib was selected as a potentially useful compound due to successful detection by 
MALDI from tissue and its reported usefulness in SRS microscopy studies.128 A further 
sample of mouse brain tissue was spiked with erlotinib for analysis by LESA mass 
spectrometry. An example LESA mass spectrum from drug spiked tissue is displayed in 
Figure 3.4. These data demonstrate for the first time that multiple analyte classes can be 
detected and analysed simultaneously by LESA MS.  Erlotinib, heme, a variety of PC 
lipids and ubiquitin were all detected in a single extraction/electrospray event. 
 
Figure 3.4. Example LESA mass spectrum acquired from erlotinib spiked mouse brain 
tissue. Erlotinib was detected as the [M+H]+ ion at m/z 394.1779, heme was detected at 
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m/z 616.1797, ions in the range m/z 700-900 are tentatively assigned as various PC 
lipids and ubiquitin was detected in a variety of charge states including (+10) shown 
inset at m/z 857.3751. 
3.3.3 Optimisation of MALDI sample preparation 
Sample preparation is a critical stage in MALDI MSI analysis and can have a large 
effect on results and experimental success. The choice of matrix application method is 
of particular interest for mass spectrometry imaging due to the balance which must be 
struck between efficient analyte extraction and preservation of analyte location. 
Solvent-free matrix application – often achieved by sublimation – can provide images 
with high spatial resolution and good retention of spatial integrity.186 However in 
pharmaceutical studies sensitivity is often critical and molecules of low abundance such 
as drugs might not be successfully extracted via solvent-free matrix application 
methods. In this work a TM-Sprayer (HTX Technologies, LLC) was used for matrix 
application. This system deposits user-defined quantities of matrix onto the surface via a 
heated nebuliser. The ‘wetness’ of the spray can be controlled via spray temperature, 
proportion of organic solvent composition, speed of spray travel and flow rate. Each of 
these parameters was used at its maximum recommended value in order to provide as 
dry a deposition as possible (i.e. high temperature, high organic solvent composition, 
maximum speed of travel and minimum flow rate). A sample of mouse brain tissue was 
coated using this method and optical images were taken after each cycle of coating – up 
to a final number of 8 cycles, see Figure 3.5. Visual analysis of these images suggests 
that complete coverage is achieved after 5/6 cycles of this deposition method. A slight 
change in crystal morphology at the edge of the tissue suggests that some residue from 
the tissue has been incorporated into matrix crystals beyond the tissue boundary. This 
region extends ~30 μm from the tissue edge. After one cycle of matrix deposition 
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crystals have an approximate diameter of 10 μm.  The morphology of crystals formed 
on glass and tissue is very different. CHCA on glass forms small regular individual 
crystals whereas individual crystals on tissue are not clearly discernible. An important 
point of note is that crystals are smaller than the 50/100 μm pixels used for MALDI 
imaging experiments. If crystals are larger than the laser spot size or pixel size it cannot 
be assumed that the spatial location of analytes within tissue has been maintained.  
 
Figure 3.5 Optical images of mouse brain tissue after deposition of subsequent cycles or 
‘passes’ of matrix. All images are presented on the same scale. 
Visual analysis of tissue images provides an indication of crystal sizes and surface 
coverage but only mass spectrometry analysis can provide information about efficiency 
of analyte extraction. The sample prepared with increasing amounts of matrix was 
analysed by MALDI MSI to assess the number of ions detected under different sample 
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preparation methods, see Figure 3.6. A number ion images are presented in Figure 3.6; 
including various ions identified as PC lipids and characteristic fragment ions including 
the phosphatidylcholine headgroup detected with m/z 184.1. It is clear from these 
images that larger amounts of matrix result in higher numbers of ions detected but also a 
larger degree of lipid delocalization. 
 
Figure 3.6 MALDI MS images of various lipids after application of different amounts 
of matrix, a) illustration of sample, numbers indicate no. cycles of matrix deposition, b-
f) ion intensity maps of ions with m/z 798.6, 772.6, 739.6, 826.6 and 184.1. Increased 
ion intensity towards the top of these images demonstrates how increased amounts of 
matrix aid desorption/ionisation yields. Increased ion intensity in the background 
towards the top also suggests delocalisation of analytes occurs after repeated deposition 
cycles. 
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3.3.4 Combined LESA and MALDI MS imaging experimental design 
A workflow was designed to investigate the combined use of LESA and MALDI MS 
imaging on the same tissue sample. In order to establish a suitable order of techniques, 
serial sections of mouse brain tissue were subject to LESA then MALDI or MALDI 
then LESA analysis as outlined in Figure 3.7. A third serial section was used as a 
morphological reference to which any apparent changes in tissue structure could be 
compared. The mouse brain was spiked with erlotinib prior to analysis in order to assess 
the capabilities of each technique with respect to how useful each would be in 
pharmaceutical distribution studies. 
 
Figure 3.7 Illustration of combined method: 3 serial sections each underwent a different 
workflow. 
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3.3.5 Combined LESA and MALDI MS imaging of drug in mouse brain tissue: 
LESA MS Imaging 
An automated surface sampling routine was defined and implemented using the 
TriVersa Nanomate. The locations selected for LESA sampling are illustrated in Figure 
3.8. Full scan mass spectra were obtained from each sample location (for example, see 
Figure 3.8). This approach demonstrates how LESA-MS is able to detect multiple 
classes of analyte in a single extraction/electrospray event. Peaks in the m/z range 700-
900 correspond to various phosphatidylcholine (PC) lipid ions, preferentially detected as 
the protonated species. Ions detected with m/z 734.5708, 760.5870 and 782.5703 are 
tentatively assigned as protonated molecules of (PC) 32:0 (Δppm = 1.9), (PC) 34:1 
(Δppm = 2.5), and (PC) 36:4 (Δppm = 1.2), respectively. Multiply charged protein ions 
predominantly appear in the m/z range 600 – 1200. Ions centred at m/z 857.5714 (charge 
state +10) are tentatively assigned as ubiquitin (Δppm = 2.1), which has previously been 
detected from mouse brain tissue using LESA MS.
110
 Other protein ions (unidentified) 
were detected with charge states ranging between +7 and +22. The tissue was spiked 
with 0.3 µL of 200 nM erlotinib solution. Taking into account the area over which the 
droplet spread, it is estimated that approximately 4.8 femtomoles erlotinib was present 
per 0.4 mm
2 
(the approximate area covered by a single contact LESA extraction, more 
discussion to follow). The drug was detected in every LESA spectrum sampled from this 
region. Example LESA MS images are displayed in Figure 3.8, indicating the different 
distributions of PC 32:0, ubiquitin, haem and erlotinib, across the tissue section. In this 
work it was found that a LESA solvent system comprising 70% MeOH, 1% formic acid 
is suitable for the simultaneous analysis of singly charged small molecules, multiply 
charged protein species and the drug compound erlotinib, which was detected with m/z 
394.1773 corresponding to [M+H]
+ 
ions.  
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Figure 3.8 LESA MS of mouse brain tissue: a) locations selected for LESA sampling, b) 
example full scan LESA mass spectrum, peaks with m/z in the range 700 – 900 
correspond to lipid ions, enlargements of peaks corresponding to erlotinib (m/z 
394.1773) and ubiquitin (m/z 857.3743) are shown inset, c) circle indicates location 
selected for erlotinib deposition, covering both grey and white matter as indicated using 
H&E stained reference, d) LESA MS image of ions with m/z 184.0739 corresponding to 
the phosphotidylcholine lipid headgroup, e) LESA MS image of ions with m/z 760.5870 
corresponding to [M+H]+ ions of PC 34:1, f) LESA MS image of ions with m/z 
616.1782 corresponding to haem, g) LESA MS image of ions with m/z 857.3743 
corresponding to ubiquitin (+10 charge state), h) LESA MS image of ions with m/z 
394.1773 corresponding to [M+H]+ ions of erlotinib. 
59 
 
3.3.6 Investigations into ‘contact’ LESA sampling 
The spacing between LESA sampling locations was defined as 1mm; the minimum 
distance permitted by LESA Points software. The sampling routine used to acquire this 
dataset was modified to minimise solvent spreading and allow for greater sampling 
precision; the method will be referred to as ‘contact’ LESA. A more detailed discussion 
about the development of the contact method is presented in Chapter 8, and was 
published in Analytical Chemistry.
108
  The method involves bringing the sampling 
pipette into contact with the sample surface prior to solvent dispensation and an 
assumption that the solvent is entirely contained within the pipette tip during sampling – 
‘plugged’ by the sample itself. Optical images of the tissue section after ‘non-contact’ 
(in which only the solvent was allowed to come into contact with the surface and all 
other sampling parameters remained the same) and ‘contact’ LESA demonstrate a 
decrease in relative size of area sampled (spot diameter decreased from ~1158 μm to 
~690 μm), Figure 3.9. These images also highlight un-sampled regions of tissue which 
result from sample spacing of 1 mm and sampling diameter of less than 1 mm. 
Reliability of sampling was found to be improved using contact LESA because there 
was no requirement for formation of a stable liquid microjunction. Sampling precision 
was also found to be improved using contact LESA; the pipette tip walls prevent solvent 
droplet spreading to the same extent observed during normal LESA sampling, although 
some spreading beyond the expected contact area of the pipette tip is still observed.  
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Figure 3.9 Optical images of tissue after LESA sampling: a) optical image of LESA 
sampled region using normal LESA sampling allowing only the solvent to come into 
contact with the sample surface, the sampled region was measured using imageJ and the 
diameter was found to be ~1158 μm, b) optical image of LESA sampled region using 
contact LESA sampling, the diameter of area sampled is measured to be ~690 μm, c) 
optical image taken after contact LESA sampling in which the pipette tip exerted a 
larger force of the tissue, the inner and outer diameter of the pipette tip can now be seen. 
It appears that the solvent spread ~150 um beyond the outer edge of the pipette. 
3.3.7 Combined LESA and MALDI MS imaging of drug in mouse brain tissue: 
Post-LESA MALDI MS Imaging 
After the sample had been imaged by LESA MS, both this section and a serial section 
placed adjacent on the slide were coated with matrix and imaged using MALDI MS. 
There were several reasons for doing this: to provide higher resolution tissue images 
which complement the LESA MS data, to establish whether performing LESA prior to 
MALDI in a multimodal workflow is feasible (i.e., to determine whether MALDI image 
integrity is maintained) and to ascertain whether higher resolution MALDI MS images 
can be used to better understand LESA sampling. The adjacent tissue section served as a 
control and allowed changes induced by LESA sampling to be assessed. 
61 
 
 
Figure 3.10 MALDI MS imaging of tissue after LESA sampling: a) (left) example 
single pixel spectrum, peaks in the m/z range 700 – 900 correspond to lipid ions, (right) 
MALDI MS image of ions with m/z 826.6, tentatively assigned as [M+K]+ ions of PC 
36:1, blue circle indicates region spiked with erlotinib solution, b) (left) overlaid 
MALDI MS ion images of protonated and potassium adduct of PC 36:1, (right) overlaid 
intensity line profiles across centre of one LESA sampled region, plot in pink 
corresponds to [M+H]+ ion intensity which peaks sharply towards the centre of the 
spot, plot in green corresponds to [M+K]+ ions which are more homogeneously 
distributed across the spot. 
The MALDI MSI method was optimised for lipid analysis; an example single pixel 
spectrum from the tissue section which had not been sampled by LESA is displayed in 
Figure 3.10. A number of lipid species were detected in the m/z range 600-900, an 
example ion image (tentatively assigned as PC 36:1) can also be seen in Figure 3.10. 
The lipids were preferentially detected as the potassium adduct. Ions detected at m/zs 
corresponding to the sodium adduct and protonated molecule were also observed but 
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with a lower intensity. In these images it is possible to see the regions which were 
sampled by LESA. These features are generally classified by a region of higher ion 
intensity surrounded by a dark ring in which very few ions were detected. These features 
were not observed in the control image. It would appear that LESA sampling acts as a 
localised tissue wash, enhancing lipid detection via the extraction of analyte to the tissue 
surface and extraction and washing of salts resulting in a concentration gradient – 
highest at the edge of the spot.  The region of tissue which was spiked with erlotinib 
solution appears as a similar although larger feature in the image. This supports the 
theory that analyte extraction, rather than mitigation of suppression effects, is 
responsible for the observed intensity increase because the spiked solution was allowed 
to remain on the tissue and therefore didn’t remove any dissolved species. To further 
probe the distribution of lipid species across the LESA sampled area, a composite ion 
image of the protonated and potassiated molecules of PC 36:1 was generated, and 
intensity line profiles across a single LESA spot were plotted, see Figure 3.10. It was 
found that [M+H]
+ 
ions were preferentially detected towards the centre of the LESA 
sampled area, whereas [M+K]
+ 
ions were more abundant towards the outside or 
homogeneously distributed across the spot. This behaviour was also observed for a 
number of other lipid species. Accumulation of salt at the outer perimeter could also be 
responsible for the ‘dark ring’ observed in MALDI MS lipid images; matrix crystals 
exhibit different morphology when formed from solution containing different 
proportions of salts.
13
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Figure 3.11 Example lipid ion images of protonated, potassium and sodium adducts for 
three PC lipid species, demonstrating the effect of LESA sampling on the distribution of 
multiple lipid species and adducts. 
Optical images of a LESA-sampled tissue section before and after coating with matrix 
are displayed in Figure 3.12. The regions sampled by LESA appear as darker regions 
compared to un-sampled tissue; a circular imprint can be observed in the middle of this 
region which results from the pipette tip coming into contact with the tissue. A larger, 
more irregular dark region surrounds this mark which suggests the solvent spread further 
than the confines of the pipette tip.  
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Figure 3.12 a) Optical image of tissue section after LESA MS, darker regions indicate 
solvent contact with tissue, smaller circle in middle of dark region is caused by imprint 
of pipette tip, b) optical image of LESA sampled region after coating with CHCA 
matrix, lighter region at perimeter of LESA spot indicates thinner crystal layer, c) 
overlaid MALDI MS image of ions with m/z 826.6 and optical image, d) enlargement 
of MALDI MS image of ions with m/z 826.6  to show same LESA sampled region as 
displayed in (b), dark region in ion image corresponds with thinner region of matrix 
crystals in optical image. 
The image displayed in Figure 3.12 demonstrates the size and distribution of CHCA 
crystals on the tissue surface after matrix coating. A region of sparse, thin crystals can 
be seen around the outer edges which correspond with the dark region of the ion image 
displayed in Figure 3.12; suggesting changes to matrix morphology resulting in poor 
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analyte inclusion and subsequent ablation/ionisation are responsible for low ion counts 
from this region. An example MALDI MS image (m/z 826.6) overlaid with the optical 
image demonstrates that regions of higher intensity in the ion image correspond with 
darker regions observed in the optical image, see Figure 3.12.  
MALDI MS ion images reveal details about locations, size and variation of LESA 
sampled areas. Previous work has relied on optical images alone to provide this 
information, whereas this method provides mass spectral data which verifies visual 
changes to the tissue correspond with spectral changes indicative of solvent contact. 
Additionally, delocalisation and other changes in analyte distribution within the sampled 
area (which appears as a homogeneous area in the optical image) can be visualised using 
MALDI MSI. Two MALDI MSI datasets were obtained from tissue sampled by LESA, 
with pixel sizes of 100 and 50 μm respectively. Whilst no further features could be 
observed with the increased image detail afforded by 50 m pixels, the outer limits of 
the sampled region could be more accurately defined. As such, MALDI MS images with 
50 μm pixels were used to determine the size of regions sampled by LESA. The average 
area sampled per contact LESA spot is 0.41 mm
2
. Differences in size of these areas is 
caused either by differing degrees of solvent spreading during sampling or differing 
volumes of residual solvent left on the tissue after LESA sampling, or some combination 
of both. The distance between these areas in x and y dimensions varies considerably, as 
indicated by images in Figure 3.12. In order to maximise the total surface sampled by 
LESA in an imaging experiment, individual samples should be taken next to each other 
with as small a gap between them as possible but without overlapping (this would result 
in oversampling which although common practice in MALDI MSI, is inappropriate for 
LESA MS because signal can be acquired multiple times from the same location). The 
spacing required between points for maximum coverage using contact LESA would be 
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~700 μm, providing sampling spatial precision was accurate. However, MALDI MSI 
images reveal that inter-sample distances (measured from centre to centre) vary between 
0.8 and 1.3 mm. Improved positional accuracy of the sampling robot is required to 
improve LESA MS as an imaging technique. 
 
An experiment in which contact LESA was performed without any solvent confirmed 
that solvent washing effects and not compression or damage of the tissue during contact 
were responsible for the observed intensity changes in MALDI images, Figure 3.13.  
 
Figure 3.13 Results after performing LESA with and without solvent: a) locations 
selected for sampling, b-d) example lipid ion images, b) m/z 798, c) m/z 782, d) m/z 760. 
Increases/decreases in ion intensity in LESA sampled regions are only observed when 
solvent is used, therefore it is unlikely that these changes are caused by compression or 
damage of the tissue during contact. 
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3.3.8 Multivariate analysis of MALDI MSI data 
In order to fully assess changes between the LESA-sampled section and serial control it 
is necessary to consider variation of multiple ions simultaneously. This also aids in 
interpretation of MALDI data obtained after LESA sampling. A number of multivariate 
analysis techniques were applied to the data in an attempt to uncover other trends. 
Principal component analysis (PCA) score images are displayed in Figure 3.14. The 
score image of PC1 indicates that the largest source of variance in the dataset is the 
difference between tissue and background. PC5 indicates variance between LESA 
sampled areas and background tissue. PC6 identifies LESA sampling regions on areas of 
white matter but not grey matter. The latter is interesting because it suggests that 
changes associated with LESA sampling do not appear uniformly across the tissue. This 
has implications for any sample preparation procedures which undergo a wash step 
because it implies that inhomogeneous washing occurs across the tissue and therefore 
false contrast could be introduced in ion images. Thresholded PCA score images were 
used as a mask to segment the background from the tissue for further multivariate 
analysis. k-means clustering (K=7) was applied to the PCA-reduced dataset to identify 
pixels with similar spectral profiles and label them with a randomly assigned colour. k-
means clustering successfully separated the different brain anatomies and LESA 
sampled regions on white and grey brain tissue. The results from this analysis are easy to 
interpret and demonstrate agreement with individual lipid ion images. Two clusters are 
identified which are unique to the LESA-sampled tissue section and are labelled red and 
pale blue in Figure 3.14. Clustering, with the parameters used, does separate the outer 
perimeter of these regions into a unique cluster. In general, k-means clustering provides 
no visual indication of how spectrally similar the identified clusters are. t-Distributed 
stochastic neighbour embedding (t-SNE) is a dimensionality reduction technique which 
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has been used in MSI for visualisation of complex datasets.
188
 The colour of each pixel 
is related to its location in the reduced space, thus providing a visual indication of how 
similar two pixels are spectrally. When applied to this dataset, t-SNE reveals very 
similar results for control tissue and unsampled regions of section sampled by LESA. 
The regions sampled by LESA appear significantly different to the unsampled regions, 
with slight differences observable depending on whether the sampled region was grey or 
white matter, see Figure 3.14. Although this data visualisation approach is useful in 
identifying regions of spectral similarity and gradients of change affected by LESA 
sampling, no spectral information about the different regions is provided and therefore it 
is hard to identify which spectral features have contributed. Non-negative matrix 
factorisation (NMF) decomposes the data into a set of unique spatial distributions and 
associated spectral profiles. NMF applied to this dataset identifies a number of spatial 
distributions arising from LESA sampling. The image in Figure 3.14 identifies a 
distribution corresponding to white matter in the tissue sections. Major m/z values 
contributing to this distribution are 798 and 826, which are tentatively assigned as the 
potassium adducts of PC 32:0 and PC 36:1 respectively – i.e. the most abundant lipid 
species detected from mouse brain tissue. The image in Figure 3.14 identifies regions at 
the centre of the LESA sampled regions; examination of individual ion images revealed 
that protonated molecules of lipids were detected with higher intensity here. Peaks with 
m/z 760 and 788 (tentatively assigned as protonated molecules of PC 32:0 and PC 36:1 
respectively) are identified by NMF as major contributors to this distribution, supporting 
conclusions drawn from manual analysis.  
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Figure 3.14 Results from multivariate analysis: a-c) score images of principal 
components 1, 5 and 6 respectively, principal component 1 indicates that the greatest 
variance is between tissue and background, principal component 5 indicates variance 
between LESA sampled areas and the rest of the tissue, principal component 6 indicates 
that LESA sampled regions on white matter are more different from the original tissue 
type than those from grey matter, d) k-means clustering (k=7) on masked image to 
remove background, the same clusters corresponding to anatomical features within the 
tissue are found in both LESA sampled tissue and the control section indicating that 
LESA only induced localised changes, these are identified as different clusters in grey 
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and white matter, further clusters identify the outer perimeter of LESA sampled regions, 
e) t-SNE reveals the same clusters identifying different tissue anatomies in LESA 
sampled tissue and control tissue, LESA sampled regions are assigned different clusters 
depending on the original type of tissue however these are more similar to each other 
than the original type of tissue, the region where the drug was spiked is also similar to 
the LESA sampled regions but more similar to the original tissue type presumably 
because the solvent was not removed from the tissue and therefore didn’t deplete the 
tissue in the same way, f) examples of three factors identified by NMF, their spatial 
distributions and contributing spectral components. 
3.3.9 Investigation into normalization strategies for MALDI MSI data 
It was found that features introduced into some MALDI MS ion images can be largely 
removed via total intensity normalisation, see Figure 3.15. For other ion images this 
normalisation strategy is less successful, see Figure 3.15. This is to be expected based 
on asserted changes to distribution of lipid adducts. An understanding of MALDI mass 
spectral changes associated with LESA sampling could help inform more sophisticated 
and appropriate normalisation methods – for example, factors identified by NMF could 
be used to correct for changes in intensity and distribution. 
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Figure 3.15 MALDI MS image of ions with m/z 826.6 before and after normalisation 
using various different strategies as indicated. 
3.3.10 Combined LESA and MALDI MS imaging of drug in mouse brain tissue: 
Post-MALDI LESA MS sampling 
In order to determine the ideal order of techniques in a multimodal workflow, the 
control section imaged by MALDI MS was subjected to LESA MS. The same sampling 
and mass spectrometry parameters were used as before. Full scan mass spectra were 
obtained from discrete locations across the tissue section. It was found that the low m/z 
range (150-500) was dominated by peaks corresponding to matrix ions and matrix ion 
clusters. The m/z range was adjusted to 500-2000 to account for this. Localised washing 
of the tissue with ethanol/water (50/50 v/v) via LESA sampling (to remove matrix) prior 
to sampling with the usual methanol solvent was found to slightly reduce spectral 
complexity and increased the intensity with which some lipids were detected, but had 
little effect on the number and type of lipid species observed, see Figure 3.16. All of the 
most abundant lipid species detected by LESA MS prior to MALDI MS were detected 
post-MALDI MS, again predominantly as [M+H]
+ 
ions. This observation is surprising, 
the addition of matrix is expected to introduce additional salts to the sample. It was 
found that no multiply charged protein ions were detected in LESA mass spectra in the 
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presence of matrix. Washing the tissue with ethanol or methanol and reducing the acid 
content of the solvent system did not enable protein desorption/ionisation.  
 
 
Figure 3.16 Example LESA mass spectrum from tissue analysed by MALDI MS before 
and after washing tissue with ethanol. Lipid ion intensity is improved after the wash 
step, no protein ions were detected from this sample. 
3.3.11 MALDI MSI analysis of DESI sampled tissue 
The combined method was extended to investigate a different ambient MSI technique. 
DESI MSI is a commonly used mass spectrometry imaging technique which benefits 
from operation under ambient conditions in addition to good spatial resolution. An 
experiment in which MALDI MS was performed on tissue which had been previously 
analysed by DESI was designed. MALDI MS images of various lipids are displayed in 
Figure 3.17. No significant enhancement of lipid ions in regions analysed by DESI is 
observed. This suggests that DESI extraction is not as efficient as LESA and could be 
responsible for the lower sensitivity of DESI and the inability to detect larger species. 
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Figure 3.17 MALDI MS imaging of DESI sampled tissue: a) location of DESI sampled 
areas, b) optical image of tissue after DESI sampling, lateral resolution was measured as 
approximately 510 µm, c) MALDI MS image of ions with m/z 798.6 overlaid with 
single line ion image acquired by DESI MS (also m/z 798.6), d) MALDI MS image of 
ions with m/z 826.6 at various magnifications, no obvious delocalisation or 
enhancement of intensity by DESI is observed. 
3.4 Conclusions 
A combined workflow is presented which exploits the advantages of LESA and MALDI 
MSI and additionally provides insight into aspects of ambient surface sampling. For the 
first time LESA has been used for the detection of a drug compound, lipids and proteins 
simultaneously. MALDI provided high spatial resolution images which detailed the 
exact locations sampled by LESA allowing for the registration of data from both. This 
has important implications for pharmaceutical research; high resolution MALDI images 
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can be used to detail exactly where drug, lipid and protein signals originated from. 
Several multivariate techniques were employed to assess changes to distribution 
induced by LESA. Future implementations of MALDI MSI after LESA analysis could 
assess different washing protocols, or how the same wash affects different regions of 
tissue. This could also be used to assess improvements or changes made to the 
automated LESA sampling routines described here, for example to determine the 
spacing of sampled areas and ensure that no oversampling had occurred. LESA MS is 
somewhat limited as an imaging technique by the poor spatial resolution it affords, 
however there are opportunities for further decreasing pixel size via contact LESA and 
smaller sampling pipette tips. As the technique improves in terms of sampling precision 
and repeatability, combining with MALDI will become an even more attractive option. 
The potential for inclusion of standards by LESA is also attractive, and provides 
possible routes towards quantitative analysis. The combined LESA-MALDI MSI 
workflow could then be applied to drug in tissue studies which could provide 
quantitative analysis of drug/lipid/protein via LESA and a higher spatial resolution 
reference in MALDI MS images. 
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Chapter 4  
SRS Microscopy of MALDI Sample 
Preparation and Sampling Effects 
4.1 Overview 
In the previous chapter it was demonstrated that MALDI MS ion images of LESA 
sampled tissue can provide information about LESA sampling effects. The work 
presented in this chapter uses a similar approach to investigate how a higher resolution, 
quantitative imaging technique could be used to provide insight into MALDI sample 
preparation and sampling effects. Various aspects of MALDI sampling remain unclear; 
better understanding of ionisation processes, the behaviour of different matrices and 
combinations of matrix and laser parameters are of primary importance for successful 
analytical applications of the technique.189 Insight into these parameters could lead to 
optimum analysis in terms of improved limits of detection for a wider variety of 
analytes and could be instrumental in the drive towards higher-throughput analysis.10 
SRS microscopy has been used for a number of successful imaging applications in 
biology and has been demonstrated as a quantitative technique.123,126-129 This chapter 
presents an investigation into the use of SRS microscopy for imaging and quantification 
of samples analysed by MALDI MS. The preparation of model samples of analyte and 
matrix compounds deposited on glass, and assessment of their use in fundamental 
MALDI MS studies is also discussed. 
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4.2 Experimental 
4.2.1 Preparation of model samples 
4.2.1.1 PNA sample for calibration: 
Thin films of PNA were deposited on glass coverslips. A solution of PNA (5 mg/mL in 
80:20 MeOH:H2O) was sprayed at a flow rate of 0.115 mL/min, track speed of 1333 
mm/min, track spacing of 3 mm and a spray nozzle temperature of 90°C. One cycle of 
this deposition method was applied before a mask was used to cover a 5mm portion of 
the slide. Another cycle was applied and the mask was moved 5 mm after each 
subsequent cycle. The coverslip was turned face down onto a glass slide and sealed at 
the edges with nail varnish to protect the sample from the objective lens immersion oil. 
4.2.1.2 Fluence response study: 
For the study into fluence response combined thin films of PNA and erlotinib were 
prepared on glass coverslips using the TM-Sprayer method described in section 2.2.1.1. 
The total amount of erlotinib deposited was 0.42 μg/mm2, total PNA was 1.15 μg/mm2. 
4.2.1.3 Repetition rate response study: 
Thin films of erlotinib and PNA and erlotinib and SA were prepared on glass coverslips 
using the TM-Sprayer method described in section 2.2.1.1. The molar ratio of 
analyte:matrix was fixed at 1:100 for both samples and the total amount of analyte was 
also fixed. The total amount of erlotinib deposited on each sample was 0.184 μg/mm2, 
total PNA was 6.46 μg/mm2, and SA was 10.5 μg/mm2. 
4.2.2 Spontaneous Raman spectroscopy 
Spontaneous Raman spectra of matrix compounds were acquired using a custom built 
system. Samples were irradiated using a frequency doubled Nd:YAG laser (λ=532.5 
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nm) the integration time was optimised for each matrix compound: CHCA: 10 s, SA: 10 
s, DHB 20 s. The spontaneous Raman spectrum from erlotinib was acquired using a 
Renishaw instrument, the sample was irradiated at 633 nm with a 30 second integration 
time. 
4.2.3 SRS microscopy of PNA calibration sample 
SRS images were acquired as described in section 2.2.2.4. 3 regions of 75 x 75 μm were 
selected and a stack of 10 images spanning 10 μm in the z-dimension was acquired for 
each region. The pump beam was tuned to 1110 cm-1 and an integration time of 0.1 ms 
was found to give sufficient image contrast. The total summed intensity in each image 
region was calculated along with the mean image intensity over 3 regions. To produce 
the calibration curve, mean image intensity was plotted against number of molecules 
deposited as calculated from the TM-Sprayer method. Linear regression analysis was 
performed on these data. 
4.2.4 MALDI MS for fluence response study 
A thin film of erlotinib and PNA described above was fixed into the MALDI plate 
holder and placed in the ion source. A frequency tripled Nd:YAG (355 nm) laser was 
coupled to the source via a 100 μm core fibre, the laser was triggered by a function 
generator (TTi – TG2000 20 MHz DDS) at a frequency of 1 KHz. The energy delivered 
per pulse was controlled by a variable attenuator (Motorized Watt Pilot; Altechna, 
Lithuania) and measured using a pyroelectric sensor (PD10-C, Ophir Photonics). Laser 
beam spot size was calculated by measurement of the fluorescent region of an irradiated 
sample of CHCA. The stage raster speed was also held constant at 0.2 mm/second. Data 
were acquired in the positive ion mode in the m/z range 50 - 1000. Single line raster 
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images were acquired at a range of laser fluences (34.22, 61.58, 89.45, 117.51, 145.34, 
173.92, 201.80 and 229.60 J m-2) with a lateral resolution of 100 μm.  
4.2.5 SRS microscopy for fluence response study 
The sample described above was removed from the mass spectrometer and turned face-
down on a glass slide and sealed with nail varnish. SRS images were acquired from 3 
regions of each irradiated region and one non-irradiated region. For each image region 
(50 x 50 μm, 10 images spanning 10 μm in the z-dimension) 2 sets of images were 
acquired, one tuned to the resonance frequency of PNA (1110 cm-1) and one to erlotinib 
(2110 cm-1). The total summed intensity in each image region for each compound was 
calculated along with the mean image intensity over 3 regions.  
4.2.6 MALDI analysis for repetition rate response study 
Thin films of erlotinib and PNA or SA were fixed into the MALDI plate holder and 
placed in the ion source. An Nd:YVO4 (355 nm) laser was coupled to the source via a 
100 μm core fibre, the laser was triggered by a function generator (TTi – TG2000 20 
MHz DDS) at frequencies of 1-6 KHz. The energy delivered per pulse was kept 
constant across all repetition rates and was controlled by a variable attenuator 
(Motorized Watt Pilot; Altechna, Lithuania). The stage raster speed was also held 
constant at 0.2 mm/second. Data were acquired in the positive ion mode in the m/z 
range 50 - 1000. Single line raster images were acquired for each repetition rate 
(1,2,3,4,5,6 KHz) on each sample with a lateral resolution of 100 μm.  
4.2.7 SRS microscopy for repetition rate response study 
Samples were removed from the mass spectrometer and turned face-down on a glass 
slide and sealed with nail varnish. SRS images were acquired from 3 regions of each 
irradiated region and one non-irradiated region of each sample. For each image region 
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(50 x 50 μm, 10 images spanning 10 μm in the z-dimension) 2 sets of images were 
acquired, one tuned to the resonance frequency of PNA (1110 cm-1) or SA (1644 cm-1) 
and erlotinib (2110 cm-1). The total summed intensity in each image region for each 
compound was calculated along with the mean image intensity over 3 regions.  
4.2.8 Spontaneous Raman spectroscopic imaging 
Spontaneous Raman mapping of erlotinib/SA irradiated thin film was performed using a 
custom built system. Samples were irradiated using a frequency doubled Nd:YAG laser 
(λ=532.5 nm), the integration time was 5 seconds per pixel and the pixel size was 1 μm. 
The total image region covered an area of 40 x 128 μm.  
4.2.9 SRS imaging of matrix-coated tissue 
Mouse brain tissue was coated with DHB as described in section 2.2.1.2. SRS 
microscopy was performed at the resonance frequency corresponding to lipid species 
(2860 cm-1). Images regions of 30 x 30 μm were selected and 10 images spanning 10 
μm in the z-dimension were acquired. An integration time of 2ms per pixel was used. 3-
dimensional image reconstructions were performed in imageJ. 
 
4.3 Results and Discussion 
4.3.1.1 Equivalence of SRS with spontaneous Raman spectroscopy 
Single channel SRS images of a thin film of PNA were acquired over a range of Raman 
shifts (1200-1400 cm-1). The average image intensity was calculated and plotted against 
Raman shift, see Figure 4.1. This trace demonstrates the same peak shape as the 
spontaneous Raman spectrum acquired from another sample of PNA and thus 
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demonstrates that resonance frequencies for SRS interrogation can be determined by 
examination of spontaneous Raman spectra. 
 
Figure 4.1 a) spontaneous Raman spectrum of PNA, b) SRS ‘spectrum’ of PNA 
acquired by calculation of mean image intensity over a selected range of wavenumbers. 
4.3.1.2 Developing a model sample 
In order to perform combined MALDI and SRS analysis on the same sample it is 
important that analytes and matrices are compatible with both types of instrumentation. 
A survey of three commonly used matrix compounds was performed; spontaneous 
Raman spectra were acquired from CHCA, PNA and DHB, see Figure 4.2. Examination 
of these spectra revealed resonance frequencies which could then be probed by SRS. 
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Images of thin films of each matrix compound were acquired at one resonance 
frequency and one off-resonance frequency. As demonstrated by the images in Figure 
4.2, strong off-resonance absorption was observed for CHCA. This would present a 
problem when imaging CHCA in combination with another analyte or tissue because it 
would be impossible to determine the molecular origin of the signal. A low intensity 
off-resonance signal was also observed for PNA. Only very weak signals were observed 
for DHB either on or off-resonance, suggesting that samples coated with DHB crystals 
could be imaged using SRS with confidence that no off-resonance absorption had 
occurred, however it would not be possible to image DHB crystals directly. It is 
possible that CHCA and PNA exhibit off-resonance absorption due to their strong 
absorption of UV radiation, which is of course why they are used in MALDI MS. The 
wavelength of the Stokes beam was 1064 nm and the pump beam was 840 nm (CHCA) 
and 868 nm (PNA). Both CHCA and PNA exhibit a strong absorption band in their UV-
Vis absorption spectra at 350-450 nm,190 therefore when irradiated at 800-900 nm it is 
possible that two-photon absorption occurs.  
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Figure 4.2 Spontaneous Raman spectroscopy and SRS microscopy of MALDI matrices, 
a) CHCA, SRS on-resonance (left image) 2235 cm-1, off-resonance (right image) 2500 
cm-1, b) PNA, SRS on-resonance 1283 cm-1, off-resonance 2115 cm-1, c) DHB, SRS on-
resonance 1665 cm-1, off-resonance 2250 cm-1. 
To further probe the properties of PNA, SRS images of a PNA thin film were acquired 
at a range of Raman shifts which correspond to pump beam wavelengths of 800 – 905 
nm, see Figure 4.3. For comparison, the equivalent region of the spontaneous Raman 
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spectrum of PNA is also displayed. There are no Raman bands in the 2500 – 3100 cm-1 
region of the spontaneous spectrum however the SRS ‘spectrum’ shows increasing 
average image intensity with Raman shift. This increase in intensity corresponds with a 
decrease in pump beam wavelength. As the pump beam nears 800 nm PNA absorption 
increases. Considering the absorption profile of PNA, see Figure 4.3, these data support 
the hypothesis that two-photon absorption is responsible for off-resonance signal. Such 
properties have been reported for a number of chemical species such as chlorophyll and 
haemoglobin.127,135,136 Whilst such absorption phenomena would clearly present a 
problem in the imaging of higher frequency resonances, it would still be possible to 
image resonance frequencies of PNA below 2500 cm-1 with confidence that no off-
resonance absorption had occurred. 
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Figure 4.3 SRS microscopy of PNA thin film, a) SRS spectrum acquired by plotting the 
average image intensity measured at each Raman shift, b) spontaneous Raman spectrum 
PNA, c) UV-Vis absorption spectrum PNA. 
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The suitability of three matrices have now been assessed for use in model samples for 
combined MALDI and SRS studies, a suitable matrix compound has been identified and 
appropriate resonance frequencies have been established. In Chapter 3 the drug 
compound erlotinib was identified as a useful compound for MALDI MS imaging 
experiments. Erlotinib has been reported in a number of SRS microscopy studies and 
has been identified as particularly useful for bio-distribution studies due to the carbonyl 
group which exhibits a strong Raman active mode in the biologically silent region of the 
spectrum. This means that drug and endogenous biological species in the same sample 
can be imaged separately. SRS images were acquired from a thin film of erlotinib 
deposited on a glass slide, see Figure 4.4. SRS spectra surrounding two known 
resonance frequencies of erlotinib168 were reconstructed by calculating the average 
image intensity at each Raman shift. This demonstrates that no off-resonance absorption 
phenomena occur during irradiation of erlotinib at these frequencies.  
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Figure 4.4 SRS images and spectra acquired from erlotinib thin film, a) resonance 
frequency around 2110 cm-1, b) resonance frequency around 1395 cm-1. 
A model sample for combined MALDI and SRS studies requires matrix and analyte 
compounds which can be imaged separately by SRS within a dual-compound thin film. 
Therefore each compound must exhibit unique Raman signals which do not interfere 
with the other. Spontaneous Raman spectra from samples of erlotinib and PNA were 
acquired, see Figure 4.5. A suitable Raman shift for SRS imaging was identified for 
each compound and it was confirmed that neither compound would interfere with the 
other.  
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Figure 4.5 Spontaneous Raman spectra from: a) erlotinib and b) PNA. The red and blue 
lines indicate the Raman shifts selected for SRS imaging of each compound. 
4.3.1.3 Quantitative SRS analysis of MALDI matrix compound 
After careful optimisation and development of a suitable model sample for combined 
studies, several experiments were designed to investigate the use of SRS to probe 
MALDI MS sampling effects. SRS microscopy has been demonstrated to provide 
quantitative data.127 An experiment was designed to establish whether SRS could 
quantitatively measure a sample of known composition. PNA matrix was deposited at a 
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range of concentrations on a glass coverslip, see Figure 4.6. SRS images of PNA (1110 
cm-1) at each concentration were acquired and average image intensity was plotted 
against number of molecules deposited. The number of molecules deposited was 
calculated via equation 4.1, where Md is the mass of matrix deposited per unit area, NP 
is the number of passes or cycles of matrix deposition, Cm is concentration of matrix 
(mg/mL), Fm is the flow rate (μL/min), V is nozzle velocity (mm/min) and TS is track 
spacing (mm). Linear regression was performed and a line fitted to the data with an r2 of 
0.964. The variation observed in the data is likely to be due to inhomogeneity of the 
sample surface which can be observed in white light and SRS images of the sample. 
Reduced error could be acheived by depositing a more uniform layer of matrix, which 
would be difficult using a solvent spray based deposition technique. Sublimation of the 
matrix could provide a more homogeneous layer and smaller crystals, but determination 
of exact quantities deposited would be more complicated by this method. Alternatively, 
larger regions of the sample could be imaged and averaged, however the maximum field 
of view of the instrument used in this work was 80 x 80 μm and therefore numerous 
individual regions would have to be imaged separately which is a lengthy process.  
𝑀𝑑 =  
𝑁𝑃 ∗ 𝐶𝑚 ∗ 𝐹𝑚
𝑉 ∗ 𝑇𝑆
 
4.1 
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Figure 4.6 Quantitative analysis by SRS microscopy: a) preparation of calibration 
reference sample using TM-Sprayer, final concentrations of PNA: 0.14, 0.29, 0.43, 
0.57, 0.72, 0.86, 1.01, 1.16 μg/mm2, b) example white light images of the sample, rings 
of small crystals demonstrate how crystals have formed at the edges of droplets 
deposited on glass, c) example SRS images of PNA sample, each SRS images spans a 
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region of 75 x 75 μm, d) calibration curve, error bars represent ±1 standard deviation of 
the mean, r2 = 0.964. 
4.3.2 SRS analysis of MALDI sampling: fluence response study 
SRS was demonstrated to produce a linear intensity response with concentration for a 
sample of known composition which suggests that the technique could be used to 
provide quantitative measurements from an unknown sample. An experiment was 
devised to study the response of an analyte/matrix system under varied laser fluence, see 
Figure 4.7. Known amounts of erlotinib and PNA were deposited on a glass coverslip 
and then subject to MALDI mass spectrometry using a laser operated at a range of 
fluences. Mass spectra were recorded for each fluence value, the sample was removed 
from the instrument and SRS images were acquired from irradiated and non-irradiated 
regions. The intensity difference observed in different irradiated regions could be 
equated to number of molecules removed because the total number of molecules 
originally deposited was known. The number of molecules removed via MALDI can be 
calculated by equation 4.2. 
𝑚𝑟 =
(𝐼0 − 𝐼𝑛)
𝐼𝑚𝑎𝑥
∗ 𝑚𝑑 
4.2 
Where mr is no. molecules removed, I0 is intensity measured from non-irradiated area, In 
is intensity measured from irradiated area, Imax is the maximum possible range of 
intensity values observed (I0 minus background) and md is the number of molecules 
originally deposited.  
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Figure 4.7 Schematic describing the use of SRS to measure MALDI sampling effects: a) 
deposition of analyte, b) deposition of matrix, c) acquisition of MALDI MS data, d) 
acquisition of SRS data. 
The mass spectrometry results of this experiment are displayed in Figure 4.8. The 
boxplot of ion intensity vs fluence indicates a sigmoidal curve shape which has 
previously been reported for a variety of other analyte molecules.144,191-194 There is a 
threshold energy above which detected ion intensity rapidly increases, this is typically 
reported to be between 20 and 1700 J/m2.191 The threshold for this system appears to be 
~34 J/m2 although more data points within this region would be required to give an 
accurate figure. The steep increase observed above threshold can be attributed to the 
rapid conversion of photons into heat which leads to particle ejection and hence 
ionisation.195,196 A plateau in ion intensity can be observed at ~117 J/m2. Steven et al. 
report an ionization threshold of ~24 and plateau at 72 J/m
2
 for a thin film system of 
lipid standard and CHCA, the difference in these results can presumably be attributed to 
the different matrix and analyte compounds.
191 
92 
 
 
Figure 4.8 MALDI mass spectrometry results from fluence study: a) schematic of the 
sample, 1-8) fluence values of 34.22, 61.58, 89.45, 117.51, 145.34, 173.92, 201.80 and 
229.60 J m-2 respectively, b) example single pixel spectrum acquired with a fluence of 
34.22 J m-2, c) example ion images of drug (m/z 394.2) and matrix cluster (m/z 785.2) a 
cluster ion was selected because the molecular ion was not detected, d) boxplot of 
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MALDI MS ion data for m/z 394.2, this indicates increasing ions detected with 
increasing laser fluence. 
The sample was removed from the mass spectrometer and was imaged using SRS. 
Lasers were tuned to resonance frequencies of PNA and erlotinib in turn, three regions 
of each irradiated region were imaged at each frequency, see Figure 4.9 and Figure 4.10. 
The horizontal stripes which become obvious at fluence values ~89 J/m2 are a result of 
uneven fluence distribution across the beam profile which has been well 
characterised.64,192,193,197,198 The laser beam is coupled to the MALDI ion source via a 
patchcord fiber; the beam profile post-fiber has a characteristic ‘speckle pattern’. This 
means there is variation in fluence across the area irradiated by the laser and some 
regions may be below the threshold fluence for desoption/ionisation. As the sample 
moves beneath the laser, unablated regions of material become stripes. At higher laser 
fluence ~230 J/m2 the stripes disappear because the total energy delivered by the laser is 
high enough that even regions of lower fluence are above threshold. It is clear from 
these images that an increasing amount of material has been removed at higher laser 
fluence. This is in accordance with mass spectrometry data and suggests that larger 
numbers of ions are detected at higher laser fluence because more material has been 
ablated during desorption events. However the plateau in ions detected at ~120 J m-2 in 
the mass spectrometry data is not obvious in SRS images; it would appear that complete 
ablation of the sample occurs ~230 J m-2. This suggests that there is a maximum 
detected ion intensity for this analyte/matrix combination which cannot be overcome by 
irradiating the sample with larger amounts of energy. It is most likely that detector 
saturation is responsible; the sensitivity of the detector is insufficient to detect any more 
ions even though they have been produced from the sample.  
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Figure 4.9 SRS images of PNA after MALDI analysis at a range of laser fluences. 
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Figure 4.10 SRS images of erlotinib after MALDI analysis at a range of laser fluences. 
It is possible to infer some information just by visual analysis of the SRS images, 
however quantitative data requires calculation of total intensity observed at each 
location and average intensities at each laser fluence value. The results from this 
analysis are displayed in Figure 4.11. Graphs demonstrating the number of ions detected 
by MS vs fluence and the number of molecules removed (as calculated from SRS 
images) are largely in agreement. Similar sigmoidal curve shapes are observed by each 
technique. The steep increase in erlotinib ion intensity observed by MS occurs at a 
threshold value of 34 J/m2, however the steep increase in the number of molecules 
removed doesn’t occur until a fluence of 80-90 J/m2 is reached. This suggests that the 
increased ion intensity detected by MS is not a direct result of increased desorption. 
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Photoacoustic measurements have been used to measure ablation volumes during 
MALDI MS.144,199 A report by Rohlfing et al. found that for a system of substance P (a 
protein) and glycerol matrix, significant ablation occurred at fluence below threshold.199 
Due to the number of data-points collected in this experiment it is difficult to determine 
whether similar levels of ablation occur below threshold, however at threshold the 
number of molecules removed from the surface is 1-1.5 x 1014. Similar features were 
observed in the work described here and the photoacoustic measurements, such as the 
steeper gradient observed for ion intensity with fluence compared to that observed for 
material removed. Additionally the plateau in ion intensity occurs at lower fluence 
compared with material removed. This suggests that the method described in this work 
provides an accurate picture of desorption/ionisation events. The benefit of this method 
over photoacoustic measurements is the absolute quantification of molecules removed 
during ablation – this is the first report of a method with such capabilities. 
The variation observed in SRS data could again be caused by inhomogeneity in the 
sample. The graph of ions detected vs number of molecules removed tells us the 
ionisation efficiency of this MALDI analysis which is 1-2 in 109. Ion yields are 
typically quoted in the literature between 1 in 103 - 104,9 however it is possible that the 
method described in this thesis is the first capable of calculating an accurate value. An 
ionisation efficiency of 1 in 109 is less favourable than the picture painted in the 
literature but this could be due in part to detector inefficiencies. The important point to 
note is that this method can be used to quantitatively measure efficiencies and so 
performance under different experimental parameters may now be compared. 
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Figure 4.11 Results from SRS analysis of MALDI sample: a) ions detected vs fluence, 
b) molecules removed from surface vs fluence (as calculated from SRS data), c) number 
of ions detected vs number of molecules removed from the surface. 
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4.3.3 A quantitative study of the effects of laser repetition rate in MALDI MS 
After demonstrating how SRS could be used to quantify MALDI surface sampling with 
respect to laser fluence, a further experiment was designed to use SRS to provide insight 
into the effects of laser repetition rate on desorption/ionisation. Laser repetition rates, or 
the number of laser shots delivered to the surface per unit time have been found to 
critically affect ionisation in MALDI.19,141 Lasers capable of operating at high repetition 
rates are now commonly used in commercial MALDI MSI instruments and therefore 
the behaviour of different matrices at different repetition rates must be understood in 
order to optimise experiments.  
Thin films of erlotinib and SA and PNA matrices were prepared. SA is a cinnamic acid 
derivative containing a carboxylic acid group which has been proposed to undergo 
photomodification effects under high laser repetition rate irradiation.141,142,200 PNA is an 
aniline derivative which contains no such carboxylic group and can therefore be 
expected to exhibit different behaviour upon irradiation. The molar ratio of matrix to 
analyte and total amount of drug deposited were kept constant for each sample. Single 
line raster images were acquired from each sample at a range of different laser repetition 
rates (1-6 KHz). The average drug and matrix ion intensity detected at each repetition 
rate is displayed in Figure 4.12 and Figure 4.13. When PNA was used as matrix the 
average number of ions detected steadily increases with repetition rate and reaches a 
maximum at ~4 KHz, after which a slight decrease in ion intensity is observed. 
However when SA was used as the matrix, the inverse relationship was observed and 
fewer ions were detected as the repetition rate increased. This cannot be explained by 
increased levels of fragmentation at higher repetition rates because the same 
relationship is observed for major fragment ions of erlotinib, see Figure 4.13. This is 
counter-intuitive because the energy per laser pulse and raster speed were kept constant, 
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therefore the only thing changing is the number of laser shots delivered per area per unit 
time. This suggests that energy build up or heating within the matrix is causing 
decomposition in the sample which results in lower desorption yields.  
 
Figure 4.12 Boxplots of MALDI MS data acquired from PNA sample at different laser 
repetition rates: a) TIC, b) ions with m/z 394.2 corresponding to [M+H]+ ions of 
erlotinib, c) ions with m/z 336.2 corresponding to the major fragment ion of erlotinib, d) 
ion with m/z 139.0 corresponding to [M+H]+ ions of PNA. 
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Figure 4.13 Boxplots of MALDI MS data acquired from SA sample at different laser 
repetition rates: a) TIC, b) ions with m/z 394.2 corresponding to [M+H]+ ions of 
erlotinib, c) ions with m/z 336.2 corresponding to the major fragment ion of erlotinib, d) 
ion with m/z 225.1 corresponding to [M+H]+ ions of SA. 
Both samples were imaged using SRS after MALDI analysis to quantify the amounts of 
material removed under different conditions. Example white light and SRS images of 
each sample can be seen in Figure 4.14. Images of PNA reveal an intuitive relationship 
with repetition rate, in which more material is removed when larger numbers of laser 
shots are incident on the samples, which agrees with the MALDI data. Images of SA 
show that the largest amount of material is removed at a repetition rate of 1 KHz, under 
which conditions the largest number of ions is detected. At higher repetition rates SRS 
image intensity is similar to non-irradiated regions; however white light images reveal 
changes to surface morphology which look similar to those reported by Fournier et 
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al.141 As previously mentioned, it has been postulated that photomodification of matrix 
molecules after repeated irradiation results in lower absorption efficiency and therefore 
lower desorption/ionisation yields. Cinnamic acids are known to undergo 
configurational changes in lattice structure upon irradiation with UV light.201 The 
thermal stability of CHCA and SA were investigated by Tarzi et al. who proposed 
mechanisms for the decarboxylation and photo-dimerisation of cinnamic acids upon 
UV-irradiation.142 By comparison of the number of ions detected in subsequent analyses 
using CHCA and an alternative non-carboxylate matrix compound (PNA) Steven et al. 
found additional evidence for such photomodifications.10 SRS data acquired in this 
work provides further evidence that laser-induced changes to SA crystal morphology 
are responsible for decreased ion intensity at high repetition rates. 
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Figure 4.14 Example white light (top) and SRS (bottom) images from a) SA and b) 
PNA samples irradiated with different repetition rates. 
In order to further probe changes in surface chemistry of the SA thin film, spontaneous 
Raman mapping of a small region of the irradiated sample was performed, see Figure 
4.15. This imaging technique is much slower than SRS due to the inefficiency of the 
Raman scattering process, hence the small image region selected. The image region 
spans the edge of one irradiated region so that both irradiated and non-irradiated regions 
feature in the image. An example Raman spectrum from each region is presented in 
Figure 4.15. A number of subtle effects can be seen in these spectra, multivariate 
analysis was performed to further investigate these spectral changes.  
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Figure 4.15 Spontaneous Raman spectroscopic imaging of irradiated erlotinib and SA 
sample, a) optical image of imaged region, b) example Raman spectra from irradiated 
and non-irradiated region. 
Principal component analysis (PCA) was performed on the full dataset in order to 
identify the largest sources of variation within the image. Score images for principal 
components 2 and 3 are displayed in Figure 4.16. These images indicate that there is a 
large amount of variation between non-irradiated and irradiated material. Loadings plots 
for these principal components show the Raman bands which contribute to this 
variation. Two intense peaks at ~ 1600 cm-1 and 1650 cm-1 localised in the non-
irradiated region, could be due to the C=C aliphatic stretching mode and C=O stretching 
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mode of the carboxyl group. These modes are known to decrease in intensity on 
formation of the dimer because the aliphatic C=C rearranges to form a cyclobutane ring 
and the C=O forms a hydrogen bond.202 These modes are less intense in the irradiated 
region of the sample. This data supports the theory that photodimerisation of sinapinic 
acid occurs under higher repetition rate laser irradiation. 
 
 
Figure 4.16 Principal component analysis of spontaneous Raman map of sinapinic acid 
sample, score images and loadings plot: a) principal component 2, b) principal 
component 3. 
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4.3.4 SRS imaging of MALDI sample preparation 
In addition to quantifying MALDI surface sampling, SRS could be used to image 
sample preparation for optimisation purposes, for example to quantify analyte extraction 
and incorporation in matrix crystals. Matrix application is a critical step in the MALDI 
process; understanding of analyte distribution and extraction in matrix crystals could 
inform optimum sample preparation.  
SRS image stacks were obtained from a thin film of erlotinib and PNA. 3-D 
reconstructions of these images are displayed in Figure 4.17. Images of the analyte and 
matrix have been overlaid so that the distribution of analyte in matrix crystals can be 
observed. It is apparent from these images that the two compounds are not completely 
co-localised. Erlotinib appears to be inhomogeneously distributed through matrix 
crystals; small green ‘hotspots’ of analyte can be seen within the larger purple crystals. 
 
Figure 4.17 3-D reconstructions of SRS images of PNA (pink) and erlotinib (green). 
To demonstrate how the technique could be used to assess sample preparation in 
biological studies, a further sample was prepared. A section of mouse brain tissue was 
coated with DHB matrix which was shown earlier to exhibit very weak SRS signals. 
This is important because it would be difficult to separate signals from the tissue and 
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any of the other matrices we have studied. It would therefore be difficult to image the 
analyte with confidence that the matrix had not contributed to the signal. SRS lasers 
were tuned to the resonance frequency of lipids and regions of tissue and matrix were 
selected for SRS imaging. 3-D reconstructions of image stacks were generated and are 
displayed in Figure 4.18. It can be seen that lipids are not homogeneously distributed 
throughout crystals but are localised in ‘hotspots’ which are similar to those seen in the 
simpler model system. 
 
Figure 4.18 SRS imaging of lipids in mouse brain tissue and DHB crystals, a) white 
light image of imaged region of sample, b and c) 3-D reconstructions of SRS images of 
lipids. 
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4.4 Conclusions 
This work has demonstrated for the first time how SRS can be used to visualise and 
quantify MALDI MS surface sampling under different laser conditions. Similar trends 
were seen to those reported by other techniques suggesting the data is reliable. The error 
associated with these measurements is likely due to inhomogeneity of the sample which 
would need to be addressed in order to make the method more accurate and repeatable. 
SRS imaging of MALDI sample preparation has for the first time been reported. The 
information such images provide could be crucial for the optimisation of sample 
preparation in MALDI. Several different matrix compounds were assessed for use in 
combined MALDI and SRS studies and PNA was identified as an ideal candidate. The 
absorption phenomena observed using CHCA and PNA at certain resonance frequencies 
present a problem in the future application of the method in more complicated and 
varied experimental set-ups. 
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Chapter 5  
Multimodal Chemical Imaging of Biological 
Tissue: LESA, MALDI and SRS 
5.1 Introduction 
The previous two chapters have discussed the individual capabilities of LESA, MALDI 
and SRS. This chapter presents a combined ‘multimodal’ workflow in which the three 
techniques are executed on a single tissue section to provide complementary 
information and a more complete analysis of the sample. The ability to combine 
established imaging techniques could allow for the advantages of one method to 
overcome limitations in the other, for example limited spatial resolution. The highly 
specific nature of mass spectrometry data could be used to increase confidence in 
assignment of SRS data and the excellent spatial resolution of SRS images could be 
combined with mass spectral data for improved image resolution. Quantitative SRS 
could also be used to calculate absolute quantities of drug targets in dosed organisms. 
SRS, MALDI and LESA produce images over a length scale which spans 6 orders of 
magnitude. This scale of magnification is illustrated in Figure 5.1. If we take the 
example of imaging the Earth, these differences could be approximately equated to 
distinguishing between land and water (LESA), countries in Europe (MALDI) and 
navigating the streets of London (SRS). A single field of view in the SRS microscope is 
smaller than a typical single pixel in a MALDI imaging experiment. Primarily the 3 
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techniques will be used for absolute quantification of a drug compound, high resolution 
mass spectrometry images with good specificity and sensitive analysis of multiple drug 
compounds and classes of analyte simultaneously. 
The sample used is this work was taken from an animal which had been cassette-dosed. 
This involves dosing several carefully selected drug compounds simultaneously for 
higher throughput screening of physiochemical and pharmacokinetic properties. Such 
an approach reduces the number of animals required which is an important step towards 
the  ‘three Rs’ concept (reduce, refine, replace)203 and has also been shown to reduce 
time and financial costs.153,204,205 Such samples provide an ideal platform on which to 
test the relative sensitivity and versatility of LESA, MALDI and SRS.  
 
Figure 5.1 Illustration of relative length scales involved in LESA, MALDI and SRS 
imaging. 
110 
 
 
5.2 Experimental 
5.2.1 Tissue sample preparation 
Tissue from control and cassette-dosed animals was sectioned as described in section 
2.2.1.1 and prepared for MALDI analysis as described in section 2.2.1.2 using CHCA as 
the matrix. 
5.2.2 SRS microscopy of mouse brain tissue 
SRS microscopy of mouse brain samples was performed as described in section 2.2.2.4. 
Lipids, proteins and water (2860, 2930 and 3253 cm-1 respectively) were imaged by 
adjusting the OPO. Regions of tissue were identified via white light images of the 
sample and 50 x 50 μm regions were selected for SRS imaging. Integration time of 3 ms 
per pixel was found to provide sufficient contrast within the imaged region, images of 
256 x 256 pixels were acquired.  
5.2.3 Preparation of erlotinib calibration sample 
The calibration sample was prepared using a TM-Sprayer (HTX Technologies LLC). 
Known amounts of erlotinib were deposited on a glass coverslip to the following final 
concentrations: 0.197, 0.262, 0.328, 0.393, 0.458 μg/mm2. The coverslip was sealed 
face-down onto a standard glass slide.  
5.2.4 SRS microscopy of calibration sample 
Three regions of each erlotinib concentration were selected and imaged by the SRS 
system. Image regions of 80 x 80 x 15 μm (15 images, separated by 1 μm in the z-
dimension) were scanned with laser beams tuned to the nitrile group of erlotinib (2110 
cm-1). A pixel dwell time of 100 μs and laser power of 70 mW were used.  
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5.2.5 SRS microscopy of cassette-dosed tissues 
Cassette-dosed tissues were imaged as described in section 2.2.2.4. Image regions of 80 
x 80 x 15 μm (15 images, separated by 1 μm in the z-dimension) were scanned with 
laser beams tuned to the nitrile group of erlotinib (2110 cm-1). A pixel dwell time of 100 
μs and laser power of 70 mW were used.  
5.2.6 LESA mass spectrometry imaging 
Surface sampling of cassette-dosed kidney tissue was performed as described in section 
2.2.2.1. A grid of 220 sampling locations was selected with an x,y spacing of 1mm.  
5.2.7 MALDI mass spectrometry imaging 
Kidney tissue which had been sampled by LESA MS was coated with CHCA matrix as 
described in section 2.2.1.2. MALDI MS imaging was performed as described in 
section 2.2.2.2. Data were acquired in positive ion mode with a pixel size of 100 x 100 
µm. 
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5.3 Results and Discussion 
5.3.1.1 SRS microscopy of mouse brain tissue 
To demonstrate the capabilities of SRS microscopy in terms of tissue analysis, images 
of various species endogenous to brain tissue were acquired from a sample of mouse 
brain tissue, see Figure 5.2. Images reveal anatomical details of what appears to be a 
blood vessel containing red blood cells. Lipid images (2860 cm-1) reveal circular 
features of ~8 μm diameter, which is approximately the size of a red blood cell and 
could therefore correspond to the phospholipid cell membrane. Images of water (3253 
cm-1) reveal an inverse intensity distribution as compared with the lipid image, the 
higher water intensity seen inside the blood vessel corresponds to the high water content 
of blood plasma. Protein images (2930 cm-1) reveal a similar distribution to lipids; it is 
not possible to further discern cellular features in this particular region. Images acquired 
at an off-resonance frequency (2245 cm-1) reveal no anatomical features and a low 
background signal, thus validating the SRS images acquired. The pixel sizes used in this 
study (~200 nm) are sufficient to reveal cellular and intracellular features.  
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Figure 5.2 SRS microscopy of mouse brain tissue, a) sample set-up: tissue section was 
sandwiched between a glass coverslip and a microscope slide, b) white light image of 
tissue region imaged by SRS, c) SRS image of lipids (2860 cm-1), d) lower 
magnification image of lipids in same region, e) SRS image of water (3253 cm-1), f) 
SRS image of protein (2930 cm-1), g) overlay of lipid (red), water (blue), and protein 
(yellow) images, h) SRS image acquired off-resonance (2245 cm-1). 
5.3.2 Cassette dosed tissue samples  
Tissue sections from various organs of a rat dosed with erlotinib, terfenadine, 
olanzapine and moxifloxacin were analysed by SRS microscopy, LESA and MALDI 
mass spectrometry imaging. It was not previously known where each drug would 
accumulate within organs of the body. A survey of the different organs was performed 
to ascertain which organ would be most suitable for a multimodal imaging study. SRS 
images of lipids (2860 cm-1), proteins (2930 cm-1) and erlotinib (2111 cm-1) were 
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acquired from each tissue type, see Figure 5.3. Of the dosed drug compounds, only 
erlotinib exhibits Raman bands outside of the biological ‘fingerprint’ region, therefore 
SRS images of this drug only were acquired. Images acquired at an off-resonance 
frequency (1800 cm-1) are also displayed for comparison. Tissue structures can be 
observed in lipid and protein images from every tissue type. Hotspots of high intensity 
can be observed in images of kidney, liver and lung; these signals are likely to be due to 
two-photon absorption by haemoglobin135 in blood because they appear in images at all 
resonance frequencies measured, including the off-resonance frequency in which no 
SRS should be observed.127,136 Images of erlotinib demonstrate very low signal 
compared with lipid and protein which is to be expected due to its relative abundance. 
The only tissue type from which the observed signal from erlotinib seems significantly 
higher than the background noise is kidney. It was therefore concluded that kidney 
tissue would be the most suitable tissue type for a study in which SRS was used to 
quantify erlotinib in tissue. 
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Figure 5.3 SRS images acquired from thin tissue sections of various organs taken from 
cassette-dosed rat, lipids (2860 cm-1), proteins (2930 cm-1), erlotinib (2111 cm-1) and an 
off-resonant frequency (1800 cm-1) were imaged. 
A further set of samples from the dosed rat organs were subject to LESA MS. Example 
mass spectra acquired by LESA MS from each tissue type are displayed in Figure 5.4. 
This region of the mass spectrum demonstrates the different lipids preferentially 
detected from each tissue type and their relative abundances. Lipids were preferentially 
detected as the [M+H]+ species in every tissue type. The most abundant lipid species 
detected from each tissue type are labelled in Figure 5.4. Lipids could be detected from 
116 
 
every tissue type studied, as could each of the dosed drug compounds. However 
multiply charged protein ions could only be detected from brain, kidney and lung (under 
these specific sampling conditions). Unidentified protein ions centered at m/z 993.70 
(+5) and 828.25 (+6) were detected from brain, kidney and lung. 
 
Figure 5.4 Example spectra acquired by LESA mass spectrometry analysis of various 
organs from cassette-dosed rat, a) brain, b) kidney, c) liver, d) lung. 
LESA MS intensity profiles of each drug compound detected from each different tissue 
type are displayed in Figure 5.5. All four drug compounds were detected as the [M+H]+ 
species and were detected from every tissue type using LESA MS. Particularly high 
relative abundances were noted for olanzapine and moxifloxacin from kidney tissue. 
This indicates that kidney would be a promising model tissue for a combined study. In 
addition, the anatomical features within rat kidney tissue (cortex and medulla) are of 
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sufficient size that contact-LESA pixel sizes could be capable of distinguishing the two 
tissue types. 
 
Figure 5.5 Intensity of cassette dosed drug compounds in various organs from cassette-
dosed rat acquired over three repeats: b) ions detected with m/z 760.5827 (endogenous 
lipid for comparison), c) ions detected with m/z 394.1752 (erlotinib), d) ions detected 
with m/z 472.3197 (terfenadine), e) ions detected with m/z 313.1472 (olanzapine), f) 
ions detected with m/z 402.1813 (moxifloxacin). 
A further set of organ sections was coated with CHCA matrix and imaged using 
MALDI MSI. Single pixel spectra from each tissue type are displayed in Figure 5.6. 
Good lipid signal intensity was observed from each tissue type. Lipids were 
predominantly detected as the potassium adduct. Interestingly, in the case of brain, liver 
and lung tissue, the most abundant lipid species detected were the [M+K]+  species of 
the same lipid detected by LESA MS. This correlation suggests that the differences 
spectral abundance reflects true differences in abundance in the tissue and not ionisation 
or desorption efficiencies because different ionisation mechanisms occur in each 
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method. The methanol based solvent system was used both as LESA extraction system 
and matrix carrier during sample preparation for MALDI, therefore the result could be 
due to relative lipid solubilities in methanol/water.  
 
Figure 5.6 Example single pixel spectra acquired from various organs from cassette-
dosed rat, the most abundant lipid species is labelled in each spectrum: a) spectrum 
acquired from brain tissue, most abundant lipid species was PC(34:1), b) spectrum 
acquired from kidney tissue, most abundant lipid species was PC(36:4), c) spectrum 
acquired from liver tissue, most abundant lipid species was PC(34:2), d) spectrum 
acquired from lung tissue, most abundant lipid species was PC(32:0). 
Ion images from each tissue type are displayed in Figure 5.7. Partial section images 
were acquired from brain and liver tissue in order to save time. Lung and liver tissue 
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images do not reveal any particular anatomical features because they are relatively 
homogeneous tissue types. Ion images from brain and kidney tissue reveal features such 
as the hippocampus (brain) and the cortex/medulla (kidney). Such features present an 
additional facet to chemical imaging studies because the ability of a given technique to 
spatially resolve differences can be assessed. None of the dosed drug compounds could 
be detected as the [M+H]+ or [M+K]+ species or as any commonly reported 
metabolite.153 This provides an early indication that the sensitivity of MALDI MS is 
lower than that of LESA (as used in combination with the particular instruments 
reported here).  
 
Figure 5.7 MALDI MS ion images of various organs from cassette-dosed rat, a) layout 
of sample, b-f) ions detected with m/z 826.6, 772.5, 741.6, 820.6, 848.6. 
The abilities of each technique to detect a variety of analytes within these samples is 
summarised in  
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Table 5.1. SRS has been shown to be capable of detecting various pure drug compounds 
but the lack of specificity and the complex nature of Raman spectra acquired from 
biological tissue result in difficulties in imaging drug distribution in tissue. By careful 
selection of drug compounds which exhibit Raman scattering in the biologically ‘silent’ 
region, such as the nitrile group of erlotinib, it is theoretically possible to image a drug 
in tissue. However the sensitivity of the technique needs to be further assessed because 
if high dose levels (higher than the therapeutic level) are required to generate sufficient 
signal then this limits the usefulness of the technique. The sensitivity of MALDI MS 
was not sufficient to detect any of the dosed drug compounds but did detect a large 
number of lipid ions. Whist it is not possible to simultaneously detect proteins, the 
sample could be washed, re-coated with a different matrix compound and analysed 
again.15 The relative sensitivity of LESA was demonstrated to be better than MALDI, 
and was sufficient to detect all four drug compounds, lipids and proteins 
simultaneously. A method in which all three techniques are applied sequentially to a 
single tissue section was subsequently implemented on a further section of kidney tissue 
which has been identified as a suitable target organ. 
 
Table 5.1 Summary of the capabilities of each technique in terms of analytes detected. 
 Analyte 
Analytical 
technique 
Protein Lipid Erlotinib Moxifloxacin Terfenadine  olanzapine 
SRS       
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MALDI 1      
LESA       
 
5.3.3 High resolution imaging and quantification of erlotinib in tissue using SRS 
microscopy 
Further tissue sections were taken from the cassette-dosed kidney tissue and used to 
investigate the potential usefulness of a multimodal SRS, LESA and MALDI imaging 
method. As a non-destructive technique which should not alter the sample, SRS was 
performed first. Kidney tissue was selected as a suitable tissue type in terms of expected 
analytes (all 4 drug compounds had been detected in kidney in a previous study153 and 
in preliminary work) and size of anatomical features which could be visualized by the 
different resolution imaging modalities. Example SRS images of lipids and erlotinib in 
three different regions of the kidney section are featured in Figure 5.8. Different tissue 
structures and features can be observed in each of the images, in the medulla and inner 
cortex individual renal cell nuclei can be seen as darker spots in the lipid images. The 
renal cortex is responsible for ultrafiltration and the medulla is responsible for 
maintaining the salt and water content of the blood. It does not appear to be possible to 
distinguish individual cell boundaries or membranes within these images. The large 
branched structure appearing as a dark feature predominant in images of the outer 
cortex is possibly a proximal convoluted tubule – which forms part of a glomerulus. The 
                                                 
1 Cannot be detected simultaneously with lipids; separate sample preparation methods 
required. 
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apparent signal from erlotinib is relatively high in these images – the difference in 
intensity between this and the previous dataset can be explained by the higher laser 
power used for image acquisition in this set. The difference in intensity between images 
of erlotinib and images acquired off-resonance is similar to that observed in the 
previous dataset. This could present a problem during quantification of the signal 
because good characterization of the background signal will be required in order for the 
true signal from erlotinib to be calculated.   
 
Figure 5.8 White light and SRS images acquired from three different regions of 
cassette-dosed kidney tissue. SRS images correspond to a 50 x 50 μm region. 
An external calibration of pure erlotinib was prepared using a robotic spray device as 
outlined in the section 5.2.3. The SRS intensity of each known quantity of erlotinib 
could then be measured and plotted as a calibration curve. Three different regions of 50 
x 50 μm were selected for each concentration of drug and the summed intensity of 10 
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images spanning 10 μm in the z-dimension was calculated for each region. The average 
intensity for the three different regions was then calculated. Example SRS images from 
the calibration sample are displayed in Figure 5.9. The calibration curve plotted from 
these data is also displayed in Figure 5.9. The SRS images suggest that the thin film 
deposited by the robotic sprayer is fairly inhomogeneous; this is therefore likely to be 
the largest source of error/variation within the calibration. Linear regression was 
performed to fit the data and an R2 value of 0.96 was obtained. This demonstrates 
satisfactory linearity over the range of concentrations used in this work and suggests the 
method should be suitable for use in quantification studies. It is difficult to obtain a 
value for limit of detection from this graph because data points were not sufficiently 
closely spaced in order to find the lower limit of linearity.  
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Figure 5.9 SRS images of erlotinib standard calibration sample and calibration curve. 
Average intensity was calculated over the summed intensity of three regions of each 
concentration. Error bars represent ±1 standard deviation, linear fit has an r2 value of 
0.96. 
SRS data were acquired from the calibration sample and the tissue sample under the 
same conditions (controlled for image region size, laser power and integration time). 
The different regions of kidney selected for SRS imaging demonstrate different signal 
intensities for erlotinib from different tissue types. These will later be compared with 
relative concentration distributions observed by mass spectrometry imaging.  
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The concentration of erlotinib in kidney tissue can be calculated by converting 
measured intensity from tissue to concentration via equation 5.1 which was calculated 
by fitting to the calibration data.  
𝐼 = 4.8 ∗ 𝐶 + 1.8 
5.1 
For each set of SRS images the summed intensity of the erlotinib signal was calculated 
and the average signal which was detected off-resonance was subtracted. Once the 
concentration value had been obtained, this value was related back to the concentration 
of drug in tissue (in units of µg/g tissue) via the approximation of tissue density as 1 
g/cm3. The calculated concentration values for erlotinib in cortex kidney tissue are 
displayed in Table 5.2. These calculated values vary a lot from region to region and this 
is likely to be due to the poorly characterized background signal. This means that the 
calculated values must be treated with caution because they are likely to be inaccurate. 
The measured signal from erlotinib was very low and in some regions was lower than 
the measured signal off-resonance – this means that the concentration of erlotinib is 
very close to the limit of detection. In order to be confident that the SRS signal from 
tissue was real, an SRS spectrum should be acquired from the region around 2110 cm-1 
to determine whether a real peak occurs here or whether background signal is measured 
in the erlotinib channel. A further experiment in which the animal was dosed with a 
larger amount of erlotinib would also establish whether this is a sensitivity problem. 
This should be a last resort in order to minimize animal studies. Having said this the 
amount of erlotinib detected in the cortex is higher than that detected in the medulla, 
which does suggest the method has worked to an extent because this was observed by 
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mass spectrometry imaging in the work by Swales et al. when they studied the same 
samples.  
Table 5.2 Concentration of erlotinib in tissue as measured using SRS microscopy. 
Kidney region 
Total intensity 
erlotinib 
µg erl per 
mm
3
 
Conc. in tissue 
(µg/g) 
Outer 
cortex 
1 9.08E+04 0.043319448 43.3 
2 8.69E+04 0.010612477 10.6 
3 1.11E+05 0.208616958 209.0 
 
Inner 
cortex 
1 9.03E+04 0.039368595 39.4 
2 9.28E+04 0.059640722 59.6 
3 5.94E+04 -0.219298487 0 
 
medulla 1 8.78E+04 0.017962625 18.0 
2 6.41E+04 -0.179573862 0 
3 5.39E+04 -0.264964157 0 
 
5.3.4 Sensitive analysis of multiple targets by LESA MS imaging 
The tissue section which had been analysed by SRS was then imaged using LESA MS. 
It was established in Chapter 3 that in order to take full advantage of the sensitivity of 
LESA it must be performed prior to MALDI analysis. An example LESA mass 
spectrum and representative ion images are displayed in Figure 5.10. Using LESA MS it 
was possible to detect all four drug compounds, lipids and proteins simultaneously. 
Each of the four drug compounds (erlotinib, terfenadine, olanzapine and moxifloxacin) 
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was detected as the intact protonated species (ions detected with m/z 394.1808, 
472.3264, 313.1517 and 402.1874 respectively). Erlotinib, terfenadine and olanzapine 
were detected with higher intensity in the cortex and lower intensity in the medulla. 
Moxifloxacin was detected with lower intensity in the cortex and higher intensity in the 
medulla. This is in agreement with the results from SRS analysis and with the findings 
of Swales et al.153 Lipids were preferentially detected as the protonated species which is 
in agreement with results outlined in Chapter 3 in which LESA MS was used to analyse 
brain tissue. Intact, multiply charged protein ions were also detected. The species 
detected with ions centered at m/z 857.48 (charge state +10) is tentatively assigned as 
ubiquitin. The species detected at m/z 894.82 (+17) is tentatively assigned as α-
hemoglobin. This simultaneous detection of multiple analyte classes under ambient 
conditions is a quality unique to LESA MS, typically with other techniques such as 
DESI or MALDI different sample preparation strategies or experimental parameters 
would be required to detect different classes of analyte and separate imaging procedures 
would need to be executed. 
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Figure 5.10 LESA MS imaging of drug dosed tissue: a) points selected for LESA 
sampling (220 pixels), b) example single pixel spectrum, (c-d) example LESA MS 
images corresponding to [M+H]+ ions of: c) erlotinib, d) moxifloxacin, e) olanzapine, f) 
terfenadine, g) PC 34:2, h) PC 39:6, i) unidentified protein ion (m/z 800.78 charge state 
+18), j) α-hemoglobin (m/z 894.93 charge state +17). In a single LESA extract singly 
charged lipid and drug species and multiply charged intact protein ions were detected – 
indicated inset (b).  
The minimum pixel size possible using contact LESA MS is ~700 μm and is limited by 
the diameter of the pipette tip used for sampling; this could provide a route towards 
further reducing pixel size because smaller pipette tips could be used. A restriction in 
the software used to control the Triversa NanoMate puts a minimum restriction on the 
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spacing between points at 1 mm which means gaps between pixels resulting in 
unsampled tissue when contact LESA is used. The pixel size used in this experiment 
allowed sufficient spatial resolution to distinguish between gross anatomy within the 
organ (cortex vs medulla) but very little else. A higher resolution mass spectrometry 
imaging technique is required to provide this level of detail. 
 
5.3.5 Specific analysis with high resolution imaging by MALDI MS 
The kidney tissue section which had been sampled by LESA and SRS, along with a 
serial control section placed adjacent on the slide, was then imaged using MALDI MS.  
An example single pixel spectrum and ion images of various lipids from both tissue 
sections are displayed in Figure 5.11. The only class of analyte detected in this 
experiment was lipids, predominantly phosphatidylcholine lipids originating from the 
cell membrane. As indicated by the images in Figure 5.11, the spatial resolution 
possible with MALDI MS is far superior to LESA (pixel size used in this experiment 
was 100 μm). The total image region is approximately 1.5 x 2.5 cm which is large 
enough to image the entire tissue section. Total acquisition time for this MALDI MS 
image was approximately 2.5 hours. To image the equivalent region using SRS under 
the conditions used here would have taken 2730 hours or 113 days, which is 
fundamentally unfeasible. Faster SRS acquisition times are possible but would require 
higher laser power to produce the same signal for a shorter integration time. Differences 
in the structure of cortex vs medulla can clearly be seen in various MALDI lipid ion 
images, also structure within the kidney cortex which could be connective tissue can be 
seen as ‘stripes’. The regions which were sampled by LESA are clearly visible in the 
MALDI MS images, characterized by a region of higher intensity in the middle of the 
spot and surrounded by a darker ring of lower intensity. This phenomenon was 
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described in Chapter 3, and it is suggested that this is caused by salt washing towards 
the outside of the LESA sampled spot, subsequent poor matrix crystal formation and 
desorption/ionization. It is interesting to note that similar effects are observed for a 
different tissue type in which higher concentrations of salt were expected. Ion images of 
some lipid species (PC 34:1, see Figure 5.11.d) show that in certain regions of the 
kidney, ions are enhanced by LESA more than they are in other regions i.e. the effect of 
LESA sampling is not uniform across the tissue section. These image features are useful 
for understanding the LESA sampling process (in terms of area sampled, sampling 
precision and repeatability) and could also help explain unexpected intensity 
distributions in LESA images. For example LESA pixels with low intensity might 
correspond with regions where a smaller region was sampled relative to the other pixels, 
although that was not observed in this experiment.  
 
Figure 5.11 MALDI MSI performed after SRS and LESA: a) description of sample, b) 
example single pixel MALDI mass spectrum, (c-e) example ion images of abundant 
lipid ions tentatively assigned as [M+K]+ molecules of: c) PC 36:4, d) DG 42:3, e) PC 
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32:0. Regions sampled by LESA can be identified in MALDI images by a localised 
increase in lipid ion intensity. 
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5.4 Conclusions 
The work presented in this chapter has explored the possibility of a multimodal 
workflow to extract more information from a sample of relevance to pharmaceutical 
research. SRS was shown to provide high resolution images of biological tissue in 
which sub-cellular spatial resolution was possible. A possible route towards quantifying 
a drug in tissue using SRS was also investigated. It was found that further work to 
establish SRS off-resonant signals in kidney tissue would be required before this could 
be used for absolute quantification although this does show promise. LESA MS was 
capable of detecting all four dosed drug compounds along with lipids and proteins in a 
single extraction/analysis. MALDI MS imaging was capable of acquiring high 
resolution images of a single class of analyte over a wide ‘field of view’ in an 
acceptable time-frame. This workflow demonstrates the potential for combining 
separate techniques with individual benefits but requires further investigation to take 
full advantage of the capabilities of SRS. It would not have been possible to acquire this 
data via any single technique thus demonstrating the need for multimodal methods
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Chapter 6  
Liquid Surface Sampling Techniques: 
Quantitative Analysis by LESA 
6.1 Introduction 
The work presented in chapters 3, 4 and 5 showed how combining various chemical 
imaging methods could lead to improved understanding of fundamental processes 
whilst providing a more complete analysis of the sample. The remainder of the work 
focuses on the development of ambient mass spectrometry imaging methods for 
improved analysis in terms of quantification (Chapter 6), spatial resolution (Chapter 7) 
and sample types (Chapter 8). 
The need for quantitative analysis was discussed in Chapters 4 and 5 and SRS 
microscopy was assessed for the quantification of pharmaceuticals in tissue. The 
potential benefits of using such a technique have been outlined; however, limitations in 
terms of sensitivity and range of analytical applications could hinder further 
development. Liquid chromatography coupled to mass spectrometry (LC-MS) is 
commonly employed in the routine quantification of proteins in biological samples. 
Usually this involves tagging the protein with a stable isotope, which can be introduced 
via metabolic, chemical or enzymatic means.206,207 Relative quantification can be 
achieved by comparing the intensity of protein signals in different physiological states, 
absolute quantification requires comparison to the ion intensity detected from samples 
135 
 
of known composition. Commonly used methods include isotope-coded affinity tags 
(ICAT)208, isobaric tags for relative and absolute quantification (iTRAQ)209 and stable 
isotope labelling by amino acids in cell culture (SILAC).206,207  Methods employing LC-
MS do not typically retain spatial information; this means the specific origin of the 
protein cannot be accurately determined and potentially valuable biological information 
could be lost.  
Various types of mass spectrometry imaging have been reported for quantitative 
analysis, for example MALDI, DESI and nano-DESI.73-76,210-212 If one was to use MSI 
for quantitative analysis, an ambient method would seem to be the most appropriate 
choice due to the limited sample preparation (and hence alteration). Mass spectra 
acquired in the absence of a matrix compound would be simpler to interpret and lower 
ion suppression effects should be observed. Liquid sampling techniques in which 
desorption and ionisation stages are decoupled (such as LESA) are even more attractive 
because this affords the opportunity for off-line incorporation of an internal standard.  
The work presented in this chapter explores the use of LESA MS for the quantification 
of intact proteins in biological tissue. Applications of such a method would include 
studies seeking to quantify differences in protein expression between control animals 
and disease models   in which a certain protein was implicated; quantification of 
antibody or other protein-based therapeutic compounds; and quantification of multiple 
analytes simultaneously, for example a lipid or protein and a drug. This could enable the 
expression of an endogenous molecule to be monitored in relation to the concentration 
of a drug. Limitations in the current methods for absolute quantification of proteins  
such as the loss of spatial information, lengthy sample preparation and problems with 
bottom-up protein identification (inefficient digestion, failure to identify peptides and 
loss of post-translational modifications) could be overcome using a LESA 
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quantification method.111 Furthermore, in some situations seeking to quantify two 
different variants of a protein it would be difficult to quantify by bottom-up methods.  
6.2 Experimental 
6.2.1 Tissue samples 
Tissue samples were sectioned as described in section 2.2.1.1 at a thickness of 14 μm.  
6.2.2 Preparation of mimetic tissue models for quantification 
Mimetic tissue models were prepared using the method described in Figure 6.1. Ten 
whole rat brains (thawed) were homogenized using a handheld homogenizer. 
Approximately 2.5 mL of homogenate was apportioned into individual pre-weighed 
tubes and final weight homogenate per tube was calculated. Labelled ubiquitin solutions 
were prepared in methanol and water (30:70), to final concentrations such that 1% final 
volume of tissue was added to each sample, this prevented large volumes of solvent 
diluting the homogenate. 5mm magnetic stir bars were added to each tube and vortexed 
for 1 minute. Spiked homogenates were pipetted into plastic moulds before freezing for 
1 hour at -80 °C. The final concentration of labelled ubiquitin in tissue was 0, 9.9, 19.9, 
67.4, 68.6, 94.7, 122.6 and 163.0 nmol/g. 
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Figure 6.1 Method used to prepare mimetic tissue models: rat brains were homogenised, 
portions were separated into pre-weighed tubes, appropriate quantities of labelled 
protein were added, sampled were vortexed to mix, homogenate was portioned into 
moulds and frozen at -80°C, mimetics were sectioned at 14 μm and thaw-mounted on 
glass slides before LESA MS was carried out. 
6.2.3 Direct infusion of labelled and unlabeled ubiquitin standard  
Solutions of ubiquitin standard were prepared in methanol and water with 1% formic 
acid (69.3:29.7:1) to final concentrations of 117, 23.4, 4.67, 0.93, 0.18 and 0.037 μM. A 
solution of labelled ubiquitin was prepared at a concentration of 25 μM in methanol and 
water with 1% formic acid (69.3:29.7:1). 3 μL of each solution was introduced to the 
mass spectrometer via the Triversa NanoMate electrospray ionization chip with a gas 
pressure of 0.3 psi and a tip voltage of 1.75 kV. The AGC was turned off and the fill 
time was fixed at 0.6 ms. This fill time was optimized for the highest concentration 
solution; injection of lower concentration solutions with this fill time resulted in under-
fill. Full scan mass spectra were recorded in the m/z range 200-2000 for 3 minutes; each 
scan comprised 5 coadded micro-scans.  
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6.2.4 LESA mass spectrometry 
The surface sampling method was optimized for the analysis of rat brain and rat brain 
homogenate. Sampling coordinates were selected (a grid of 8 points per tissue mimetic 
and a grid of 7 x 11 points spanning one sagittal rat brain section) for LESA MS. The z 
coordinate was set to a height 1.2 mm above the sample surface; it was found that 
contact LESA was not suitable for this application due to high lipid signal observed 
using contact. The solvent system for extraction and electrospray was methanol, water 
and formic acid (69.3:29.7:1). A volume of 2.0 μL solvent was aspirated from the 
solvent well, 1.3 μL was dispensed on the surface and 1.5 μL was re-aspirated to ensure 
good recovery from the surface. The liquid microjunction was maintained for 10 
seconds before re-aspiration. The sampling routine was repeated once before 
electrospray. Each sample was delivered for 3 minutes via the Triversa Nanomate with a 
gas pressure of 0.3 psi and a tip voltage of 1.75 kV. Positive ion mass spectra were 
acquired in full scan mode (m/z 600-2000) at a resolution of 120 000 at m/z 400. The 
Automatic Gain Control was turned off and the injection time fixed at 1 ms. Each scan 
was comprised of 5 coadded microscans. 
6.3 Results and Discussion 
6.3.1 Mass spectrometry analysis of stable-isotope labelled ubiquitin by direct 
infusion electrospray and LESA 
Quantification by surface sampling methods such as LESA requires the incorporation of 
a structural analogue into the sample which acts as internal standard.65 This compound 
is added to the sample in known quantities and acts as a reference to which endogenous 
signals can be compared. Chemical properties of the standard and the compound of 
interest can be assumed to be equivalent and therefore extraction, desorption and 
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ionisation efficiencies are likewise assumed to be the same. The internal standard can be 
spiked onto control tissue at a range of concentrations or added as a homogeneous layer 
to which endogenous signals can be normalised. These methods do not allow for 
differences in extraction from within the tissue, which may not be representative of the 
extraction of endogenous compounds. Alternatively the standard can be added  in 
different concentrations to homogenised tissue to produce a series of tissue-like models 
with known composition from which a calibration curve can be produced.73 Signal 
intensities observed from endogenous species may then be compared to this curve and 
unknown concentrations can be determined. Commonly a stable-isotope labelled 
version of the drug or compound to be quantified is used as the internal standard. This 
compensates for differences in extraction and ionisation efficiency between different 
tissue types.65,74-76,210 It should be noted that previous work has only considered the 
quantification of small molecules. In this work carbon-13 and nitrogen-15 labelled 
ubiquitin was used to quantify ubiquitin in brain tissue. This is the first report of using 
such an approach to quantify intact proteins. Ubiquitin was selected as a suitable 
candidate because it is readily detected from brain and other tissue types using LESA-
MS.  
An example mass spectrum acquired by direct infusion electrospray ionisation of 
labelled ubiquitin is displayed in Figure 6.2. It was possible to detect the standard in a 
variety of charge states, the most abundant charge state was +7 (in the m/z window 
recorded in this work), which was detected with m/z centred around 1808.30. This 
corresponds with an intact monoisotopic mass of 9033.4779 which demonstrates that 
98% of carbon and nitrogen atoms in ubiquitin have been isotopically labelled. 
Therefore signals from labelled and endogenous ubiquitin should be easily separable, 
which can be seen in Figure 6.2. Labelled ubiquitin was spotted onto a section of mouse 
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brain and LESA MS was performed; both endogenous and labelled ubiquitin were 
detected simultaneously.  
 
Figure 6.2 Mass spectrometry analysis of stable-isotope labelled ubiquitin, a) direct 
infusion electrospray ionisation mass spectrum, b) LESA mass spectrum acquired from 
brain tissue spotted with protein standard, both labelled (l-Ub) and endogenous (e-Ub) 
ubiquitin can be detected simultaneously. 
6.3.2 LESA MS analysis of tissue mimetics 
After establishing that labelled ubiquitin can be detected from a sample of brain tissue, a 
series of mimetic tissue models were prepared, see Figure 6.1. Example LESA mass 
spectra acquired from these samples can be seen in Figure 6.4. Ions with m/z attributed 
to labelled ubiquitin decrease in intensity with concentration, whereas the intensity of 
ions with m/z attributed to endogenous ubiquitin remain relatively constant. This 
suggests the method is capable of detecting differences in abundance. 
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Figure 6.3. Example LESA mass spectra acquired from different concentration mimetic 
tissue models a) 163.0 nmol/g, b) 122.6nmol/g, c) 94.7 nmol/g, d) 68.6 nmol/g. Peaks 
corresponding to labelled ubiquitin (l-Ub) and endogenous ubiquitin (e-Ub) are labelled 
in each spectrum. 
The intensity of labelled and endogenous ubiquitin (in +9 and +10 charge states) 
detected from mimetic tissue models are displayed in Figure 6.4. Eight separate 
locations were sampled per mimetic and each row of 8 pixels in the image corresponds 
to a different concentration mimetic. A gradient can clearly be observed for labelled 
ubiquitin whereas endogenous ubiquitin remains relatively constant. Variation observed 
within the intensity of endogenous ubiquitin represents either the error within the LESA 
method or variation in the concentration of labelled ubiquitin which could occur due to 
poor mixing during mimetic preparation. In order to probe which of these is responsible 
a further experiment was designed. 
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Figure 6.4. LESA MS data from mimetic tissue models, each horizontal line of pixels 
represents a different concentration mimetic, bottom-top: 0, 9.9, 19.9, 67.4, 68.6, 94.7, 
122.6 and 163.0 nmol/g, a) ions with m/z 904.6543 (+10) labelled ubiquitin, b) ions with 
m/z 1004.9486 (+9) labelled ubiquitin, c) ions with m/z 857.3632 (+10) endogenous 
ubiquitin, d) ions with m/z 952.6230 (+9) endogenous ubiquitin. 
6.3.3 Variation in LESA MS  
Two sections were taken from the top and one from the bottom of the mimetic tissue 
model (see Figure 6.5) and all three were subject to LESA MS under the same sampling 
conditions. Ion images of endogenous and labelled ubiquitin were produced which 
reveal that a similar level of variation is seen for both species. This suggests that the 
labelled ubiquitin was distributed uniformly throughout the homogenate prior to 
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freezing. It also suggests that the variation in intensity is due to variation in LESA 
sampling and not due to inhomogeneity in the sample. 
 
Figure 6.5 Clockwise from top left: schematic describing section locations within 
mimetic, locations selected for LESA sampling, LESA MS image of ions detected at 
m/z 904.6543 (l-Ub) and LESA MS image of ions detected at m/z 857.3632 (e-Ub). 
 
6.3.4 Quantification of ubiquitin in rat brain 
Using the LESA mimetic data the average intensity of the most abundant charge state 
(+10) of ubiquitin was calculated for each mimetic. Some electrospray injections failed 
due to liquid microjunction instability and loss of solvent on the sample surface, these 
data points were not included in the average. Average intensity was then plotted against 
concentration to produce a calibration curve, see Figure 6.6. Linear regression was 
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performed and the line fitted to the data with an R2 of 0.986 demonstrating good 
linearity between ion intensity and concentration. The 3 lowest concentration data 
points were below the limit of linearity so were not included in the linear fit. The limit 
of detection is difficult to determine due to the small number of data points and the 
large variation observed in this work. The error bars plotted on the curve, which 
represent ±1 standard deviation, are large. The high degree of variation could be due to 
a number of reasons: sample inhomogeneity (which can be somewhat ruled out due to 
investigations presented above), variation in sampling and extraction efficiency and 
variation in electrospray stability. Observations made during data acquisition suggest 
that a combination of unstable liquid microjunctions and electrospray were responsible. 
In a number of samples the detected ion intensity was low and a corresponding failure 
in electrospray was noted.  Variation could be reduced by improving the repeatability of 
the LESA method. It might be possible to improve the stability of the microjunction 
through further optimisation of sampling height relative to the surface and increasing 
the aqueous content of the solvent. The concentration range used in this work spans the 
limit of detection and only covers 2 orders of magnitude. A calibration curve was also 
plotted for the +9 charge state of labelled ubiquitin, see Figure 6.7. Linear regression 
from these data give an R2 value of 0.958. 
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Figure 6.6 Calibration curve generated from LESA MS data from mimetic tissue 
models, a) location of different concentration mimetics (nmol/g), b-c) ion intensity 
diagram of labelled ubiquitin in +10 and +9 charge states, d) calibration curve plotted 
from average ion intensity detected the +10 charge state over 8 pixels against 
concentration; error bars represent ±1 standard deviation. 
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Figure 6.7 Calibration curve for labelled ubiquitin in the +9 charge state.  
A single sagittal section of rat brain tissue was imaged using LESA MS under the same 
sampling parameters as the mimetic samples in order to quantify endogenous ubiquitin, 
see Figure 6.8. The average concentration of ubiquitin detected across the whole brain 
section was 113.45 nmol/g. Assuming an average rat brain mass of 2g, this equates to 
~385 μg ubiquitin per brain. Kaiser et al. used a protein standard absolute quantification 
(PSAQ) method which uses LC-MS to quantify ubiquitin in mouse brain tissue and 
found that the total concentration of ubiquitin was ~121 pmol/mg tissue.213 This equates 
to ~416 (±17) μg ubiquitin per brain. These numbers are in approximate agreement, the 
difference could be due to the biological differences between rat and mouse. The 
concentration of ubiquitin in rat brain was also calculated using the calibration curve for 
labelled ubiquitin in the +9 charge state. This gave a concentration of 94.54 nmol/g. The 
difference can be accounted for by the difference in linearity of the two curves which 
could be caused by the lower abundance of the +9 charge state. LESA images indicate 
that a higher concentration of ubiquitin is detected in the cerebellum compared with the 
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rest of the brain. Hsu et al. performed nano-DESI MSI on mouse brain tissue and found 
the distribution of ubiquitin to be near uniform, although the section they imaged was 
coronal and taken from a different region of the brain.214 This work has demonstrated 
that LESA MS may be suitable for the quantification of proteins in biological tissue; 
however the limitations in spatial resolution mean accurate concentration values cannot 
be assigned to different anatomical regions of the tissue. To improve this, significantly 
smaller sampling pipettes or capillaries would be required so that inter-pixel distances 
could be reduced without over-sampling. Alternatively, a different surface sampling 
technique which allows for continuous surface sampling to be performed might present 
a more practical route towards higher resolution imaging.  
148 
 
 
Figure 6.8. LESA MS imaging of rat brain tissue, a) optical image of tissue post-
sampling, the ring indicates the location of the cerebellum, b) example LESA mass 
spectrum and enlarged section showing peaks at m/z 857.3632 owing to ubiquitin in the 
+10 charge state, c-e) ion images of ions with m/z 616.1717 (heme), m/z 857.3632 (Ub 
+10) and m/z 952.6230 (Ub+9). 
6.4 Conclusions 
A novel method for quantitation of intact proteins in biological tissue by LESA MS was 
developed. This method used stable-isotope labelled protein standard spiked into tissue 
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homogenate was developed and tested on a protein previously detected in LESA MS 
experiments. A calibration curve was produced from mimetic tissue models which had 
good linearity although variation in LESA sampling resulted in a large degree of 
variation. Further optimisation of the surface sampling method could help overcome 
this problem. The concentration of ubiquitin in rat brain was quantified and was found 
to be in approximate agreement with a value quoted in the literature for mouse brain. 
This observation suggests that the method is successful and has accurately measured the 
concentration of a protein in tissue under ambient conditions whilst maintaining spatial 
integrity.  
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Chapter 7  
Liquid Surface Sampling Techniques: Flow-
probe Mass Spectrometry Imaging 
7.1 Introduction 
LESA has now been demonstrated as an excellent tool for the analysis of intact proteins 
from tissue samples. Whilst LESA MS does provide spatial information, the pipette tips 
used for sampling limit the spatial resolution of images produced. Work towards liquid 
surface sampling with improved spatial resolution using the Flow-probe is presented in 
this chapter. Flow-probe mass spectrometry has been demonstrated in the analysis of 
lipids, drugs and metabolites.49,114-117 Van Berkel and Kertesz demonstrated the 
detection of multiply charged ions by Flow-probe mass spectrometry, however the 
resolution of the mass spectrometer was insufficient to identify the ions.113 This chapter 
presents the development of a Flow-probe MS method for imaging proteins in tissue 
and a comparison of the capabilities of Flow-probe and LESA mass spectrometry in 
terms of their relative sensitivity, spatial resolution and throughput. 
7.2 Experimental 
7.2.1 Tissue samples 
Tissue samples were sectioned as described in section 2.2.1.1. 
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7.2.2 Flow-probe mass spectrometry 
7.2.2.1 Tissue sampling 
Flow-probe mass spectrometry was performed using the Prosolia™ (Indianapolis, US) 
system, as illustrated in Figure 7.1. Solvent was delivered to the sample surface via the 
outer of two coaxial capillaries. Solvent was aspirated from the surface via the inner 
capillary which is introduced to the mass spectrometer via an electrospray ionization 
source. The solvent system used in this work was 50:50 methanol:water with 1% formic 
acid and was optimized for the detection of proteins from tissue using the flow probe. 
Solvent was delivered at a flow rate of 2 μL/min, sheath gas pressure was manually 
altered based on visual inspection of the liquid microjunction stability. For static mode 
analysis of tissue, sampling locations were selected with an x,y spacing of 2 mm which 
allowed for spreading of the liquid microjunction without over-sampling, a total of 32 
locations were sampled. The probe dwelled on the surface for 3 minutes before 
retracting and flushing with solvent for 162 seconds before moving to the next location. 
For raster mode analysis line locations were selected with y-spacing of 1mm – it was 
found that less spreading of the microjunction occurred when operating in raster mode. 
The raster stage speed used was 80 μm/second. The probe height above the surface was 
set to 4 μm. At the end of each acquisition the method was paused and the signal from 
heme was monitored to indicate when the system was flushed, the next line of data was 
then acquired. 
7.2.2.2 Model system sampling 
A model system of marker pen ink on glass was produced. This was sampled using the 
Flow-probe in raster mode. The solvent system was 50:50 methanol:water with 1% 
formic acid and the flow rate was 10 μL/min. The raster stage speed was 80 μm/second 
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and the spacing between lines in the y-dimension was 5 mm. The AGC was turned off 
and the fill time was fixed at 30 ms. 
7.2.3 LESA mass spectrometry 
Surface sampling was performed as described in section 2.2.2.1. Sampling locations (32 
points) were selected for LESA MS across a single rat kidney section (serial to the one 
imaged by the Flow-probe). The z coordinate was set to a height 0.6 mm above the 
sample surface. The same solvent system was used for LESA and Flow-probe MS.  
7.3 Results and Discussion 
7.3.1 Flow-probe mass spectrometry: Static or ‘spot mode’ analysis of various 
tissue types 
The Flow-probe allows surface sampling via a continuous flow of solvent which is 
delivered to the surface and aspirated away at a user-defined flow rate; the instrumental 
set-up is outlined in Figure 7.1. The probe tip has a diameter of approximately 600 μm 
and offers the possibility of improved throughput and spatial resolution by sampling the 
surface in a continuous raster mode. 
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Figure 7.1 Schematic illustration of Flow-probe surface sampling experimental set-up: 
pump driven syringe delivers solvent to surface at user-defined flow rate through the 
outer of two co-axial capillaries, solvent with dissolved analytes is continuously 
aspirated from the surface via the inner capillary which is delivered to an electrospray 
ionisation source coupled to the inlet of the mass spectrometer. 
Experiments were designed to assess the capabilities of the Flow-probe and to compare 
results with LESA mass spectrometry. Example mass spectra acquired from mouse 
brain using the Flow-probe are displayed in Figure 7.2. Peaks with m/z corresponding to 
ions of ubiquitin in a variety of charge states dominate the spectrum. Ions with m/z 
857.56 were selected for CID and the mass spectrum of fragment ions is presented in 
Figure 7.2.b. Major fragment ions could be assigned to b and y fragment ions of 
ubiquitin. Sequence coverage of the assignment was 7.8% which is low; this is likely to 
be because the signal intensity of ions detected was low. A decrease in sensitivity 
relative to LESA is expected because the continuous flow of solvent acts to dilute the 
extracted sample at the tissue surface. In cases where the identity of the protein was not 
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known in advance it would be difficult to make an assignment from so few fragment 
ions. 
 
Figure 7.2. Example Flow-probe mass spectrum acquired from mouse brain tissue, a) 
full scan mass spectrum, the most abundant species detected was ubiquitin, b) CID mass 
spectrum acquired by fragmentation of ions with m/z 857.56, confirming the presence of 
ubiquitin which was identified with 7.8% coverage. 
A further dataset was acquired using the Flow-probe to analyse mouse liver tissue. An 
example mass spectrum is presented in Figure 7.3. An abundance of proteins was 
detected in the m/z region 700 – 1300. Major protein peaks were identified as liver 
fatty-acid binding protein detected with monoisotopic mass of 14279.5935 (Δppm = 
6.5) in charge states +13 to +16, haemoglobin subunit alpha detected with monoisotopic 
mass of 14972.7045 (Δppm = 2.3) in charge states +13 to +20 and haemoglobin subunit 
beta detected with monoisotopic mass of 15608.0580 (Δppm = 4.1) in charge states +13 
to +19. This finding is in agreement with analysis of human liver tissue by LESA MS 
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reported by Sarsby, in which they detected liver fatty acid binding protein, haemoglobin 
subunit alpha and beta.215 
 
Figure 7.3 Example Flow-probe mass spectrum acquired from mouse liver tissue, the 
most abundant proteins detected were liver fatty-acid binding protein (L-FABP), 
hemoglobin subunit alpha (α-Hb) and hemoglobin subunit beta (β-Hb).  
7.3.2 Static imaging of pharmaceutical dosed kidney tissue for direct comparison 
with LESA 
After demonstrating that the Flow-probe is capable of producing data comparable with 
LESA, a further experiment to assess the imaging capabilities of the Flow-probe was 
carried out. Rat kidney tissue was selected due to the large anatomical features which 
could potentially be differentiated by pixel sizes of 1 or 2 mm. Example spectra 
acquired from the same location on serial sections of rat kidney are presented in Figure 
7.4. Heme, α and β-hemoglobin dominate the spectra acquired using both techniques. It 
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should be noted that whilst lipids can be detected simultaneously with proteins by 
LESA, lipids are not detected in the Flow-probe mass spectrum. This is likely to be due 
to the relative solubility of lipids and proteins in the solvent system used which means 
the two classes of analyte are detected at different time points. Alternatively the reason 
could be due to signal suppression. Other than this, spectra look very similar. 
 
Figure 7.4. Comparison of spectra acquired by LESA and Flow-probe mass 
spectrometry, a) spectrum acquired by LESA mass spectrometry of rat kidney tissue, α- 
and β-Hb dominate the spectrum, b) spectrum acquired by Flow-probe mass 
spectrometry of same location on serial section of kidney tissue. 
Imaging datasets were acquired from serial sections of rat kidney by both Flow-probe 
and LESA mass spectrometry. The Flow-probe was used to interrogate 32 discrete 
locations in a ‘spot mode’ analysis in which the probe descended onto the tissue and 
remained still before retracting, flushing for a set period of time and moving to the next 
coordinates. Spectra were acquired in a single datafile and a chromatogram of the 
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intensity of different ions over time was produced, see Figure 7.5. There is a delay 
between the probe coming into contact with the sample and the signal being detected 
which can be observed from this chromatogram. The total volume of the capillary is 5.3 
μL, therefore at a flow rate of 2 μL/min, the time for analytes to travel from sample to 
inlet is ~2.6 minutes. The delay observed is actually ~5 minutes. This suggests there is a 
dead volume within the capillary or that flow phenomena occur at the surface. Such 
effects were observed by ElNaggar et al. where they found that the probe-to-surface 
distance and inter capillary distance was crucial to successful aspiration of analytes 
from the surface and solvent/analyte ‘plugs’ can form when these distances are too 
large. The co-localisation of chromatogram traces indicates that analytes do not separate 
within the capillary and are detected at the same time.  
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Figure 7.5 Illustration of data acquired by Flow-probe mass spectrometry, top – 
schematic illustration of surface sampling routine, bottom – example section of 
chromatogram acquired by sampling multiple locations on kidney tissue, time points 
marked demonstrate different stages in the sampling routine and indicate the delay 
between surface sampling and detection of analytes. 
Example ion images acquired by each technique and the locations selected for sampling 
are presented in Figure 7.6. These images demonstrate that approximately the same 
distribution of ions is observed by each technique. The high concentration of heme and 
haemoglobin around the renal pelvis is expected due to the large blood vessels which 
are responsible for transporting blood into and out of the kidney at this location. Similar 
distributions were observed in separate LESA imaging experiments outlined in Chapter 
5. 
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Figure 7.6. Comparison of LESA and Flow-probe mass spectrometry images acquired 
from serial sections of cassette-dosed rat kidney tissue with 2 mm pixel spacing, a) 
imaging using Flow-probe mass spectrometry, (left to right) ion intensity distributions 
of ions with m/z 394.18 (erlotinib), m/z 616.18 (heme) and m/z 894.86 (α-Hb), b) 
equivalent images of serial section and same ions using LESA mass spectrometry. 
Visual inspection of the sample after Flow-probe analysis enabled identification and 
measurement of regions sampled, see Figure 7.7. The size of region sampled varied due 
to inconsistencies in stability of the liquid microjunction. This means that the region 
sampled per pixel varied and therefore images produced from this data cannot be 
assumed to be entirely representative of the sample and could account for differences 
observed between LESA and Flow-probe data. The method described in Chapter 3 
could be used here. MALDI MS imaging of tissue which had been sampled by the 
Flow-probe could provide information about the regions surveyed, the repeatability of 
the technique and the differences observed between Flow-probe and LESA data. 
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Figure 7.7. Optical image of rat kidney tissue after Flow-probe mass spectrometry, dark 
regions indicate contact with solvent. Inter-pixel distance in the x and y dimensions 
should be fixed at 2 mm however this can be seen to vary due to inconsistencies in 
solvent spreading. 
 
7.3.3 Preliminary investigations into raster mode tissue imaging for higher spatial 
resolution MS imaging 
The true benefits of Flow-probe mass spectrometry would be realised if sampling could 
be performed in raster mode in which the sample was continuously moved beneath the 
probe tip without retracting between pixels. This would allow for complete analysis of 
the tissue without gaps between pixels and higher-throughput analysis. Raster analysis 
is commonly used for DESI and nano-DESI MS imaging of tissue samples and is 
generally considered the preferred method of analysis.85,211 To produce an image from 
data collected in raster mode, a single data file (containing a pre-defined number of 
scans) is acquired per line. Data for each pixel is produced by combining a certain 
number of scans. The time taken to acquire a single scan and the distance moved by the 
probe during that time determines the lateral resolution of the technique.  
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Before Flow-probe raster imaging can be performed, an understanding of the data 
produced is needed – this ensures confidence in the data and the location different 
signals originate from. It was demonstrated in the previous section that there is a delay 
between the probe contacting the surface and the detection of analytes from that surface. 
Measurement of this delay and analysis of model samples in which the location of 
analytes is known in advance will ensure confidence in data. An additional point of 
consideration for raster mode analysis is expected decrease in sensitivity over spot 
mode – the probe dwells on the surface for a shorter amount of time per unit area 
therefore has a shorter opportunity for desorption of analytes. Whether sensitivity is still 
sufficient to detect biological analytes will need to be assessed. 
An experiment in which raster sampling of rat kidney tissue could be assessed was 
performed, see Figure 7.8. An example mass spectrum in which all scans across the 
tissue section were summed together is displayed in Figure 7.8.b. It was found that the 
liquid microjunction repeatedly failed when it encountered the edge of the tissue 
section. An example chromatogram of a single line raster is presented in Figure 7.9. A 
delay of approximately 5 minutes between the probe encountering the tissue and the 
detection of biological analytes was observed.  
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Figure 7.8 Flow-probe mass spectrometry imaging of rat kidney tissue using ‘raster’ 
mode sampling, a) optical image of section before sampling, the locations selected for 
sampling (lines separated by 1 mm in the y-dimension) and image taken after sampling, 
b) example mass spectrum acquired from tissue by flow-probe raster sampling, this 
spectrum is the sum of all scans acquired from tissue.  
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Figure 7.9 Example chromatogram of single line Flow-probe raster on kidney tissue, 
shaded region indicates the time point at which the probe was sampling tissue, grey 
lines indicate the approximate start and end time points of the detected signal. 
In order to properly characterise the signal a simple model sample with known 
composition and dimensions was prepared; a red marker pen containing rhodamine B 
dye was used to draw a line on a glass slide which was then photographed prior to 
sampling. The time at which the signal should be observed relative to the start of the 
datafile was calculated as 128 seconds which accounts for the time taken for the probe 
to reach the ink (a distance of 8mm) and the time taken for the solvent to travel through 
the capillary which has a volume of 4.7 μL (NB a different capillary was used in section 
7.3.2). This is in agreement with what was observed, with a major peak appearing in the 
chromatogram at ~2.1 minutes see Figure 7.10. It was calculated the width of the line 
was 400 μm and therefore with a stage speed of 80 μm/second the signal should last for 
approx. 5 seconds. It was found that the signal was detected for ~18 seconds which 
suggests that some diffusion of analytes could be occurring when the solvent travels 
through the capillary. Alternatively the analyte could be adhering to the capillary or the 
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probe which results in peak broadening. This would affect the size of features which 
could be successfully resolved in a raster imaging experiment. The chromatogram for 
the second raster line demonstrates that ink was detected before the probe reached the 
line on the glass. This suggests that either there was residual ink on the glass slide, in 
the capillary or on the probe. An alternative explanation would be that analytes were 
spread across the glass during the sampling and have been genuinely detected at 
different locations/time points. Optical images of the slide were acquired to investigate 
whether there was any evidence of this, see Figure 7.11. Whilst a small indentation 
appears where the probe travelled there is no indication of red ink smeared across the 
slide. This suggests that residual ink in the capillary is the cause of higher baseline 
intensity. 
166 
 
 
Figure 7.10 Investigations into Flow-probe raster sampling, top: red marker pen on 
glass slide and regions selected for raster sampling, bottom: example chromatograms 
(for ions with m/z 443.23) from the raster lines indicated. 
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Figure 7.11 Optical image of sample after Flow-probe raster sampling, arrow indicates 
direction of travel of Flow-probe and dashed lines indicate approximate tracking of 
probe. There is little evidence here to suggest that the probe has caused delocalisation of 
ink across the sample indicating that carry over is caused by build-up within the 
capillary and not on the surface of the slide. 
7.4 Conclusions 
A method was developed which demonstrates for the first time that the imaging of 
proteins by Flow-probe MS is possible. It was found that Flow-probe MS can provide 
equivalent data to LESA mass spectrometry but with the potential for improved spatial 
resolution, through-put and financial costs (due to the lack of consumable items such as 
pipette tips and electrospray ionisations chips). The operation of the Flow-probe in 
raster mode was considered for the first time, and questions surrounding the diffusion of 
analytes within the capillary system were raised. Further work to ascertain and measure 
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dead volumes within the system must be performed before this mode of operation can 
be used with confidence. It is possible that spot mode analysis is the only suitable mode 
of operation for Flow-probe mass spectrometry, in which case the minimum pixel size 
possible would be 600 μm which is similar to that achieved with LESA MS imaging. 
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Chapter 8  
Application of LESA Mass Spectrometry: 
Analysis of Proteins Directly from Bacterial 
Colonies 
Work presented in this chapter was published in the following paper: Randall, E. C.; 
Bunch, J.; Cooper, H. J. Analytical Chemistry 2014, 86, 10504-10510. This is included 
in Appendix 2. 
Introduction 
This thesis has so far concentrated on the development of chemical imaging methods for 
the analysis of biological tissue. Methods for tissue samples are well established, but 
other sample types are highly relevant to both biomedical and pharmaceutical research. 
Bacterial samples have been the subject of mass spectrometry research since the 
1970s.
216,217
 Advances in software and instrumentation have helped create powerful 
tools for microbiological differentiation and identification.
42,218
  
The analysis of intact protein species from bacterial colonies via LESA mass 
spectrometry will be the focus of this chapter. The limited spatial resolution of LESA 
MS imaging would not present a problem for this particular application because the size 
of spatial features is not expected to be smaller than the typical pixel sizes.
219
 Here is 
presented the development of LESA mass spectrometry methods for the analysis, 
identification and imaging of intact proteins directly from living Escherichia coli 
colonies in petri dishes.  
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Experimental 
8.1.1 Surface Sampling 
Petri dishes containing E. coli K-12 colonies were placed directly into the TriVersa 
Nanomate chip-based electrospray device (Advion, Ithaca, NY) adjacent to half a 96-
well microtitre plate (ABgene PCR plate Thermo Fisher Scientific, Leicestershire, 
U.K.) into which the extraction solvent system is placed, see Figure 8.1. Surface 
sampling was performed using the advanced user interface (AUI) feature of the 
TriVersa NanoMate ChipSoft Manager software which allowed for more flexibility in 
selection of sampling locations. The volume of solvent for sampling was 3 μL solution 
and the solvent system was acetonitrile and water (39.6:59.4) with 1% formic acid. The 
exact sampling height of the pipette tip varied (from -9 mm to -11 mm from initial 
position of robotic arm), depending on the size of the colony and spread of agar in 
different samples; for increased extraction of proteins the pipette tip came into contact 
with the top surface of the colony but did not penetrate the agar below. Once in contact 
with the colony, the tip dispensed 2 μL solvent onto the colony which was held in 
contact for 3 seconds. The solution was then re-aspirated into the pipette and the tip 
engaged with the nanoelectrospray chip in order to start electrospray ionization and 
introduction of the sample into the mass spectrometer. The sample was electrosprayed 
with a gas pressure of 0.3 psi and a tip voltage of 1.75 kV. Mass spectra were collected 
in full scan mode (m/z 500-2000) at a resolution of 100 000 at m/z 400. AGC target was 
1 x 10
6
 charges. Each scan was comprised of 30 coadded microscans. Data were 
recorded for 5 minutes (~ 11 scans). (Note that a stable electrospray could be 
maintained for ~ 50 mins from a single LESA analysis).  
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8.1.2 Protein identification 
CID was carried out in the linear ion trap and the fragment ions were detected in the 
orbitrap at a resolution of 100 000 at m/z 400. AGC target was 5 x 10
4
 charges. CID 
experiments were performed with helium gas at normalized collision energy of 35% 
(optimized for sequence coverage – data not shown) and an isolation width of 10 Th. 
MS/MS spectra were collected in the range m/z 300-2000 and are comprised of 10 
coadded microscans. Data were analyzed using Xcalibur 2.10 software (Thermo Fisher 
Scientific) where the Xtract program was used to calculate monoisotopic masses. For 
data analysis using ProSightPTM 2.0, CID MS/MS spectra were deconvoluted using the 
Xtract program (S/N threshold 3). Xtracted monoisotopic fragment masses were 
searched against the E. coli K-12 database in ProSightPTM 2.0, with a fragment 
tolerance of 10 ppm, precursor tolerance 100 ppm, in order to assign putative protein 
identifications. Two search types were used in Prosight, ‘absolute mass search’ and 
‘sequence tag search’. Absolute mass search involves searching the mass of the 
precursor ion against intact masses of proteins within the chosen database. If a match is 
found then fragment masses can be matched to theoretical fragments of that protein. 
Sequence tag search involves compiling lists of amino acids which could correspond to 
observed fragment masses or differences in mass between two fragments. The amino 
acid sequences are then searched against the appropriate database to see if they 
correspond to sequences of known proteins. Protein identities were confirmed by 
manual analysis using Protein Prospector 
(http://prospector.ucsf.edu/prospector/mshome.htm). 
8.1.3 LESA MS imaging 
LESA MS imaging of bacterial colonies was performed using the advanced user 
interface of Chipsoft software (Advion). Coordinates were selected for 25 points in a 
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grid covering bacterial colony and surrounding media. Height relative to surface was ~ -
0.2 mm and was manually adjusted according to sample topology. Surface sampling 
was performed as described above. Data were recorded for 8 minutes per pixel, an 
injection time of 1 ms was found to give sufficient signal, 30 microscans were coadded 
per scan. Data were processed using matlab and in-house software.  
8.1.4 Post-sampling image analysis 
Photographs of the colony surface were taken after LESA sampling. Areas which came 
into contact with solvent during sampling were measured using ImageJ software. 
Contact with solvent caused discolouration of the colony surface so the diameter of 
these regions could be visually identified in the photos. The image scale was set using 
features of known size in the image, either a ruler or coordinate spots of the universal 
adaptor plate.  
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Results and Discussion 
8.1.5 Development of LESA MS for analysis of proteins from bacterial colonies 
A sample of E. coli K-12 was inoculated on agar and incubated at 21°C for 3 days. The 
sampling set-up used in this work is illustrated in Figure 8.1. A set of coordinates was 
printed and attached to the bottom of the tray to allow more space for samples. The 
solvent system was placed into a 96-well plate adjacent to the petri-dish. The advanced-
user interface function of Chipsoft was used to perform surface sampling; the sample 
plate required for LESA Points software was too deep to allow a petri dish to sit on top 
and still allow the robot to move freely. Coordinates for sampling were selected 
manually. 
 
Figure 8.1 Experimental set up: (A) sample tray of Triversa Nanomate; (B) photocopy 
of the universal adaptor plate – for x,y coordinates; (C) adhesive putty (Blu-tack) to 
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secure petri dish in position: (D) E. coli colony: (E) petri dish containing agar; (F) half 
96-well plate containing extraction/electrospray solvent system. 
It has previously been demonstrated that acetonitrile and water is the best solvent 
system for the extraction of proteins from biological tissue.
215
 Therefore acetonitrile and 
water was used as the solvent system for LESA in this work. It was found that 
numerous peaks corresponding to protein ions in various charge states were detected 
using this method, as demonstrated in Figure 8.2. It was found that the mass spectrum 
contained approximately 150 peaks corresponding to ~60 bacterial proteins in a range of 
charge states. The molecular weights of these proteins ranged from approx. 5 to 32 kDa. 
This mass range is in agreement with the findings of McFarland et al who report the 
detection of intact proteins in the range 4-37 kDa from S. Typhimurium by ESI orbitrap 
mass spectrometry.
220
 The benefit of performing such analyses by LESA rather than ESI 
MS is the retention of spatial information. This could allow for the mapping of proteins, 
peptides and secondary metabolites produced in the presence of competing microbes.  
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Figure 8.2 LESA mass spectrometry of E. coli K-12 bacterial colony stored at 4 °C. a) 
Full scan mass spectrum; b) Photograph of bacterial colony growing on solid agar 
medium in petri dish. Red spot marks region sampled by LESA; c) Enlarged m/z region 
from full scan mass spectrum (m/z 900 – 1300) which contains the majority of peaks 
corresponding to protein ions. Symbols indicate peaks subsequently selected for CID. 
The height to which the pipette tip descended during surface analysis was investigated 
to see how this affected mass spectra acquired. The surface was sequentially sampled at 
a single location, starting at approximately 0.2 mm above the surface, allowing the tip to 
descend 0.2 mm lower each time. Spectra were recorded at each respective sampling 
height, see Figure 8.3. It was found that proteins were only extracted when the pipette 
tip came into contact with the colony surface. Although a larger number of proteins 
were detected when the pipette tip sampled further below the colony surface (Figure 
8.3.c), a compromise was made between good extraction of proteins and electrospray 
instability due to capillary blocking. The mass spectrum shown in Figure 8.3.d contains 
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peaks corresponding to singly-charged species as well as protein peaks indicating that 
the pipette tip may have punctured the agar below the colony.  
 
Figure 8.3 Mass spectra obtained by sampling the same location on the surface at 
different heights relative to the surface: a) 0.2 mm above surface; b) 0 mm above 
surface; c) -0.2 mm above surface; d) -0.4 mm above surface. Only when pipette tip 
comes into contact with the colony surface (b) and below are proteins extracted. 
It is possible that the observation of increased numbers of proteins in mass spectra 
obtained following contact between the pipette tip and the surface is due to the insoluble 
nature of the extracellular matrix produced by colony bacteria. In placing the pipette tip 
in contact with the surface, this insoluble layer could have been physically disrupted 
allowing more efficient extraction of proteins contained within the colony. It should be 
noted that this ‘contact’ method of surface sampling is different from other LESA 
methods described in the literature, see Figure 8.4. Kai et al report the extraction of 
small molecule antibiotic compounds using LESA – a method in which only the solvent 
droplet came into contact with the bacteria.
43
  
177 
 
 
Figure 8.4 Improved sampling precision obtained from ‘contact’ LESA sampling: a) 
Schematic illustrating the surface area of sample covered by each solvent droplet when 
sampled by a liquid micro-junction (contact between surface and solvent only); b) 
schematic illustrating the smaller surface area covered by each sample droplet with the 
‘contact’ method (contact between surface and pipette tip); c) sampled area following 
liquid microjunction sampling; d) sampled area following ‘contact’ LESA. 
Measurement of the relative areas sampled using contact and non-contact LESA is 
presented in Figure 8.4. The process of placing the pipette tip in contact with the colony 
surface during sampling appears to limit the spread of solvent to the area of the pipette 
tip. It is possible that the low pressures used to dispense and aspirate the solvent droplet 
are insufficient to push the solvent beyond the end of the pipette tip and therefore the 
colony acts as a plug. This sampling mechanism appears to be slightly different from 
contact LESA described in previous chapters due to the soft nature of the sample. It is 
possible that the relatively large number of proteins detected is due to residual bacteria 
on the sampling pipette. This would effectively increase the sampling time so that 
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analytes could continue to dissolve into the solvent during electrospray. This would also 
happen to some extent during tissue analysis but only the very tip of the pipette would 
contact the tissue. Therefore one might expect this effect to be less pronounced. The 
total surface area sampled by the contact LESA method is ~0.24 mm
2
, as measured 
using ImageJ on images of the puncture mark on colony surface after sampling. This 
observation represents a significant improvement when compared to the area covered by 
the usual LESA solvent droplet, which was measured to be ~10.64 mm
2
 (solvent 
sampling discoloured the colony surface allowing for measurement of the area from 
photographic images). Note that the droplet volumes (3 μL) were the same for both 
methods.  
The outer diameter of the pipette tips used for LESA sampling is 600 μm. The inner 
diameter of the pipette tips is 400 μm. As it is impossible to ascertain without further 
investigation whether solvent is contained fully within the inner portion of the pipette, it 
should be assumed that the minimum pixel size accessible by LESA is 600 μm. There 
are numerous reports of MALDI imaging of microbial colonies; these have a typical 
pixel size of 50-200 μm.41,48,164,221 Whilst this is obviously better than LESA, there are 
various experimental problems encountered during MALDI analysis of wet agar 
samples. Deposition of a matrix onto a wet sample is not ideal due to the potential for 
lateral diffusion of analytes which could compromise spatial integrity of the sample.
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Alternative approaches have included a dehydration
222
 or transfer step in which 
microbial samples are imprinted onto a more suitable substrate.
223
 Dehydration of the 
sample results in a flat, dry sample which is more amenable to certain sampling 
techniques, however the colony cannot be assumed to remain chemically unaltered 
during this step. Imprinting methods have provided a possible route for indirect imaging 
however selective transferal of analytes could occur leading to inaccurate results. 
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DESI and nano-DESI have both been reported for the ambient MS imaging of microbial 
samples. Typically pixel sizes in the range 150-200 μm have been used.222,223 This has 
provided insight into the distribution and production of secondary metabolites and other 
small molecules under ambient conditions. As discussed in previous chapters, LESA 
MS has the capability to detect multiple classes of compound simultaneously. Whilst 
alternative solvent systems for LESA analysis of microbes have not been fully explored 
in this work, it is possible that by optimization of sampling conditions multiple analyte 
classes – such as lipids, proteins, drugs, and metabolites from more than one microbial 
species - could be simultaneously detected. This would be of interest for research 
focused on the behavior, interaction and response of microbes under varied conditions, 
for example assessment of drug efficacy. 
8.1.6 Top-down identification of proteins from E. coli colonies 
CID mass spectrometry experiments were carried out to identify a number of protein 
ions detected during LESA MS. Ions centered at m/z 923.51 (+10 charge state), 933.91 
(+7), 954.43 (+10), 1028.14 (+15), 1190.31 (+7), and 1212.94 (+6) were fragmented. 
The product ions were searched against the E. coli K-12 database in ProSightPTM 2.0, 
using either the ‘absolute mass search’ or the ‘sequence tag search’. Tentative protein 
identifications were confirmed by manual analysis. The proteins identified and the 
protein sequence coverages are shown in Table 8.1. The sequence coverages ranged 
from 13 to 40%. A representative MS/MS spectrum from one of the identified proteins, 
DNA-binding protein HU-beta, is shown in Figure 8.5. MS/MS spectra from the other 
protein ions along with fragment assignments are included in Appendix 3. 
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Figure 8.5 CID mass spectrum of ions centred at m/z 923.51 (+10 charge state), 
identified as DNA-binding protein HU-beta.  Fragment ions observed are shown inset.  
A total of 6 proteins were identified, see Table 8.1. DNA binding protein HU-alpha and 
HU-beta are both histone-like DNA binding proteins which are capable of wrapping 
DNA to stabilize and prevent its denaturation under extreme environmental 
conditions.
224
 DNA binding protein H-NS increases thermal stability of DNA and 
inhibits transcription at low temperatures.
225
 The function of protein YjbJ is poorly 
understood but is recognized as a highly abundant protein in E. coli.
226
 CspA is a cold 
shock response protein, known to be induced at temperatures of 15°C or lower.
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Multiple stress resistant protein BhsA is known to be induced under a range of stressful 
conditions including drastic pH changes, heat shock, presence of heavy metals and 
hydrogen peroxide. As a result this protein inhibits biofilm formation by repressing cell 
aggregation and increases cell viability under stressful conditions.
228
 A number of these 
proteins (HU-alpha, HU-beta, YjbJ, H-NS) were also detected by ESI top-down MS/MS 
of S. Typhimurium reported by McFarland et al.
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Table 8.1 Details of proteins identified from LESA MS  
m/zmeas m/zcalc Δppm 
Charge 
state 
% 
Sequence 
Coverage 
Protein 
identity 
954.5104 954.5133 
-3.0 
 
+10 28 
DNA binding 
protein HU-alpha 
1027.6038 1027.6069 
-3.0 
 
+15 18 
DNA binding 
protein H-NS 
1189.5921 1189.5919 
0.2 
 
+7 23 
UPF0337 
protein YjbJ 
1212.2801 1212.2719 
6.8 
 
+6 13 CspA 
923.0039 923.0067 
-3.0 
 
+10 40 
DNA-binding 
protein HU-beta 
933.4871 933.4822 5.2 +7 32 
Multiple stress 
resistance protein 
BhsA 
 
It should be noted that whilst a number of proteins have been identified in this study, it 
was not possible to identify all proteins from their MS/MS spectra. Ions of m/z 1254.99 
(+7 charge state), were also fragmented and the product ions searched against the E. coli 
K-12 database in ProSightPTM 2.0, using both the ‘absolute mass search’ and the 
‘sequence tag search’. Neither search returned hits corresponding to the correct intact 
mass. Top-down methods are used relatively infrequently compared to bottom-up 
identification techniques and as such the demand for software for top-down methods is 
lower. Whilst several platforms are available, e.g., Prosight PTM 2.0,
229
 ROCCIT 
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(roccit.caltech.edu), neither reliably fully characterized the proteins in this work and a 
large amount of manual characterization was required. This aspect would need 
addressing if top-down methods were to become more established. 
8.1.7 Investigation into storage effects 
The selection of proteins detected and identified from colonies stored at 4°C are 
indicative of extreme environmental conditions, consistent with prolonged refrigerated 
storage conditions. After the initial incubation period to grow the colonies, samples 
were stored at 4°C for a number of days, which explains the induction of a cold shock 
response. For comparison, a further set of bacterial samples were grown. These colonies 
were stored at room temperature (~20°C) prior to mass spectrometric analysis and were 
never exposed to low temperatures.   
LESA mass spectra obtained from bacteria grown and stored at room temperature are 
displayed in Figure 8.6. For comparison, a LESA mass spectrum acquired from a 
colony grown at room temperature for 3 days and then stored at 4 °C for two days is 
also presented. Peaks corresponding to all the proteins identified from the LESA mass 
spectrum shown in Figure 8.6 (in which bacteria had been grown for 3 days at room 
temperature before being stored at 4°C for 7 days) were observed, albeit with differing 
relative abundances. This could be due to differences in protein expression as a result of 
prolonged cold shock or may be due to differences in LESA extraction efficiency either 
as a result of prolonged cold shock or colony topology. Figure 8.6.b shows a mass 
spectrum obtained from a colony stored at room temperature for 3 days. The colony was 
sampled at three separate locations, as indicated on the photograph inset. At location 1, 
peaks corresponding to HU-alpha and HU-beta were observed but none of the other 
proteins identified above. At location 2 (Figure 8.6.b), peaks corresponding to HU-
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alpha, HU-beta, and CspA were observed. At location 3, none of the proteins identified 
above were observed. The proteins BhsA and YjbJ were not observed in any location. 
 
Figure 8.6 LESA mass spectra of bacteria stored at (a) 4 °C for 2 days (b) at room 
temperature (20 °C) for 3 days and (c) at room temperature (20 °C) for 10 days (y-axes 
are equivalent). Symbols denote identified stress response proteins. Inset: Photographs 
of colonies with sampling locations indicated.  
A repeat analysis was carried out after the colonies had been stored at 20 °C for a 
further 7 days (Figure 8.6.c). Again, three separate locations were analysed, as 
indicated. In two of the locations, all but one (BhsA) of the stress response proteins 
previously detected in bacteria stored at 4°C were detected.  At the other location, all 
but BhsA and YjbJ were detected. These results suggest that prolonged storage can 
induce various stress responses in bacteria. Multiple stress resistance protein BhsA, 
however, was not detected at any location from colonies stored at 20°C, either after 3 or 
10 days, suggesting that either temperatures lower than 20°C, or storage for longer than 
10 days is required for expression of this protein. As mentioned above BhsA has been 
shown to inhibit biofilm formation. It is possible that expression of BhsA under 
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refrigerated conditions resulted in reduced biofilm formation thus aiding the LESA 
process. These results suggest that bacterial response to external stimuli – in this case 
temperature – can be assessed by LESA mass spectrometry. It would be interesting to 
see whether proteomic responses to other factors, such as drug compounds could also be 
detected.  
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8.1.8 LESA MS imaging of bacterial colonies 
After demonstrating the successful detection of proteins from bacterial samples an 
experiment was conducted to assess whether LESA was capable of detecting different 
distributions of species within a colony and the surrounding media. A grid of 
coordinates was selected for sampling, with an inter-pixel spacing of 2mm. Example ion 
images are displayed in Figure 8.7, these images indicate that it is possible to detect 
different distributions of ions and that different ions are more abundant in the centre of 
the colony and some at the edges. The distribution of HU-alpha (m/z 954.12) and H-NS 
(m/z 1027.36) have similar but not identical distributions. Protein species were only 
detected from samples extracted from the colony itself and not the surrounding media. 
Species detected from media were generally singly charged, two example ions are 
displayed in Figure 8.7. Without assessing the reproducibility of the method it is 
impossible to say whether differences in detected abundance are due to true differences 
in concentration or differences in extraction efficiency. Therefore differences in protein 
abundance between pixels taken from the colony could be due to real biological 
differences in expression or variation in extraction efficiency or electrospray stability.  
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Figure 8.7 LESA MS imaging of E coli colony: a) example LESA mass spectrum 
acquired from location labelled in blue, b) locations for LESA sampling and example 
ion images of proteins and species located in the agar, (clockwise from top left) m/z 
954.12 (HU-alpha), m/z 1027.36 (H-NS), m/z 933.97 (unidentified singly charged 
species), m/z 1133.35 (unidentified singly charged species). 
By visual and photographic inspection of the sample after LESA it was clear that 
portions of the colony adhered to the pipette tip during sampling. The dimensions of an 
E. coli cell are approximately 1 x 2 μm and the diameter of the electrospray nozzle is 
5.5 μm. It would therefore only require 2 or 3 bacteria to block the nozzle and prevent 
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stable electrospray ionisation. This is consistent with the instabilities and frequent 
nozzle blocking observed during experiments. It might be possible to overcome such 
problems by diluting the extracted sample in a separate solvent well after surface 
sampling. This could also act as a pipette wash and help remove residual bacteria from 
the tip. Alternatively, approaches reported in the literature such as imprinting, 
dehydrating or growing samples on a paper substrate could prevent nozzle blocking and 
make the method more reproducible.221,223 Problems associated with these approaches 
have previously been discussed. In order to be confident that differences in abundance 
were true, a reproducible method would have to be established.  
As discussed, a variety of other mass spectrometry methods have also been used for the 
imaging of microbiological samples. Each technique is associated with advantages and 
limitations. As previously stated the level of spatial detail provided by LESA is 
probably sufficient because the size of features within an image (such as excreted 
secondary metabolites) is unlikely to be smaller than 1 or 2 mm. A further advantage of 
LESA is that the sampling height can be varied between pixels which allows for 
variation in topology. Techniques which employ raster sampling such as DESI, nano-
DESI and the Flow-probe encounter problems during the analysis of microbiological 
samples due to the probe to surface distance dependence of data and the varied topology 
of such samples.49,87,223  
Conclusions 
A method suitable for the top-down extraction, detection and identification of intact 
proteins from living bacterial colonies has been developed and investigated. The 
identities of these proteins appear to indicate the well-being of the colony. The method 
has implications for microbiological research as it may be suitable for the study of 
bacterial growth, communication and response to external factors such as 
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pharmaceuticals and pH. Moreover, the ‘contact’ LESA method offers improved 
sampling precision and could be useful for spatial profiling of bacterial colonies, or 
analysis of contaminated surfaces. Further investigation of complementary analysis and 
imaging methods could provide additional data regarding multiple analyte types
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Chapter 9  
Conclusions and Further Work 
This thesis has discussed the development and integration of MSI and SRS microscopy 
for the analysis of various biological sample types. The optimisation of individual 
methods for specific applications was presented, alongside the development of 
combined methods which aimed to provide a more complete analysis of the sample in 
addition to probing aspects of the fundamentals of surface sampling. Quantitative 
analysis has been a theme throughout the thesis, and assessment of both MSI and SRS 
as quantitative techniques has been presented. Issues surrounding the variation involved 
in these measurements have been identified and suggestions for improvements have 
been made – these include adjustments to data acquisition methods as well as sample 
preparation. The following chapter will discuss these in more detail; ideas for further 
work which could further improve the methods described and applications in which 
they might provide insight will also be outlined. 
The use of MALDI MSI in combination with LESA MSI was presented in Chapter 3. 
This approach enabled the analysis of drugs, lipids and proteins from a single sample, 
which has applications for pharmaceutical research in which the distribution of a drug 
and associated endogenous molecules need to be simultaneously mapped. It was found 
that MALDI imaging of LESA sampled tissue allowed for the visualisation of sampled 
regions and revealed changes in distribution of analytes within them. Accurate 
measurement of these regions allowed variation and spatial precision of LESA sampling 
190 
 
to be assessed. Changes to surface chemistry within these regions were assessed by a 
number of multivariate analysis methods and provided an indication of how analyte 
distribution changed after LESA sampling, for example the distribution of different 
lipid adducts was altered. This information would be important if one wanted to 
combine the methods in a multimodal workflow – because it is not possible to obtain 
the same data by LESA MS after a matrix has been applied for MALDI. 
A combined LESA and MALDI MSI method could have applications in a variety of 
situations. Tissue washing steps are a common sample preparation strategy during MSI 
analysis, however a thorough understanding of how washes affect and change the tissue, 
and whether these changes occur uniformly across the tissue remain unclear. Results 
obtained in both Chapter 3 and 5 of this work indicate that the same solvent system 
applied to different regions of brain and kidney tissue affect the tissue to different 
extents. This could have a profound effect on MSI results because false contrast could 
be introduced to ion images. The method could therefore be used both as a screen to 
identify the most effective washing solutions or protocols and also to understand 
uniformity of washing. As the uptake in liquid-based surface sampling increases the 
demand for robust and repeatable methods will also increase. The method could 
therefore also be used to assess the variability in sampling methods – tissue 
homogenates or samples of known uniformity could be used to assess such things. So 
far the use of LESA MS in combination with SRS has not been attempted. However the 
use of SRS methods outlined for use with MALDI could provide valuable information 
regarding LESA sampling effects – for example SRS images acquired before and after 
LESA could indicate how the sample has changed and how much of a particular analyte 
has been removed. Certain practical issues such as how to ensure that the same region 
has been imaged before and after could be resolved through the use of fiducial markers.  
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The use of SRS to study MALDI surface sampling effects was discussed in Chapter 4. 
The design of model samples which were compatible with both techniques was a major 
factor within this work. Matrix compounds are typically selected due to their high UV-
Vis absorption properties which results in a tendency to undergo two-photon absorption 
under irradiation of the lasers used for SRS microscopy. This interference results in 
non-linear absorption effects. Nonetheless a suitable model sample was produced and it 
was found that SRS was able to visualise and quantify MALDI surface sampling. The 
number of molecules of analyte and matrix removed during MALDI analysis under 
varied laser conditions (both fluence and repetition rate) were measured. SRS and 
spontaneous Raman microscopy were used to investigate ion yields produced using two 
different matrix compounds under varied repetition rate. It was found that these data 
supported theories postulated in the literature about photomodification of cinnamic acid 
derivatives preventing efficient desorption/ionisation at higher laser repetition rates. The 
SRS imaging of analyte distribution in matrix crystals was also performed. It was found 
that SRS was able to visualise the distribution of lipids extracted from tissue into DHB 
matrix crystals. This would provide insight into optimal sample preparation methods. In 
addition the level of co-crystallisation of an analyte and matrix compound was imaged 
by SRS; it was found that the two compounds investigated in this work did not 
completely co-localise and hot-spots of analyte were found within matrix crystals. 
Further work should aim to improve variability inherent in these methods which is at 
least in part due to sample preparation methods which produce inhomogeneous layers of 
crystals on glass. Investigation into other substrates should also be conducted because 
different wettabilities could aid in the formation of smaller droplets on the surface and 
result in smaller crystal sizes. Optimisation of spraying parameters could also improve 
crystal size and surface coverage – for example higher nebulising gas temperature. 
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Alternative matrix/analyte deposition methods could also be of use, sublimation has 
been shown to produce more uniform layers of compounds however more complicated 
methods would be required to measure the thickness of the deposited layer. The 
eventual goal of this method would be to examine MALDI MS methods used on tissue. 
SRS could be used to image a tissue sample before analysis, after matrix deposition to 
assess extraction efficiency and after MALDI MS to quantify amounts removed. This 
would allow for monitoring of every stage of the MALDI process and would help 
optimise the process as well as quantify ion yields. However, the complex sample type 
incorporating tissue, matrix and possibly a drug compound would be impossible to 
image using the current SRS set-up. It would be difficult to isolate specific signals in 
the complex fingerprint region of the Raman spectrum and therefore individual analytes 
could not be imaged with confidence.  
A multimodal SRS, LESA and MALDI imaging method was presented in Chapter 5. 
SRS microscopy produced images with a pixel size of ~200 nm. Individual cells and 
cell nuclei were visualised in these images – it is not possible to do this using the MS 
techniques described in this work. LESA MS was used on the same tissue sample and it 
was possible to detect multiple drug compounds, various lipid species and proteins 
simultaneously. The pixel size in these images was ~700 μm and this was sufficient to 
distinguish between different tissue anatomies in the rat kidney. MALDI MSI was 
performed after LESA imaging and enabled the exact regions sampled by LESA to be 
determined. This enabled more accurate determination of the locations where each 
analyte was detected by LESA. The quantitative abilities of SRS were also investigated 
in a method designed to quantify erlotinib in rat kidney from a dosed animal. A 
calibration curve was produced from a sample of known composition before 
measurements were taken from dosed tissue. It was concluded that the background 
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intensity detected from tissue was too high to allow for accurate determination of 
erlotinib concentration in this experiment. 
In further work the background signal from tissue could be further characterised in 
order to better understand whether SRS can be used to provide quantitative 
measurements of erlotinib in tissue. In order to establish whether the signal from 
erlotinib is real, an SRS spectrum surrounding the probed resonance frequency could be 
produced. If a peak occurs in the right place then it can be concluded that erlotinib has 
been detected. This approach would also enable the level of background to be 
determined. 
LESA MS was evaluated as a quantitative tool in Chapter 6. The sensitivity and breadth 
of analytical applications possible with LESA make it an attractive tool for ambient 
analysis. The incorporation of an internal standard into mimetic tissue models was used 
to provide a calibration which accounted for extraction efficiency. This was found to 
produce good linearity and a value for the concentration of ubiquitin in tissue was found 
to be in agreement with a literature value. The variation observed in measurements 
tallied with instable electrospray and poor liquid microjunction stability. These 
parameters can be improved via optimisation of sampling parameters and could be one 
focus of further work.  
Expansion of this work could include the assessment of a more complete workflow for 
the quantification of proteins in tissue samples. Labelled ubiquitin used in this work was 
acquired from Sigma Aldrich however it is possible to express labelled proteins by 
culture of genetically modified bacteria in isotopically-labelled media. This would 
enable researchers to tailor their experiment and quantify (in theory) any protein of 
interest.  
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In Chapter 7 the use of Flow-probe mass spectrometry for the imaging of biological 
tissue was discussed. The Flow-probe operates a similar mode of surface sampling to 
LESA but presents the opportunity for higher resolution and throughput imaging. This 
technique has the potential to provide similar data but with better spatial resolution, 
higher throughput and more cheaply due to the redundancy of certain consumable items. 
Data acquired by the Flow-probe were compared with LESA data and were found to be 
of a similar quality judging by the number and type of proteins detected. A number of 
the same proteins were detected by both methods for a range of tissues including brain, 
liver and kidney. For the first time a method was presented in which the Flow-probe 
was operated in raster mode and was found to provide equivalent protein data to that 
obtained using spot mode analysis.. An investigation into the potential spatial resolution 
of the Flow-probe was designed, however further work is required to fully characterise 
this. Experimental problems with reproducibility prevented firm conclusions being 
drawn about the usefulness of the Flow-probe operated in raster mode for tissue 
imaging. 
In further work better characterisation of raster sampling would be necessary. The use 
of tissue homogenate samples could help answer questions about whether variation in 
signal observed by raster analysis is due to real spatial differences within the sample or 
separation or flow effects within the capillary. Raster mode sampling has the potential 
to provide improved throughput but exactly how fast data of sufficient quality can be 
acquired requires further experimentation. The optimisation of stage speed, flow rate of 
solvent and scan rate of the instrument will all be integral to this analysis.  
In Chapter 8 the use of LESA MS for analysis of a different sample type was assessed. 
A novel method for the analysis, identification and imaging of intact proteins from 
living bacterial colonies under ambient conditions was developed. It was found that a 
195 
 
large number of proteins could be detected without sample preparation or modification. 
A number of these proteins were identified via top-down methods. The distribution of 
proteins and singly charged species was mapped by LESA MSI although the variation 
observed within these images requires further characterisation. One of the most 
significant problems with this method is electrospray instability; most likely due to 
residual bacteria adhered to the pipette tip. Methods to improve electrospray instability 
should be the focus of initial further work. 
There are a number of applications in which this method could prove useful. If it were 
possible to identify microbial species via MS analysis – now routinely achieved via 
MALDI-TOF MS analysis – the method could be used to analyse contaminated surfaces 
in situ. For example this would be useful in hospitals or workplaces; of course this 
would bring into question the sensitivity of the technique because a much larger number 
of cells would be present in a cultured sample. 
Multimodal methods of chemical imaging have been demonstrated to enhance analysis 
during the study of tissue samples. Using a different and complementary technique to 
image a bacterial sample after LESA could provide both additional biological 
information – such as confirmation of distribution of analytes – and also information 
about the reproducibility of the method. For example, optical imaging methods 
(confocal microscopy or SRS) could be used to image samples before and after LESA 
analysis and provide a measure of how much material has been removed and how that 
which remains has been changed. This would provide some guidance over the issue of 
how far the solvent spreads during analysis – this information is crucial for accurate 
determination of pixel size. Multimodal imaging of microbial samples was 
demonstrated by Baig et al. who used confocal Raman microscopy to guide targeted 
SIMS imaging of quinolone metabolites from Pseudomonas aeruginosa.
230
 A high 
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resolution imaging technique such as SRS could also be capable of imaging individual 
bacterial cells. It is possible that such images could indicate how bacteria have been 
affected by sampling methods such as LESA or MALDI and could help ascertain 
whether the samples are still viable. 
Work in this thesis has explored how chemical imaging methods could be used for 
improved analysis of biological samples with relevance to both pharmaceutical and 
biomedical research. Widespread applicability of such methods will help the field 
expand and become more universally useful. The expanding field of mass spectrometry 
imaging will require further validation of methods over the coming years. The 
increasing attention from clinical fields in particular will require large-scale validation 
studies making use of varied patient populations. Standardised methods and 
instrumentation will aid the problems associated with user-dependency. Aspects of both 
the fundamentals and applications of MSI and SRS have been explored and discussed. 
To summarise, further work should focus on the validation of described methods by 
repeat analysis, improvements to sample preparation and application of methods on 
novel sample types. 
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ABSTRACT: Combined mass spectrometry imaging methods in which two diﬀerent
techniques are executed on the same sample have recently been reported for a number of
sample types. Such an approach can be used to examine the sampling eﬀects of the ﬁrst
technique with a second, higher resolution method and also combines the advantages of each
technique for a more complete analysis. In this work matrix-assisted laser desorption ionization
mass spectrometry imaging (MALDI MSI) was used to study the eﬀects of liquid extraction
surface analysis (LESA) sampling on mouse brain tissue. Complementary multivariate analysis
techniques including principal component analysis, non-negative matrix factorization, and t-
distributed stochastic neighbor embedding were applied to MALDI MS images acquired from
tissue which had been sampled by LESA to gain a better understanding of localized tissue
washing in LESA sampling. It was found that MALDI MS images could be used to visualize
regions sampled by LESA. The variability in sampling area, spatial precision, and delocalization
of analytes in tissue induced by LESA were assessed using both single-ion images and images
provided by multivariate analysis.
Liquid extraction surface analysis (LESA) mass spectrom-etry oﬀers improved sensitivity through a combination of
eﬃcient analyte extraction and increase in the relative area
sampled. LESA involves use of a small droplet of solvent to
extract soluble analytes at the solid−liquid interface called the
liquid microjunction.1 In a traditional LESA experiment the
minimum pixel size is limited by the diameter of the solvent
droplet, ∼1 mm.1 Smaller pixel sizes may be achieved through a
modiﬁcation to the surface sampling routine whereby the pipet
tip makes contact with the sample surface and the pixel size is
limited by the diameter of the pipet tip.2,3 Brenton and Godfrey
have suggested alternative methods for the improvement of
spatial resolution possible by LESA mass spectrometry imaging
(MSI).4
LESA MS has been reported for detection of lipids, peptides,
proteins, drugs, and metabolites directly from thin tissue
sections under ambient conditions with no sample prepara-
tion.5−9 A further beneﬁt of LESA MS is the decoupling of
desorption and ionization events. This provides opportunities
for postextraction separation (for example, via HPLC),10
derivatization, or inclusion of internal standards for quantiﬁca-
tion.9 Electrospray ionization (ESI) can produce multiply
charged ions; therefore, mass analyzers with a limited mass-to-
charge ratio (m/z) range can be used and a wider range of
fragmentation techniques can be employed.
Through combining techniques such as matrix-assisted laser
desorption ionization (MALDI) and LESA, one can maximize
the advantages of each and use them in complement. Several
examples of such an approach exist in the literature: MALDI
MSI and LESA MS have been used on adjacent tissue sections
to study drug absorption into skin; LESA MS was used as a
veriﬁcation step to complement the MALDI MSI data.11
Quanico et al. used a MALDI MSI-guided approach to identify
regions of anatomical interest. These regions of an adjacent
section were then analyzed by LESA coupled to liquid
chromatography−mass spectrometry (LC−MS) for improved
sensitivity, resulting in more complete identiﬁcation of
proteins.9 Griﬃths et al. used MALDI MSI and LESA MS to
demonstrate that a sample preparation technique for improved
lipid analysis yielded similar results when two diﬀerent
ionization methods were employed.6 The potential for
inclusion of internal standards in LESA extraction solvents
was exploited by Tomlinson et al. who used LESA coupled to
nanoelectrospray ionization and LC−MS to investigate ion
suppression eﬀects in MALDI.12 Swales et al. demonstrated the
complementary capabilities of various MSI techniques includ-
ing MALDI MSI and LESA MS. They employed each on
adjacent sections of organs from cassette- and discrete-dosed
animals and compared their ability to detect four diﬀerent
target compounds.13 It is important to note that each of these
methods have employed MALDI MSI and LESA MS on
adjacent sections which are therefore nonidentical. This
increases the challenge when attempting to correlate, compare,
or combine the data acquired with each technique. Additionally,
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this would be impossible in situations where no adjacent
section is available.
Repeat analysis by MALDI MSI of a single tissue section was
reported by Steven and Bunch14 and Garrett et al.,15 who
demonstrated that multiple MSI data sets could be acquired
from a single sample, either by taking advantage of remaining
matrix after initial analysis or by addition of a tissue wash and
reapplication of matrix. These results show that reanalysis of
tissue samples is an avenue towards obtaining complementary
data. The importance of executing multimodal MSI workﬂows
on the same tissue section has been recognized in studies
seeking to combine other mass spectrometry techniques.
Eberlin et al. reported a method for combining desorption
electrospray ionization (DESI) MSI for lipid imaging, MALDI
MSI for protein imaging, and hematoxylin and eosin (H&E)
staining for morphological information on the same tissue
section.16 Eijkel et al. performed MALDI MSI and secondary
ion mass spectrometry (SIMS) imaging on the same tissue
section and outlined a workﬂow for correlating these data
sets.17
In addition to extracting more information about the content
of a sample, a number of “multimodal” studies have been
conducted with the aim of using one method to understand
another. Passarelli et al. reported time-of-ﬂight SIMS (TOF-
SIMS) imaging of matrix crystals prepared for use in MALDI
MS imaging experiments and determined crystal size, analyte
distribution, and delocalization of analytes upon matrix
addition. Korsgen et al. also report TOF-SIMS imaging of
analyte incorporation in matrix crystals prepared under
diﬀerent conditions, shedding light on the eﬀects of sample
preparation and leading to more optimal analysis.
As a relatively new technique LESA requires further study to
fully understand the sampling process. Recent work by Kertesz
and Van Berkel evaluated the reliability of liquid junction
formation, sampling precision, spatial resolution, and extraction
eﬃciency of a droplet-based extraction system with a simple
model sample (ink on glass).18 They found that, through
control of probe-to-surface distance, dispensation volume, and
aqueous solvent content, a stable liquid junction may be formed
with good spatial precision. The stability of a liquid junction
depends on sample surface properties such as wettability; this is
sample-dependent, and therefore, these conclusions may not
hold true when sampling tissue instead of glass.
Here we present the combination of MALDI and LESA for
analysis of lipids, drugs, and proteins in a single tissue section.
In this work MALDI MSI was used to image analyte
distributions in tissue, post-LESA and therefore indicated
how LESA sampling had altered the sample composition. This
experiment provided insight into aspects of LESA sampling
such as the area of tissue surveyed and variation and spatial
precision of sampling. Previously this has only been assessed
using optical images. Complementary multivariate analysis
techniques were applied to the MALDI MSI data to determine
spectral and spatial changes to the sample which occurred as a
result of LESA sampling. This analysis indicated how MALDI
spectra change as a result of LESA sampling.
■ EXPERIMENTAL SECTION
Materials. Ethanol, methanol, and formic acid were
purchased from Fisher Scientiﬁc (Leicestershire, U.K.).
Triﬂuoroacetic acid was purchased from Acros Organics. α-
Cyano-4-hydroxycinnamic acid (CHCA) matrix was purchased
from Sigma-Aldrich (Gillingham, U.K.), and glass slides were
from Thermo Scientiﬁc. Fresh frozen mouse brain tissue was
provided by Professor Steve Watson at the University of
Birmingham. Erlotinib was provided by Dr. Richard Goodwin
at AstraZeneca.
Tissue Sample Preparation. Mouse brain tissue was
sectioned (Leica CM 1850 cryostat, Milton Keynes, U.K.) at 10
μm thickness and thaw-mounted onto glass slides. The section
which was destined for imaging by LESA MS had 0.3 μL of 200
nM erlotinib solution (80/20 methanol/water) deposited at a
speciﬁc location (see text below).
Liquid Extraction Surface Analysis Mass Spectrome-
try. Surface sampling was performed using a TriVersa
Nanomate chip-based electrospray device (Advion, Ithaca,
NY). The electrospray device was coupled to a Thermo Fisher
Orbitrap Velos (Thermo Fisher Scientiﬁc, Bremen, Germany)
instrument. The robotic system was controlled through LESA
Points and ChipSoft 8.3.3 software. A glass slide with tissue
sections aﬃxed was mounted in the LESA universal adaptor
plate and scanned using an Epson ﬂatbed scanner. The scanned
image was imported into LESA Points, and the sampling
locations were deﬁned. A grid of 108 sampling locations was
selected with an x, y spacing of 1 mm, covering the whole tissue
section. The z coordinate was set to a height 0 mm relative to
the sample surface to allow the pipette tip to come into contact
with the sample (“contact” LESA). For “noncontact” LESA
experiments, the pipette tip descended to a height ∼0.2 mm
above the surface of the sample. The solvent system for
extraction and electrospray was methanol, water, and formic
acid (69.3:29.7:1). The robotic arm collected a conductive
pipet tip and aspirated 0.7 μL of solvent from the reservoir. The
arm relocated to the x, y coordinates speciﬁed by LESA Points
software. The pipette tip descended to the predetermined
height (see above) and dispensed 0.5 μL of solvent. The liquid
microjunction was maintained for 4 s before reaspiration. Each
sample was delivered for 1 min via the Triversa Nanomate with
a gas pressure of 0.3 psi and a tip voltage of 1.4 kV. Positive ion
mass spectra were acquired in full scan mode (m/z 150−2000)
at a resolution of 100 000 at m/z 400. The automatic gain
control was turned oﬀ, and the injection time ﬁxed at 100 ms.
Each scan was composed of ﬁve coadded microscans.
MALDI Mass Spectrometry Imaging. Mouse brain
sections were coated with CHCA matrix (5 mg/mL in 80%
MeOH, 0.1% TFA) using a TM-Sprayer (HTX Technologies,
LLC). Matrix was sprayed with a ﬂow rate 0.115 mL/min and
track speed of 1333 mm/min. The capillary temperature was 90
°C, and the spacing between tracks was 3 mm. Inspection of
microscope images revealed that eight cycles of this method,
with alternating rotation by 90° and 1.3 mm track oﬀset, was
found to produce relatively homogeneous sample coverage.
MALDI MS imaging was carried out on a QSTAR XL QqTOF
mass spectrometer (AB Sciex). An Elforlight (Daventry, U.K.)
Nd:YAG laser with λ = 355 nm was coupled to the MALDI
source via a 100 μm diameter ﬁber (OZ Optics Ltd.) and was
operated at a frequency of 1 kHz. The ﬂuence at the sample
surface was ∼120 J m−2. The sampling raster speed was 0.2
mm/s. Data were acquired in positive ion mode with a pixel
size of 100 μm × 100 μm or 50 μm × 50 μm.
Hematoxylin and Eosin Staining. H&E staining was
performed by Epistem according to standard protocols.
Optical Microscopy. Optical microscopy was performed
on a Pathscan Enabler IV slide scanner and an Olympus CX40
microscope ﬁtted with a 5× magniﬁcation objective lens.
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Image Generation. A separate RAW ﬁle was generated for
each LESA experiment (corresponding to a single pixel),
consisting of multiple scans. Data were converted from RAW to
mzML using msconvert as part of ProteoWizard.19 The mean
spectrum within a single mzML ﬁle (for each pixel) was
calculated and output to a new mzML ﬁle, resulting in a
spectrum per pixel. These were combined, along with the
spectra locations, into an imzML ﬁle using imzMLConverter to
produce an MS image.20
WIFF ﬁles generated by the QSTAR XL QqTOF mass
spectrometer were converted to mzML ﬁles using MS Data
Converter (AB Sciex). One mzML ﬁle was produced per raster
line of the image. These were converted to a single imzML ﬁle
using imzMLConverter.20
Data Analysis. Image ﬁles (imzML) were viewed and
processed using in-house software, running in MATLAB
(R2014b). Memory eﬃcient principal component analysis
(PCA) and k-means (k = 7) were applied as described by
Race et al.21 with the smoothing step in the preprocessing
workﬂow modiﬁed to dual-pass Savitzky−Golay (window size
of 11).
Principal component 1 and principal component 2 score
images were used in combination to generate a binary mask for
isolating the on-tissue spectra. MALDI MSI on tissue spectra
were further reduced by selecting peaks from the total spectrum
using a gradient-based method,21 using the modiﬁed
preprocessing workﬂow described above. NMF (k = 25.
MATLAB) and t-SNE22 were applied to the reduced data.
■ RESULTS AND DISCUSSION
LESA MS Imaging. An automated surface sampling routine
was deﬁned and implemented using the TriVersa Nanomate.
The locations selected for contact LESA sampling are
demonstrated in Figure 1a. Full scan mass spectra were
obtained from each sample location (for example, see Figure
1b). Here we demonstrate for the ﬁrst time that LESA MS is
able to detect multiple classes of analyte in a single extraction/
electrospray event. Peaks in the m/z range of 700−850
correspond to various phosphatidylcholine (PC) lipid ions,
preferentially detected as the protonated species. Ions detected
with m/z 734.5708, 760.5870, and 782.5703 are tentatively
assigned as protonated molecules of (PC) 32:0 (Δppm = 1.9),
(PC) 34:1 (Δppm = 2.5), and (PC) 36:4 (Δppm = 1.2),
respectively. Multiply charged protein ions predominantly
appear in the m/z range of 600−1200. Ions at m/z 857.3743
(charge state +10) are tentatively assigned as ubiquitin (Δppm
= 2.1), which has previously been detected from mouse brain
tissue using LESA MS.5 Other protein ions (unidentiﬁed) were
detected with charge states ranging between +7 and +22. The
tissue was spiked with 0.3 μL of 200 nM erlotinib solution, for
location of drug spike see Figure 1c. Taking into account the
area over which the droplet spread, we estimate that
approximately 4.8 fmol of erlotinib was present per 0.4 mm2
(the approximate area covered by a single contact LESA
extraction, more discussion to follow). The drug was detected
in every LESA spectrum sampled from this region. Example
LESA MS images are displayed in Figure 1d−h, indicating the
diﬀerent distributions of PC 34:1, ubiquitin, heme, and
erlotinib, across the tissue section. In this work we have
Figure 1. LESA MS of mouse brain tissue: (a) Locations selected for LESA sampling. (b) Example full scan LESA mass spectrum; peaks with m/z in
the range of 700−900 correspond to lipid ions; enlargements of peaks corresponding to erlotinib (m/z 394.1773) and ubiquitin (m/z 857.3743) are
shown the inset. (c) Circle indicates location selected for erlotinib deposition, covering both grey and white matter as indicated using H&E stained
reference. (d) LESA MS image of ions with m/z 184.0739 corresponding to the phosphatidylcholine lipid headgroup. (e) LESA MS image of ions
with m/z 760.5870 corresponding to [M + H]+ ions of PC 34:1. (f) LESA MS image of ions with m/z 616.1782 corresponding to heme. (g) LESA
MS image of ions with m/z 857.3743 corresponding to ubiquitin (+10 charge state). (h) LESA MS image of ions with m/z 394.1773 corresponding
to [M + H]+ ions of erlotinib.
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found that a LESA solvent system comprising 70% MeOH, 1%
formic acid is suitable for the simultaneous analysis of singly
charged small molecules, multiply charged protein species, and
the drug compound erlotinib, which was detected with m/z
394.1773 corresponding to [M + H]+ ions.
The spacing between LESA sampling locations was deﬁned
as 1 mm, the minimum distance permitted by LESA Points
software. The sampling routine used to acquire this data set was
modiﬁed to minimize solvent spreading and allow for greater
sampling precision; the method has previously been termed
“contact” LESA.2 The method involves bringing the sampling
pipette into contact with the sample surface prior to solvent
dispensation and an assumption that the solvent is entirely
contained within the pipette tip during sampling“plugged” by
the sample itself. Optical images of the tissue section after
“noncontact” (in which only the solvent was allowed to come
into contact with the surface, all other sampling parameters
remained the same) and “contact” LESA sampling demonstrate
a decrease in relative size of area sampled (spot diameter
decreased from ∼1158 to ∼690 μm), see Supporting
Information Figure 1. These images also highlight unsampled
regions of tissue which result from sample spacing of 1 mm and
sampling diameter of less than 1 mm. Reliability of sampling
was found to be improved using contact LESA because there
was no requirement for formation of a stable liquid micro-
junction. Sampling precision was also found to be improved
using contact LESA; the pipette tip walls prevent solvent
droplet spreading to the same extent observed during normal
LESA sampling, although some spreading beyond the expected
contact area of the pipette tip is still observed. Aspects of
sampling reliability and precision will be further discussed
below.
Post-LESA MALDI MS Imaging. After the sample had
been imaged by LESA MS, both this section and a serial section
placed adjacent on the slide were coated with matrix and
imaged using MALDI MS. There were several reasons for doing
this: to provide higher resolution tissue images which
complement the LESA MS data, to establish whether
performing LESA prior to MALDI in a multimodal workﬂow
is feasible (i.e., to determine whether MALDI image integrity is
maintained), and to ascertain whether higher resolution
MALDI MS images can be used to better understand LESA
sampling. The adjacent tissue section served as a control and
allowed changes induced by LESA sampling to be assessed.
The MALDI MSI method was optimized for lipid analysis;
an example single-pixel spectrum from the tissue section which
had not been sampled by LESA is displayed in Figure 2a. A
number of lipid species were detected in the m/z range of 600−
900; an example ion image (tentatively assigned as PC 36:1)
can also be seen in Figure 2a. The lipids were preferentially
detected as the potassium adduct. Ions detected at m/z’s
corresponding to the sodium adduct and protonated molecule
were also observed but with a lower intensity. In these images it
is possible to see the regions which were sampled by LESA.
These features are generally classiﬁed by a region of higher ion
intensity surrounded by a dark ring in which very few ions were
detected. These features were not observed in the control
image. It would appear that LESA sampling acts as a localized
tissue wash, enhancing lipid detection via the extraction of
analyte to the tissue surface and extraction and washing of salts
resulting in a concentration gradient, highest at the edge of the
spot. The region of tissue which was spiked with erlotinib
solution appears as a similar although larger feature in the
image. This supports the theory that analyte extraction, rather
Figure 2. MALDI MS imaging of tissue after LESA sampling: (a) Left, example single-pixel spectrum, peaks in the m/z range of 700−900
correspond to lipid ions; right, MALDI MS image of ions with m/z 826.6, tentatively assigned as [M + K]+ ions of PC 36:1; blue circle indicates the
region spiked with erlotinib solution. (b) Left, overlaid MALDI MS ion images of protonated and potassium adduct of PC 36:1; right, overlaid
intensity line proﬁles across the center of one LESA-sampled region; plot in pink corresponds to [M + H]+ ion intensity which peaks sharply towards
the center of the spot; plot in green corresponds to [M + K]+ ions which are more homogeneously distributed across the spot.
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than mitigation of suppression eﬀects, is responsible for the
observed intensity increase because the spiked solution was
allowed to remain on the tissue and therefore did not remove
any dissolved species. To further probe the distribution of lipid
species across the LESA-sampled area, a composite ion image
of the protonated and potassiated molecules of PC 36:1 was
generated, and intensity line proﬁles across a single LESA spot
were plotted, see Figure 2b. It was found that [M + H]+ ions
were preferentially detected towards the center of the LESA-
sampled area, whereas [M + K]+ ions were more abundant
towards the outside or homogeneously distributed across the
spot. This behavior was also observed for a number of other
lipid species. This is presumably caused by solvent washing salts
towards the edge of the sampled area and depositing larger
amounts at the outer perimeter as the residual solvent on the
surface dries postsampling. Accumulation of salt at this outer
perimeter could also be responsible for the “dark ring” observed
in MALDI MS lipid images; matrix crystals exhibit diﬀerent
morphology when formed from solution containing diﬀerent
proportions of salts.6 Optical images of a LESA-sampled tissue
section before and after coating with matrix are displayed in
Figure 3, parts a and b. The regions sampled by LESA appear as
darker regions compared to unsampled tissue; a circular imprint
can be observed in the middle of this region which results from
the pipette tip coming into contact with the tissue. A larger,
more irregular dark region surrounds this mark, which suggests
the solvent spread further than the conﬁnes of the pipette tip.
An experiment in which contact LESA was performed without
any solvent conﬁrmed that solvent washing eﬀects and not
compression or damage of the tissue during contact were
responsible for the observed intensity changes in MALDI
images, see Supporting Information Figure 2. The image
displayed in Figure 3b demonstrates the size and distribution of
CHCA crystals on the tissue surface after matrix coating. A
region of sparse, thin crystals can be seen around the outer
edges which correspond with the dark region of the ion image
displayed in Figure 3d, suggesting that changes to matrix
morphology resulting in poor analyte inclusion and subsequent
ablation/ionization are responsible for low ion counts from this
region. An example MALDI MS image (m/z 826.6) overlaid
with the optical image demonstrates that regions of higher
intensity in the ion image correspond with darker regions
observed in the optical image, see Figure 3c.
MALDI MS ion images reveal details about locations, size,
and variation of LESA-sampled areas. Previous work has relied
on optical images alone to provide this information, whereas we
now present mass spectral data which veriﬁes that visual
changes to the tissue correspond with spectral changes
indicative of solvent contact. Additionally, dislocation, leaching,
and other changes in analyte distribution within the sampled
area (which appears as a homogeneous area in the optical
image) can be visualized using MALDI MSI. Two MALDI MSI
data sets were obtained from tissue sampled by LESA, with
pixel sizes of 100 and 50 μm, respectively. While no further
features could be observed with the increased image detail
aﬀorded by 50 μm pixels, the outer limits of the sampled region
could be more accurately deﬁned. As such, MALDI MS images
with 50 μm pixels were used to take measurements. The
average area sampled per contact LESA spot is 0.41 mm2.
Diﬀerences in size of these areas is caused either by diﬀering
degrees of solvent spreading during sampling or diﬀering
volumes of residual solvent left on the tissue after LESA
sampling, or some combination of both. The distance between
these areas in x and y dimensions varies considerably, as
Figure 3. (a) Optical image of tissue section after LESA MS; darker regions indicate solvent contact with tissue; the smaller circle in the middle of
the dark region is caused by imprint of the pipette tip. (b) Optical image of LESA-sampled region after coating with CHCA matrix; the lighter region
at the perimeter of the LESA spot indicates thinner crystal layer. (c) Overlaid MALDI MS image of ions with m/z 826.6 and optical image. (d)
Enlargement of MALDI MS image of ions with m/z 826.6 to show the same LESA-sampled region as displayed in panel b; the dark region in the ion
image corresponds with the thinner region of matrix crystals in the optical image.
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indicated by images in Figure 3. In order to maximize the total
surface sampled by LESA in an imaging experiment, individual
samples should be taken next to each other with as small a gap
between them as possible but without overlapping (this would
result in oversampling which, although common practice in
MALDI MSI, is inappropriate for LESA MS because signal can
be acquired multiple times from the same location). The
spacing required between points for maximum coverage using
Figure 4. Results from multivariate analysis: (a−c) Score images of principal components 1, 5, and 6, respectively; principal component 1 indicates
that the greatest variance is between tissue and background, principal component 5 indicates variance between LESA-sampled areas and the rest of
the tissue, and principal component 6 indicates that LESA-sampled regions on white matter are more diﬀerent from the original tissue type than
those from grey matter. (d) k-Means clustering (k = 7) on masked image to remove background; the same clusters corresponding to anatomical
features within the tissue are found in both LESA-sampled tissue and the control section indicating that LESA only induced localized changes; these
are identiﬁed as diﬀerent clusters in grey and white matter; further clusters identify the outer perimeter of LESA-sampled regions. (e) t-SNE reveals
the same clusters identifying diﬀerent tissue anatomies in LESA-sampled tissue and control tissue; LESA-sampled regions are assigned diﬀerent
clusters depending on the original type of tissue; however, these are more similar to each other than the original type of tissue; the region where the
drug was spiked is also similar to the LESA-sampled regions but more similar to the original tissue type presumably because the solvent was not
removed from the tissue and therefore did not deplete the tissue in the same way. (f−h) Examples of three factors identiﬁed by NMF, their spatial
distributions, and contributing spectral components.
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contact LESA would be ∼700 μm, providing sampling spatial
precision was accurate. However, MALDI MSI images reveal
that intersample distances (measured from center to center)
vary between 0.8 and 1.3 mm. Accurate determination of these
variations is important in furthering LESA MS as an imaging
technique.
In order to fully assess changes between the LESA-sampled
section and serial control it is necessary to consider variation
within the whole spectrum, as well as individual m/z channels.
This also aids in interpretation of MALDI data obtained after
LESA sampling. Complementary multivariate analysis techni-
ques were applied to the data in order to study the eﬀects of
LESA sampling. PCA score images are displayed in Figure 4a−c
and can be used to identify sources of variance within the data.
The largest source of variance in the data set is the diﬀerence
between tissue and background, shown by principal component
1. Principal component 5 shows the “halo” region, a common
feature of MALDI MSI experiments. Principal component 6
identiﬁes LESA sampling regions, where the regions sampled
on areas of white matter are more intense than those on grey
matter. This is interesting because it suggests that changes
associated with LESA sampling do not appear uniformly across
the tissue. This has implications for any sample preparation
procedures which undergo a wash step because it implies that
inhomogeneous washing occurs across the tissue and therefore
false contrast could be introduced in ion images. Thresholded
PCA score images, principal component 1 (matrix region), and
principal component 5 (“halo” region) shown in Figure 4, parts
a and b, respectively, were used to generate a mask to segment
the background from the tissue for further multivariate analysis.
k-Means clustering was applied to the PCA-reduced data set to
identify pixels with similar spectral proﬁles and label them with
a randomly assigned color, see Figure 4d. k-Means clustering
successfully separated the diﬀerent brain anatomies and LESA-
sampled regions on white and grey brain tissue. The results
from this analysis are easy to interpret and demonstrate
agreement with individual lipid ion images. Two clusters are
identiﬁed which are unique to the LESA-sampled tissue section
and are labeled red and pale blue in Figure 4d. Clustering, with
the parameters used, does separate the outer perimeter of these
regions into a unique cluster. In general, k-means clustering
provides no visual indication of how spectrally similar the
identiﬁed clusters are. t-Distributed stochastic neighbor
embedding (t-SNE) is a dimensionality reduction technique
which has been used in MSI for visualization of complex data
sets.23 The color of each pixel is related to its location in the
reduced space, thus providing a visual indication of how similar
two pixels are spectrally. When applied to this data set, t-SNE
reveals very similar results for control tissue and unsampled
regions of section sampled by LESA. The regions sampled by
LESA appear signiﬁcantly diﬀerent to the unsampled regions,
with slight diﬀerences observable depending on whether the
sampled region was grey or white matter, see Figure 4e.
Although this data visualization approach is useful in identifying
regions of spectral similarity and gradients of change aﬀected by
LESA sampling, no spectral information about the diﬀerent
regions is provided, and therefore, it is hard to identify which
spectral features have contributed. Non-negative matrix
factorization (NMF) decomposes the data into a set of unique
spatial distributions and associated spectral proﬁles. NMF
applied to this data set identiﬁes a number of spatial
distributions arising from LESA sampling, see Figure 4f−h.
The image in Figure 4f identiﬁes a distribution corresponding
to white matter in the tissue sections. Major m/z values
contributing to this distribution are 798 and 826, which are
tentatively assigned as the potassium adducts of PC 34:1 and
PC 36:1, respectively, i.e., the most abundant lipid species
detected from mouse brain tissue. The image in Figure 4g
identiﬁes regions at the center of the LESA-sampled regions;
examination of individual ion images revealed that protonated
molecules of lipids were detected with higher intensity here.
Peaks with m/z 760 and 788 (tentatively assigned as
protonated molecules of PC 34:1 and PC 36:1, respectively)
are identiﬁed by NMF as major contributors to this
distribution, supporting conclusions drawn from manual
analysis.
It was found that features introduced into some MALDI MS
ion images can be largely removed via total intensity
normalization, see Supporting Information Figure 3. For
other ion images this normalization strategy is less successful,
see Supporting Information Figure 3. This is to be expected
based on asserted changes to distribution of lipid adducts. An
understanding of MALDI mass spectral changes associated with
LESA sampling could help inform more sophisticated and
appropriate normalization methods; for example, factors
identiﬁed by NMF could be used to correct for changes in
intensity and distribution.
■ CONCLUSION
We have presented a combined workﬂow which exploits the
combined advantages of LESA and MALDI MSI and
additionally provides insight into aspects of ambient surface
sampling. LESA provided sensitive analysis of multiple classes
of analyte simultaneously with spatial information. MALDI
provided high spatial resolution images which detailed the
anatomical features within tissue which were too small for
LESA to successfully resolve. MALDI images were also used to
accurately deﬁne the exact locations sampled by LESA, their
size, and variation. Importantly, LESA does not appear to blur
or distort anatomical features. Several multivariate techniques
were employed to assess changes to distribution induced by
LESA. Future implementations of MALDI MSI after LESA
analysis could assess diﬀerent washing protocols, or how the
same wash aﬀects diﬀerent regions of tissue. This could also be
used to assess improvements or changes made to the
automated LESA sampling routines described here, for
example, to determine the spacing of sampled areas and ensure
that no oversampling had occurred. LESA MS is somewhat
limited as an imaging technique by the poor spatial resolution it
aﬀords; however, there are opportunities for further decreasing
pixel size via contact LESA and smaller sampling pipette tips.
As the technique improves in terms of sampling precision and
repeatability, combining it with MALDI will become an even
more attractive option. The potential for inclusion of standards
by LESA is also attractive, and provides possible routes towards
quantitative analysis. The combined LESA−MALDI MSI
workﬂow could then be applied to drug in tissue studies
which could provide quantitative analysis of drug/lipid/protein
via LESA and a higher spatial resolution reference in MALDI
MS images.
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ABSTRACT: Top-down identiﬁcation of proteins by liquid extrac-
tion surface analysis (LESA) mass spectrometry has previously been
reported for tissue sections and dried blood spot samples. Here, we
present a modiﬁed “contact” LESA method for top-down analysis of
proteins directly from living bacterial colonies grown in Petri dishes,
without any sample pretreatment. It was possible to identify a number
of proteins by use of collision-induced dissociation tandem mass
spectrometry followed by searches of the data against an E. coli
protein database. The proteins identiﬁed suggest that the method may
provide insight into the bacterial response to environmental
conditions. Moreover, the results show that the “contact” LESA
approach results in a smaller sampling area than typical LESA, which
may have implications for spatial proﬁling.
I t was ﬁrst demonstrated that mass spectrometry could beapplied to the identiﬁcation and diﬀerentiation of species of
bacteria over 30 years ago;1,2 subsequent advances in software
and instrumentation now make it a powerful tool for
microbiological research.3,4 MALDI-TOF mass spectrometry
has been reported for the identiﬁcation of bacterial species from
isolates of over 1000 species. Identiﬁcation involves searching
mass spectra against spectral libraries of abundant intact
proteins which are characteristic of that species.2,3 It has been
suggested that this method will replace traditional identiﬁcation
methods such as Gram stain, colony morphology, and
biochemical tests.3 MALDI MS has also been used to image
bacterial colonies with a spatial resolution capable of capturing
metabolic output of bacteria, which can be compared between
mutant and wildtype strains.5−7 The identiﬁcation of
metabolites from mass spectral images of bacteria can help in
the elucidation of biochemical pathways underlying microbial
processes, which are often poorly characterized. Techniques
capable of detecting chemical signals in a spatially resolved
manner could also aid our understanding of bacterial inter- and
intraspecies interactions.8
The majority of proteins detected by MALDI methods are
small ribosomal proteins (typically <15 kDa) which are ideally
suited to and relied upon for the robust identiﬁcation of
bacterial species and subspecies. However, the routine
detection of larger bacterial proteins remains elusive. Electro-
spray ionization (ESI) top-down mass spectrometry methods
provide an increased mass range and total number of proteins
detected. Top-down analysis9 involves fragmentation of intact
protein ions and overcomes the limitation of information loss
suﬀered by bottom-up analysis10 of proteolytic peptides. For
example, Fenselau and co-workers11 applied top-down LC MS/
MS to the analysis of bacterial lysates from Erwinia herbicola
and Enterobacter cloacae. Fourteen proteins were identiﬁed in E.
herbicola, ten of which were ribosomal. Fifteen proteins were
identiﬁed in E. cloacae, ﬁve of which were ribosomal and three
were cold shock proteins. More recently, McFarland et al.12
applied top-down LC MS/MS to the analysis of lysates from
Salmonella enterica serovars. They identiﬁed 73 proteins in the
mass range of 4−36 kDa.
The development of ambient mass spectrometry techniques
such as desorption electrospray ionization (DESI)13 and liquid
extraction surface analysis (LESA)14 have enabled direct
sampling of bacterial colonies with little or no sample
preparation. DESI involves desorbing analytes from a surface
by directing a stream of charged electrospray droplets at the
surface of interest. The sample inlet of the mass spectrometer is
positioned above the surface at the optimum angle to capture
analyte ions which have been desorbed. LESA involves using a
droplet of solvent into which soluble analytes are extracted. The
droplet is dispensed from a pipet tip and held in contact with
the sample surface for a speciﬁed length of time to form a liquid
microjunction. The droplet is then reaspirated and injected
through an electrospray capillary into the mass spectrometer.
These techniques beneﬁt from the advantages provided by ESI-
MS, with the added bonus of direct surface sampling. One
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possible application of these methods is the direct sampling of
surfaces contaminated with unknown strains of bacteria, which
could have implications for clinical diagnostics, quality control,
and environmental monitoring.
Ambient mass spectrometry techniques are ideal for the
analysis of bacterial colonies because they can directly sample
living colonies growing in Petri dishes.15 A recent report
outlines the spatially resolved detection of glycolipids and
metabolites from living bacterial colonies using nano-DESI.16
This technique was capable of detecting metabolites secreted
by bacteria into the surrounding agar without any sample
preparation or pretreatment. A further paper detailed the use of
nano-DESI to study interactions between neighboring colonies
and in mixed-species bioﬁlms,17 with detection of a wide range
of lipids, peptides, and other small molecules reported. A
further motivator for the chemical analysis of bacteria is the
search for novel therapeutic agents: more than 60% of current
pharmaceuticals have been developed from natural products.8 It
has been demonstrated that a thiazolyl peptide antibiotic could
be extracted from Actinobacteria colonies by LESA and analyzed
by nanoelectrospray mass spectrometry.18 In 2013, the use of
an ambient electrospray ionization ﬂow-probe was demon-
strated for the metabolic proﬁling of a range of micro-
organisms. Diverse classes of natural products have been
detected using the ﬂow-probe including small redox com-
pounds, lipids, and peptides.19 Although a wide variety of small
molecules has been detected from bacterial colonies by
techniques such as DESI, nano-DESI, LESA, and the
continuous ﬂow-probe coupled to mass spectrometry, analysis
of intact proteins from bacteria by ambient mass spectrometry
has not previously been reported.
LESA-MS has been demonstrated to be capable of extracting
intact proteins directly from surfaces without any pretreatment.
In 2011, Edwards et al. reported a LESA-MS method for
detecting hemoglobin variants from neonatal dried blood spot
samples. The mass spectra obtained contained peaks
corresponding to the diﬀerent subunits of hemoglobin, and it
was possible to conﬁrm the presence of known variants,
including those diﬀering in mass by <1 Da, by MS/MS.20 It was
later shown that LESA MS/MS could be applied for the
analysis of unknown hemoglobin variants.21 Schey et al.
reported the liquid extraction of intact proteins from tissue
sections. An acetonitrile/water solvent system was used to
manually extract proteins from thin tissue sections of mouse
brain, mouse kidney, and bovine ocular lens. Peaks in the mass
spectra of extracts were fragmented by ETD and subsequently
identiﬁed.22 Sarsby et al. applied automated LESA MS/MS for
the analysis of intact protein biomarkers of nonalcoholic liver
disease.23
Here, we present LESA mass spectrometry of intact proteins
directly from Escherichia coli colonies growing on solid agar in
Petri dishes. The LESA sampling system was coupled to a high
mass resolution orbitrap mass spectrometer. Optimization of
the surface sampling process revealed that a modiﬁed surface
sampling routine, in which the pipet tip came into contact with
the colony surface, resulted in detection of greater numbers of
protein signals. This sampling process may oﬀer the additional
advantage of limiting the spread of solvent to an area the size of
the pipet tip, which has implications for the spatial resolution of
any images produced. In order to identify proteins, ions
corresponding to intact proteins were selected and subjected to
CID. The resulting MS/MS data were searched against an E.
coli K-12 protein database using Prosight PTM 2.0 software. Six
proteins were identiﬁed including DNA binding proteins and
shock response proteins.
■ EXPERIMENTAL SECTION
Materials. A strain of Escherichia coli K-12 was inoculated
onto solid LBA medium (LB 20 g L−1, agar 20 g L−1) in 6 cm
diameter Petri dishes. The smaller size of Petri dish allows it to
ﬁt inside the sample tray of the Advion TriVersa NanoMate
system. Bacteria were incubated at 21 °C for 3 days before
storing in the dark at 4 °C or were allowed to grow at room
temperature on the bench and were stored at room
temperature (∼20 °C). The solvent system for surface
sampling/electrospray ionization consisted of acetonitrile (J.T.
Baker, The Netherlands) and water (J.T. Baker, The Nether-
Figure 1. Experimental setup: (A) sample tray of Triversa Nanomate; (B) photocopy of the universal adaptor plate, for x,y coordinates; (C) adhesive
putty (Blu-tack) to secure Petri dish in position; (D) E. coli colony; (E) Petri dish containing agar; (F) half 96-well plate containing extraction/
electrospray solvent system.
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lands) (39.6:59.4) with 1% formic acid (Sigma-Aldrich
Company Ltd., Dorset, U.K.).
Surface Sampling. Petri dishes containing E. coli K-12
colonies were placed directly into the TriVersa Nanomate chip-
based electrospray device (Advion, Ithaca, NY) adjacent to half
a 96-well microtiter plate (ABgene PCR plate Thermo Fisher
Scientiﬁc, Leicestershire, U.K.) into which the extraction
solvent system is placed; see Figure 1. The electrospray device
was coupled to a Thermo Fisher Orbitrap Velos ETD (Thermo
Fisher Scientiﬁc, Bremen, Germany) instrument. Surface
sampling was performed using the advanced user interface
(AUI) feature of the TriVersa NanoMate ChipSoft Manager
software which controls the TriVersa NanoMate robotic
system. A coordinate (x,y,z) system was used to direct the
robotic arm in a surface sampling routine. The arm picked up a
conductive pipet tip from the tip rack and relocated to a
position above the well containing extraction solvent. The tip
descended into the well and aspirated 3 μL of solvent. The arm
relocated to a deﬁned position above the bacterial colony; the
tip descended to a depth just below the surface of the colony.
The exact sampling height varied (from −9 to −11 mm from
the initial position of the robotic arm), depending on the size of
the colony and spread of agar in diﬀerent samples; for increased
extraction of proteins, the pipet tip came into contact with the
top surface of the colony but did not penetrate the agar below.
Once in contact with the colony, the tip dispensed 2 μL of
solvent onto the colony which was held in contact for 3 s to
allow soluble analytes to desorb into the droplet. The solution
was then reaspirated into the pipet, and the tip engaged with
the nanoelectrospray chip in order to start electrospray
ionization and introduction of the sample into the mass
spectrometer.
Mass Spectrometry. All mass spectrometry experiments
were performed on a Thermo Fisher Orbitrap Velos ETD
(Thermo Fisher Scientiﬁc, Bremen, Germany) instrument. The
sample was introduced via the Triversa Nanomate with a gas
pressure of 0.3 psi and a tip voltage of 1.75 kV. Mass spectra
were collected in full scan mode (m/z 500−2000) at a
resolution of 100 000 at m/z 400. The AGC target was 1 × 106
charges. Each scan was composed of 30 coadded microscans.
Data were recorded for 5 min (∼11 scans). (Note that a stable
electrospray could be maintained for ∼50 min from a single
LESA analysis.) CID was carried out in the linear ion trap, and
the fragment ions were detected in the orbitrap at a resolution
of 100 000 at m/z 400. AGC target was 5 × 104 charges. CID
experiments were performed with helium gas at normalized
collision energy of 35% (optimized for sequence coverage, data
not shown) and an isolation width of 10 Th. MS/MS spectra
were collected in the range of m/z 300−2000 and are
composed of 10 coadded microscans. Data were analyzed
using Xcalibur 2.10 software (Thermo Fisher Scientiﬁc) where
the Xtract program was used to calculate monoisotopic masses.
For data analysis using ProSightPTM 2.0, CID MS/MS spectra
were deconvoluted using the Xtract program (S/N threshold
3). Xtracted monoisotopic fragment masses were searched
against the E. coli K-12 database in ProSightPTM 2.0, with a
fragment tolerance of 10 ppm and precursor tolerance of 100
ppm, in order to assign putative protein identiﬁcations. Two
search types were used in Prosight, “absolute mass search” and
“sequence tag search”. Absolute mass search involves searching
the mass of the precursor ion against intact masses of proteins
within the chosen database. If a match is found, then fragment
masses can be matched to theoretical fragments of that protein.
A sequence tag search involves compiling lists of amino acids
which could correspond to observed fragment masses or
diﬀerences in mass between two fragments. The amino acid
sequences are then searched against the appropriate database to
see if they correspond to sequences of known proteins. Protein
identities were conﬁrmed by manual analysis using Protein
Prospector (http://prospector.ucsf.edu/prospector/mshome.
htm).
Postsampling Image Analysis. Photographs of the colony
surface were taken after LESA sampling. Areas which came into
contact with solvent during sampling were measured using
ImageJ software. Contact with solvent caused discoloration of
the colony surface so the diameter of these regions could be
visually identiﬁed in the photos. The image scale was set using
features of known size in the image, either a ruler or coordinate
spots of the universal adaptor plate.
■ RESULTS AND DISCUSSION
Optimization of LESA Method. When setting up a LESA
method, there are several parameters which are user-deﬁned
and can aﬀect the extraction eﬃciency including the solvent
system used for extraction and the height to which the pipet
descends above the sample surface. These parameters were
optimized for extraction of intact proteins from bacteria. A
survey of common LESA solvent systems was conducted (data
not shown) and indicated that an acetonitrile/water mixture
was the only solvent capable of extracting proteins. The
optimum pipet tip height above the surface was investigated by
sequentially sampling the surface, starting at approximately 0.2
mm above the surface, allowing the tip to descend 0.2 mm
lower each time and recording spectra at each respective
sampling height; see Supplementary Figure 1, Supporting
Information. (Mass spectra shown in Supplementary Figure 1,
Supporting Information, were recorded from the same
location.) It was found that proteins were extracted when the
pipet tip came into contact with the colony surface. (Peaks
observed in the mass spectrum shown in Supplementary Figure
1a, Supporting Information, correspond to singly charged
species.) Although a larger number of proteins were detected
when the pipet tip sampled further below the colony surface
(see Supplementary Figure 1c, Supporting Information), a
compromise must be made between good extraction of proteins
and electrospray instability due to capillary blocking. The mass
spectrum shown in Supplementary Figure 1d, Supporting
Information, contains peaks corresponding to singly, doubly,
and triply charged species indicating that the pipet tip may have
punctured the agar below the colony. For comparison, a mass
spectrum obtained following LESA sampling of agar is shown in
Supplementary Figure 2, Supporting Information. We
hypothesize that the observation of increased numbers of
proteins in mass spectra obtained following contact between
the pipet tip and the surface is due to the insoluble nature of
the extracellular matrix produced by colony bacteria; in placing
the pipet tip in contact with the surface, this insoluble layer is
physically disrupted allowing more eﬃcient extraction of
proteins contained within the colony. It should be noted that
this “contact” method of surface sampling is diﬀerent from
other LESA methods described in the literature; see Figure
2a,b. Kai et al. report the extraction of small molecule antibiotic
compounds using LESA, a method in which only the solvent
droplet came into contact with the bacteria.18
An interesting consequence of the “contact” surface sampling
routine is illustrated in Figure 2. The process of placing the
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pipet tip in contact with the colony surface during sampling
appears to limit the spread of the solvent droplet to the area of
the pipet tip end. We postulate that the low pressures used to
dispense and aspirate the solvent droplet are insuﬃcient to
push the solvent beyond the end of the pipet tip and therefore
the colony acts as a plug. The spread of solvent during LESA
sampling determines the area of the sampling region. In the
case of hydrophilic surfaces, the area over which the
microjunction spreads is large; see Figure 2a,c. The method
described here prevents any solvent spread beyond the edges of
the pipet tip because the solvent is completely encased within
the end of the tip; see Figure 2b,d. The total surface area
sampled by this method is ∼0.24 mm2, as measured using
ImageJ on images of the puncture mark on the colony surface
after sampling. This observation represents a signiﬁcant
improvement when compared to the area covered by the
usual LESA solvent droplet, which was measured to be ∼10.64
mm2 (solvent sampling discolored the colony surface allowing
for measurement of the area from photographic images). Note
that the droplet volumes were the same for both methods.
Top-Down LESA Mass Spectrometry of E. coli
Colonies. Figure 3a shows a representative full scan mass
spectrum obtained following LESA sampling of an E. coli
colony (previously stored at 4 °C) growing on agar; see Figure
3b for the location of the spot sampled. The mass spectrum
contains approximately 150 peaks corresponding to ∼60
bacterial proteins in a range of charge states. The molecular
weights of these proteins ranged from approximately 5 to 32
kDa. This mass range is in agreement with the ﬁndings of
McFarland et al., who report the detection of intact proteins in
the range of 4−37 kDa from S. typhimurium by ESI orbitrap
mass spectrometry.12
Figure 3c shows an enlarged section of the mass spectrum
with peaks selected for CID indicated. Supplementary Figure 3,
Supporting Information, shows the same region of the mass
spectra obtained following LESA sampling at various locations
as indicated (Figure 3c is also Supplementary Figure 3c,
Supporting Information). The relative abundance of the protein
peaks is greater in the mass spectra obtained from locations
close to the edge of the colony. That observation may be the
Figure 2. Improved sampling precision obtained from “contact” LESA
sampling: (a) Schematic illustrating the surface area of sample covered
by each solvent droplet when sampled by a liquid microjunction
(contact between surface and solvent only); (b) schematic illustrating
the smaller surface area covered by each sample droplet with the
“contact” method (contact between surface and pipet tip); (c)
sampled area following liquid microjunction sampling; (d) sampled
area following “contact” LESA.
Figure 3. LESA mass spectrometry of an E. coli K-12 bacterial colony previously stored at 4 °C. (a) Full scan mass spectrum; (b) photograph of
bacterial colony growing on solid agar medium in a Petri dish. Red spot marks the region sampled by LESA; (c) enlarged m/z region from a full scan
mass spectrum (m/z 900−1300) which contains the majority of peaks corresponding to protein ions. Symbols indicate peaks subsequently selected
for CID.
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result of easier disruption of the extracellular matrix and
improved extraction eﬃciency at the colony edge.
Ions centered at m/z 923.51 (+10 charge state), 933.91 (+7),
954.43 (+10), 1028.14 (+15), 1190.31 (+7), and 1212.94 (+6)
were fragmented. The product ions were searched against the
E. coli K-12 database in ProSightPTM 2.0, using either the
“absolute mass search” or the “sequence tag search”. Putative
protein identiﬁcations were conﬁrmed by manual analysis. The
proteins identiﬁed and the protein sequence coverages are
shown in Table 1. The sequence coverages ranged from 13% to
40%. A representative MS/MS spectrum from one of the
identiﬁed proteins, DNA-binding protein HU-beta, is shown in
Figure 4. The remaining MS/MS spectra are shown in
Supplementary Figures 4−8, Supporting Information. Product
ion assignments are shown in Supplementary Tables 1−6,
Supporting Information.
A total of 6 proteins were identiﬁed. DNA binding protein
HU-alpha and HU-beta are both histone-like DNA binding
proteins which are capable of wrapping DNA to stabilize and
prevent its denaturation under extreme environmental
conditions.24 DNA binding protein H-NS increases thermal
stability of DNA and inhibits transcription at low temper-
atures.25 The function of protein YjbJ is poorly understood but
is recognized as a highly abundant protein in E. coli.26 CspA is a
cold shock response protein, known to be induced at
temperatures of 15 °C or lower.27 Multiple stress resistant
protein BhsA is known to be induced under a range of stressful
conditions including drastic pH changes, heat shock, the
presence of heavy metals, and hydrogen peroxide. As a result,
this protein inhibits bioﬁlm formation by repressing cell
aggregation and increases cell viability under stressful
conditions.28 A number of these proteins (HU-alpha, HU-
beta, YjbJ, H-NS) were also detected by ESI top-down MS/MS
of S. typhimurium reported by McFarland et al.
It should be noted that, while a number of proteins have
been identiﬁed in this study, it was not possible to identify all
proteins from their MS/MS spectra. Ions of m/z 1254.99 (+7
charge state) were also fragmented, and the product ions were
searched against the E. coli K-12 database in ProSightPTM 2.0,
using both the “absolute mass search” and the “sequence tag
search”. Neither search returned hits corresponding to the
correct intact mass. Top-down methods are used infrequently
relative to bottom-up identiﬁcation techniques, and as such, the
demand for software for identiﬁcation of proteins by top-down
methods is lower. While several platforms are available, e.g.,
Prosight PTM 2.0,29 ROCCIT (roccit.caltech.edu), the
proteins in this work were not reliably fully characterized and
a large amount of manual characterization was required. This
aspect would need to be addressed if top-down methods were
to become more established.
The selection of proteins detected and identiﬁed from
colonies stored at 4 °C is indicative of extreme environmental
Table 1. Summary of Proteins Identiﬁed from E. coli K-12 Colonies Following “Contact” LESA Top-Down Mass Spectrometry
m/zmeas m/zcalc Δppm
charge
state MWcalc % sequence coverage protein identity protein function
954.5104 954.5133 −3.0 +10 9530.24 28 DNA binding protein HU-
alpha
stabilizes DNA under extreme
environmental conditions
1027.6038 1027.6069 −3.0 +15 15399.95 18 DNA binding protein H-NS increases thermal stability of DNA
1189.5921 1189.5919 0.2 +7 8321.10 23 UPF0337 protein YjbJ predicted shock response protein
1212.2801 1212.2719 6.8 +6 7268.60 13 CspA cold shock response protein
923.0039 923.0067 −3.0 +10 9221.00 40 DNA-binding protein HU-
beta
stabilizes DNA under extreme
environmental conditions
933.4871 933.4822 5.2 +7 6528.35 32 multiple stress resistance
protein BhsA
inhibits bioﬁlm formation by repressing cell
aggregation
Figure 4. CID mass spectrum of ions centered at m/z 923.51 (+10 charge state), identiﬁed as DNA-binding protein HU-beta. Fragment ions
observed are shown the inset.
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conditions, consistent with prolonged refrigerated storage
conditions. After the initial incubation period to grow the
colonies, samples were stored at 4 °C for a number of days,
which explains the induction of a cold shock response. For
comparison, a further set of bacterial samples were grown.
These colonies were stored at room temperature (∼20 °C)
prior to mass spectrometric analysis and were never exposed to
low (refrigerated) temperatures.
Figure 5 shows LESA mass spectra obtained from bacteria
grown and stored at room temperature. For comparison, a
LESA mass spectrum from a colony grown at room
temperature for 3 days and then stored at 4 °C for 2 days is
shown in Figure 5a. Peaks corresponding to all the proteins
identiﬁed from the LESA mass spectrum shown in Figure 3 (in
which bacteria had been grown for 3 days at room temperature
before being stored at 4 °C for 7 days) were observed, albeit
with diﬀering relative abundances. That may be due to
diﬀerences in protein expression as a result of prolonged cold
shock or may be due to diﬀerences in LESA extraction
eﬃciency either as a result of prolonged cold shock or colony
topology. Figure 5b shows a mass spectrum obtained from a
colony stored at room temperature for 3 days. The colony was
sampled at three separate locations, as indicated on the
photograph inset. (Individual mass spectra from each location
are shown in Supplementary Figure 9, Supporting Informa-
tion.) At location 1, peaks corresponding to HU-alpha and HU-
beta were observed, but none of the other proteins identiﬁed
above were seen. At location 2 (Figure 5b), peaks
corresponding to HU-alpha, HU-beta, and CspA were
observed. At location 3, none of the proteins identiﬁed above
were observed. The proteins BhsA and YjbJ were not observed
in any location.
A repeat analysis was carried out after the colonies had been
stored at 20 °C for a further 7 days (Figure 5c). Again, three
separate locations were analyzed, as indicated. (Individual mass
spectra obtained from each location are shown in Supple-
mentary Figure 10, Supporting Information.) In two of the
locations (2 and 3), all but one (BhsA) of the stress response
proteins previously detected in bacteria stored at 4 °C were
detected. At location 1, all but BhsA and YjbJ were detected.
These results suggest that prolonged storage can induce various
stress responses in bacteria. Multiple stress resistance protein
BhsA, however, was not detected at any location from colonies
stored at 20 °C, either after 3 or 10 days, suggesting that either
temperatures lower than 20 °C or storage for longer than 10
days is required for the induction of this protein. As mentioned
above, BhsA has been shown to inhibit bioﬁlm formation. It is
possible that expression of BhsA under refrigerated conditions
resulted in reduced bioﬁlm formation thus aiding the LESA
process.
■ CONCLUSIONS
We have demonstrated a method suitable for the top-down
extraction, detection, and identiﬁcation of intact proteins from
living bacterial colonies. The identities of these proteins appear
to indicate the well-being of the colony. The method has
implications for microbiological research as it may be suitable
for the study of bacterial growth, communication, and response
to external factors such as pharmaceuticals and pH. Moreover,
the “contact” LESA method oﬀers improved sampling precision
and could be useful for spatial proﬁling of bacterial colonies or
analysis of contaminated surfaces.
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Appendix 3: CID mass spectra from various protein ions detected from bacterial colonies 
and fragmentation assignments. 
Table 1: Fragments observed following CID of +7 ions centred at m/z 923.51 (identified 
as HU-beta). 
m/z measured m/z  theoretical Fragment assignment Δppm  
815.4447 815.4444 b7
+
 
0.4 
878.9677 878.9667 b17
+2
 
1.1 
894.4856 894.4850 b27
+3
 
0.7 
930.4719 930.4713 b8
+
 
0.6 
949.0361 949.0363 y19-NH3
 +2
 
-0.2 
953.5203 953.5224 a75
+8
 
-2.2 
957.3126 957.3127 b48
+5
 
-0.1 
957.5332 957.5296 y55
+6
 
3.8 
959.5201 959.5213 b38-NH3
 +4
 
-1.3 
985.5389 985.5410 y67-H2O
 +7
 
-2.1 
1016.5607 1016.5605 b31-H2O
 +3
 
0.2 
1026.1294 1026.1238 b70-H2O
 +7
 
5.5 
1058.5663 1058.5663 b9
+
 
0.0 
1171.6500 1171.6504 b10
+
 
-0.3 
1242.6869 1242.6875 b11
+
 
-0.5 
1313.7247 1313.7246 b12
+
 
0.1 
1456.7910 1456.7907 y14-NH3
 +
 
0.2 
1473.8176 1473.8172 y14
+
 
0.3 
1555.8600 1555.8591 y15-NH3
 +
 
0.6 
1556.8106 1556.8101 b15
+
 
0.3 
1572.8861 1572.8857 y15
+
 
0.3 
1669.8941 1669.8942 b16
+
 
-0.1 
1700.9815 1700.9806 y16
+
 
0.5 
2610.4044 2610.4032 b26
+
 
0.5 
2794.5261 2794.5244 b28
+
 
0.6 
3594.9530 3594.9524 b36
+
 
0.2 
3764.1165 3764.1154 y36
+
 
0.3 
4139.1693 4139.1653 b41
+
 
1.0 
4700.5854 4700.5860 y45
+
 
-0.1 
4799.6483 4799.6544 y46
+
 
-1.3 
5197.8741 5197.8709 y50
+
 
0.6 
5627.0513 5627.0569 y54
+
 
-1.0 
5827.1691 5827.1730 y56
+
 
-0.7 
6057.2643 6057.2632 y58
+
 
0.2 
6823.5966 6823.6639 a67
+
 
-9.9 
7521.0290 7521.0286 b74
+
 
0.1 
7552.1256 7552.1151 y74
+
 
1.4 
7730.1764 7730.1814 b76-H2O
 +
 
-0.6 
7748.1860 7748.1920 b76
+
 
-0.8 
7979.3226 7979.3218 y79
+
 
0.1 
8033.3419 8033.3323 y80-NH3
 +
 
1.2 
8050.3528 8050.3589 y80
+
 
-0.8 
8163.4420 8163.4429 y81
+
 
-0.1 
8975.9183 8975.9185 y88
+
 
0.0 
9088.9750 9088.9485 b89
+
 
2.9 
 
 
Table 2: Fragments observed following CID of +7 ions centred at m/z 933.91 (identified 
as BhsA).  
m/z measured m/z  theoretical Fragment assignment Δppm  
715.3632 715.3621 b7
+
 
1.5 
911.4726 911.4707 b18-H2O
 +2
 
2.1 
984.5356 984.5513 y9-NH3
 +
 
-15.9 
1481.7619 1481.7594 b14
+
 
1.7 
1639.8315 1639.8286 b16
+
 
1.8 
1734.9046 1734.9021 b17-H2O
 +
 
1.4 
1752.9160 1752.9127 y51-H2O
 +3
 
1.9 
4048.0870 4048.0808 y38
+
 
1.5 
4275.2138 4275.2078 y40
+
 
1.4 
4433.2850 4433.2769 y42
+
 
1.8 
4504.3217 4504.3141 y43
+
 
1.7 
4618.3652 4618.3570 y44
+
 
1.8 
4776.4358 4776.4261 y46
+
 
2.0 
4889.5194 4889.5102 y47
+
 
1.9 
5029.5805 5029.5688 y49-H2O
 +
 
2.3 
5047.5869 5047.5793 y49
+
 
1.5 
5146.6648 5146.6477 y50
+
 
3.3 
5795.9756 5795.9661 y56-H2O
 +
 
1.6 
5813.9871 5813.9767 y56
+
 
1.8 
5915.0323 5915.0244 y57
+
 
1.3 
5984.0550 5984.0458 y58-H2O
 +
 
1.5 
6002.0658 6002.0564 y58
+
 
1.6 
6112.1149 6112.1044 y59-H2O
 +
 
1.7 
6130.1262 6130.1150 y59
+
 
1.8 
6229.1980 6229.1834 y60
+
 
2.3 
6358.2065 6358.2260 y61
+
 
-3.1 
 
  
 Table 3: Fragments observed following CID of +10 ions centred at m/z 954.43 (identified 
as HU-alpha).  
m/z measured m/z  theoretical Fragment assignment Δppm  
1430.8382 1430.8366 y14
+
 
1.1 
1643.9498 1643.9479 y16
+
 
1.2 
1714.9870 1714.9850 y17
+
 
1.2 
1786.0244 1786.0221 y18
+
 
1.3 
1857.0615 1857.0593 y19
+
 
1.2 
1970.1458 1970.1433 y20
+
 
1.3 
2211.3248 2211.3223 y22
+
 
1.1 
2441.3456 2441.3432 b22
+
 
1.0 
2696.5048 2696.5015 b25
+
 
1.2 
3197.7492 3197.7450 b30
+
 
1.3 
3268.7848 3268.7821 b31
+
 
0.8 
3381.8691 3381.8662 b32
+
 
0.9 
4241.2656 4241.2585 b40
+
 
1.7 
4312.3008 4312.2956 b41
+
 
1.2 
4878.6936 4878.6966 y46
+
 
-0.6 
5591.0415 5591.0357 y53
+
 
1.0 
6149.4036 6149.3371 y58
+
 
10.8 
7319.8853 7319.8809 b68
+
 
0.6 
7561.0638 7561.0599 b70
+
 
0.5 
7745.2929 7745.1811 b72
+
 
14.4 
7816.2066 7816.2182 b73
+
 
-1.5 
7887.2699 7887.2553 b74
+
 
1.9 
8046.3405 8046.3891 y77
+
 
-6.0 
8083.3512 8083.3401 b76-NH3
 +
 
1.4 
8100.3646 8100.3667 b76
+
 
-0.3 
9055.9353 9055.9699 y86
+
 
-3.8 
9139.0079 9139.0070 y87-H2O
 +
 
0.1 
9157.0190 9157.0176 y87
+
 
0.2 
9185.9276 9185.9900 a87
+
 
-6.8 
9285.1182 9285.1125 y88
+
 
0.6 
9384.13423 9384.0904 b89
+
 
4.7 
 
  
 Table 4: Fragments observed following CID of +15 ions centred at m/z 1028.14 
(identified as H-NS).  
m/z measured m/z  theoretical Fragment assignment Δppm  
1010.7751 1010.7776 a70-NH3
 +8
 
-2.5 
1057.1649 1057.1477 y95-NH3
 +10
 
16.3 
1061.5431 1061.5514 y8-NH3
 +
 
-7.8 
1070.4087 1070.4231 y68-H2O
 +7
 
-13.5 
1078.5599 1078.5649 b124
+13
 
-4.6 
1078.7030 1078.7096 y69-NH3
 +7
 
-6.1 
1082.4905 1082.4823 a115-NH3
 +12
 
7.6 
1096.5819 1096.5787 b57-NH3
 +6
 
2.9 
2141.0992 2141.1199 y132-H2O
 +7
 
-9.7 
5579.8547 5579.8796 b49
+
 
-4.5 
5807.9615 5807.9906 b51
+
 
-5.0 
6396.3210 6396.3521 y58
+
 
-4.9 
6710.4766 6710.5111 y61
+
 
-5.1 
6823.5621 6823.5952 y62
+
 
-4.9 
7276.7796 7276.8175 y66
+
 
-5.2 
7839.0195 7839.0590 b67
+
 
-5.0 
8009.1223 8009.1645 b69
+
 
-5.3 
8106.1335 8106.1809 b70-H2O
 +
 
-5.8 
8124.1447 8124.1915 b70
+
 
-5.8 
8335.2471 8335.2872 b72
+
 
-4.8 
8464.2807 8464.3297 b73
+
 
-5.8 
8690.4577 8690.4979 b75
+
 
-4.6 
8873.5192 8873.5623 b77-H2O
 +
 
-4.9 
9821.0766 9821.1294 y87
+
 
-5.4 
13880.1476 13880.2135 b123
+
 
-4.7 
14637.5013 14637.5741 b130
+
 
-5.0 
14752.5413 14752.6011 b131
+
 
-4.1 
14994.6602 14994.7430 b133-H2O
 +
 
-5.5 
15108.7440 15108.8111 b134-NH3
 +
 
-4.4 
15253.8508 15253.9326 b135
+
 
-5.4 
 
  
 Table 5: Fragments observed following CID of +7 ions centred at m/z 1190.31 (identified 
as YjbJ).  
m/z measured m/z  theoretical Fragment assignment Δppm  
1339.6154 1339.6178 y9
+
 
-1.8 
4500.2426 4500.2443 y36
+
 
-0.4 
4956.5011 4956.5027 y40
+
 
-0.3 
5317.5992 5317.5971 y43
+
 
0.4 
5432.6217 5432.6240 y44
+
 
-0.4 
5533.6703 5533.6717 y45
+
 
-0.3 
5646.7570 5646.7558 y46
+
 
0.2 
5831.8724 5831.8722 y48
+
 
0.0 
6128.9856 6128.9836 y50-NH3
 +
 
0.3 
6687.3295 6687.3325 y55
+
 
-0.4 
6982.4865 6982.4891 b60
+
 
-0.4 
7703.8486 7703.8517 y64
+
 
-0.4 
7797.8416 7797.8453 b66
+
 
-0.5 
7814.8725 7814.8837 y65-H2O
 +
 
-1.4 
7832.8903 7832.8943 y65
+
 
-0.5 
7929.8943 7929.9107 y66-H2O
 +
 
-2.1 
7947.9212 7947.9212 y66
+
 
0.0 
8076.0105 8076.0162 y67
+
 
-0.7 
8190.0475 8190.0591 y68
+
 
-1.4 
 
  
 Table 6: Fragments observed following CID of +6 ions centred at m/z 1212.94 (identified 
as CspA).  
m/z measured m/z  theoretical Fragment assignment Δppm  
886.4619 886.4629 y10
+
 
-1.1 
1142.6161 1142.6164 y13
+
 
-0.3 
1165.5888 1165.6030 y24-H2O
 +2
 
-12.2 
1174.6070 1174.6083 y24
+2
 
-1.1 
1177.9185 1177.9145 b67-H2O
 +6
 
3.4 
1180.9910 1180.9804 a54+
5
 
9.0 
1185.0856 1185.0781 b43
+4
 
6.3 
1257.2897 1257.2900 y37-NH3
 +3
 
-0.2 
1302.6511 1302.6483 y38-H2O
 +3
 
2.1 
6850.3496 6850.3232 b65-NH3
 +
 
3.9 
 
 
 
 
 
 
